Page last updated: 2024-10-27

fluorouracil and Hepatocellular Carcinoma

fluorouracil has been researched along with Hepatocellular Carcinoma in 1089 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)."9.51Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022)
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies."9.41A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021)
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit."9.30Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019)
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior."9.27Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018)
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)."9.24A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017)
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare."9.22Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016)
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."9.19Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014)
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib."9.17Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013)
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin."9.17Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013)
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."9.16Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012)
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)."9.16Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012)
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)."9.15Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011)
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection."9.15Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011)
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)."9.15Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011)
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)."9.14Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009)
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach."9.14Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010)
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)."9.12Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."9.12Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."9.11A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."9.11Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005)
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment."9.10Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002)
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics."9.10Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003)
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated."9.10Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma."9.10Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002)
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma."9.085-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995)
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen."8.77[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989)
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)."8.31Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."8.31Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)."8.12Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022)
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)."8.12One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022)
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells."8.02[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021)
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown."8.02Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021)
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)."8.02Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021)
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)."8.02Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021)
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)."7.96Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020)
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients."7.96Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020)
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)."7.88Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018)
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs."7.88Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018)
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)."7.88lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018)
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats."7.88Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018)
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)."7.85The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017)
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)."7.85The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017)
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism."7.83Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016)
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)."7.83Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016)
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China."7.83FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."7.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)."7.81Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015)
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)."7.81Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015)
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)."7.81Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015)
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)."7.81Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015)
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)."7.80The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."7.80Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."7.80Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma."7.80Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014)
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells."7.80Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014)
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."7.79Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma."7.79Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013)
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable."7.79Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013)
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)."7.79Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013)
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease."7.79Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013)
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)."7.79MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013)
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)."7.79[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013)
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)."7.78Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012)
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro."7.78Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012)
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma."7.78Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012)
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols."7.78Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012)
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma."7.78Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012)
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy."7.77Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011)
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings."7.77Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011)
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)."7.77Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011)
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)."7.77Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011)
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."7.77Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."7.77Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms."7.77Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011)
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization."7.77Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011)
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)."7.77[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011)
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms."7.76Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."7.76Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells."7.76Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010)
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)."7.76Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010)
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)."7.76MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010)
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."7.75Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009)
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)."7.75Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009)
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)."7.75Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."7.75Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)."7.75Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009)
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo."7.74[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."7.74[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."7.74Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007)
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis."7.74Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."7.74Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."7.74Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."7.74[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor."7.74Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007)
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results."7.74Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007)
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis."7.74Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."7.74Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)."7.74Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008)
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma."7.73Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."7.73Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)."7.73Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005)
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)."7.73[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005)
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line."7.73Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006)
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated."7.73The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006)
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression."7.72Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004)
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival."7.72Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004)
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use."7.72A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."7.72Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis."7.72Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004)
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma."7.72Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004)
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination."7.72[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004)
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)."7.72[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004)
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."7.72Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004)
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)."7.71Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002)
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously."7.71[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002)
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU."7.71Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002)
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)."7.71[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001)
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)."7.71Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002)
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)."7.71[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002)
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs."7.70Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999)
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system."7.70Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999)
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)."7.70[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999)
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies."7.70Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."7.67[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma."7.67[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984)
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma."7.67Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989)
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system."7.67Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989)
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels."7.67[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989)
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation."7.67[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987)
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia."7.67Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985)
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)."7.67Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987)
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0."7.66[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982)
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed."6.90All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."6.87Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."6.80Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15."6.79A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."6.77Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection."6.75Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."6.73Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"Pravastatin was administered at a daily dose of 40 mg."6.70Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001)
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients."6.70A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001)
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity."6.67Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992)
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation."6.50Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014)
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor."6.41[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002)
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer."5.91Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023)
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage."5.91MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023)
"5-Fluorouracil (5-FU) has been widely applied in treating cancers."5.72CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022)
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu."5.72Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022)
"To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI)."5.69Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. ( Cao, MR; Chen, HW; Cheng, Y; Deng, JD; Deng, M; Fang, CK; Guan, RG; Guo, RP; Guo, ZX; Huang, HK; Jiang, YC; Lei, QC; Li, JB; Li, Q; Li, SH; Lin, WP; Ling, YH; Lu, LH; Luo, R; Mei, J; Wang, QX; Wei, W; Wen, YH; Zhao, RC; Zheng, L; Zhong, C; Zou, JW, 2023)
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents."5.62Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021)
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure."5.56Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020)
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug."5.56CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020)
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC."5.56Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020)
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level."5.56Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020)
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)."5.51Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022)
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed."5.51Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019)
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu."5.51Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019)
"5-Fluorouracil (5-FU) is a widely used antitumor drug."5.51Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019)
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity."5.48Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018)
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties."5.43Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016)
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer."5.43Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016)
"Dioscin is a natural steroid saponin that presents in various plants."5.43Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016)
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence."5.42MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015)
"Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China."5.41Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. ( Du, Z; He, M; Kan, A; Lai, Z; Li, Q; Liu, S; Shen, J; Shi, M; Xu, L, 2023)
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies."5.41A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021)
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor."5.39Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013)
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor."5.39PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013)
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma."5.39Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013)
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor."5.39Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013)
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection."5.39Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013)
"The only drug that improves survival in hepatocellular carcinoma is sorafenib."5.38Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012)
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice."5.38Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012)
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy."5.38Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012)
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU."5.385-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012)
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC."5.38Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."5.38[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus."5.37Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL."5.37Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011)
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil."5.37Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011)
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways."5.36Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010)
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)."5.35Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options."5.35Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009)
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC."5.34Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007)
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy."5.34Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007)
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2."5.34Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007)
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor."5.33[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."5.335-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33."5.33[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."5.33[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal."5.33[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006)
"A syngeneic rat model of hepatocellular carcinoma was used."5.32[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003)
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used."5.32The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004)
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein."5.32Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."5.31Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit."5.30Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019)
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)."5.28[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990)
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior."5.27Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018)
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma."5.26Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979)
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)."5.24A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017)
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare."5.22Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016)
"To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis."5.20Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. ( Chen, H; Gao, S; Guo, JH; Liu, P; Xu, HF; Yang, RJ; Zhang, PJ; Zhu, X, 2015)
"The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC)."5.19Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. ( Bai, Y; Cheng, Y; Fan, J; Jian, Z; Li, J; Liang, H; Liang, J; Liang, L; Qin, S; Rau, KM; Shen, L; Sun, Y; Wu, G; Yang, TS; Zhang, Y, 2014)
" Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case-control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP)."5.19Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. ( Chang, ML; Chen, YC; Chien, RN; Hsu, CW; Lin, CL; Yeh, C; Yeh, CT, 2014)
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."5.19Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014)
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib."5.17Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013)
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin."5.17Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013)
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."5.16Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012)
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)."5.16Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012)
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)."5.15Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011)
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection."5.15Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011)
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)."5.15Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011)
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)."5.14Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009)
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach."5.14Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010)
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)."5.12Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007)
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches."5.12Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007)
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)."5.11A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005)
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)."5.11Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005)
"Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma."5.11Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005)
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment."5.10Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002)
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics."5.10Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003)
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated."5.10Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma."5.10Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002)
"To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B)."5.10Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Liu-Mares, W; Malogolowkin, MH; Newman, K; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2002)
"The purpose of this Phase II study was to determine the response rate, the toxicity, and the effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and alpha-IFN (PIAF) in advanced unresectable hepatocellular carcinoma."5.09Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. ( Chan, AT; Ho, SK; Johnson, PJ; Lau, WY; Leung, NW; Leung, TW; Liew, CT; Mok, TS; Patt, YZ; Tang, AM; Yeo, W; Yu, SC, 1999)
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma."5.085-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995)
"A Phase II clinical trial was conducted to evaluate the efficacy of intravenous fluorouracil (5-FU) and subcutaneous recombinant interferon-alpha-2b (rIFN-alpha-2b) in the treatment of hepatocellular carcinoma (HCC) and to define factors that might be predictive of a response to treatment."5.07Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. ( Charnsangavej, C; Cleary, K; Fischer, H; Levin, B; Noonan, CA; Patt, YZ; Pazdur, R; Roh, M; Smith, R; Yoffe, B, 1993)
"We conducted a randomized, controlled trial comparing 5-fluorouracil (5-FU) with or without biological response modifiers (BRMs) as a maintenance therapy for hepatocellular carcinoma (HCC) after treatment with percutaneous ethanol injection (PEI), transcatheter arterial embolization (TAE) or arterial infusion of antitumor agents (AI)."5.07Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. ( Fukuda, S; Moriya, N; Sakata, Y; Sasaki, D; Suto, T; Watanabe, Y; Yoshida, Y, 1994)
"Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy)."5.07Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. ( Desai, DC; Desouza, LJ; Dhir, V; Dinshaw, KA; Jagannath, P; Mohandas, KM; Nagral, A; Sharma, V; Swaroop, VS, 1992)
"In a prospective clinical trial, 39 patients with advanced hepatocellular carcinoma were randomized to receive either Adriamycin (20 patients) or a combination of 5-fluorouracil, methotrexate, cyclophosphamide, and vincristine (19 patients)."5.05Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. ( Choi, TK; Lee, NW; Wong, J, 1984)
"Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule."5.045-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. ( Bateman, JR; Durkin, WJ; Link, JS; Paroly, WS; Peters, RL, 1977)
"We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC)."4.90[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. ( Akasu, I; Fukushima, G; Kataoka, H; Kondo, K; Magata, H; Marutsuka, H; Nakamura, K; Otani, K; Sato, Y; Yano, K; Yonei, A, 2014)
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen."4.77[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989)
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)."4.31Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023)
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown."4.31Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023)
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)."4.12Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022)
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)."4.12One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022)
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells."4.02[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021)
"FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)."4.02Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021)
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown."4.02Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021)
"This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) as an alternative treatment option in advanced hepatocellular carcinoma (HCC) patients with failed or unsuitability for transarterial chemoembolization (TACE)."4.02Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. ( Chen, MP; Chen, RX; Chen, Y; Ge, NL; Hsu, SJ; Luo, JF; Ren, ZG; Wang, Y; Wang, YH; Xu, X; Yin, X; Zhang, L; Zhao, ZY, 2021)
"This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC)."4.02Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. ( Al Meanazel, AT; Al Meanazel, OT; Alanazi, FK; Alanazi, SA; Alomrani, AH; Badran, MM; Elzayat, E; Harisa, GI, 2021)
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)."4.02Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021)
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)."4.02Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021)
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)."3.96Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020)
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients."3.96Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020)
"Currently, 5-fluorouracil (5-FU) resistance became a major obstacle to its clinical use for patients with hepatocellular carcinoma (HCC)."3.91H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. ( Li, F; Li, Z; Wang, J; Wei, N; Wu, N; Zhang, H, 2019)
" In this study, a biotin-/lactobionic acid-modified poly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer was synthesized, and curcumin- and 5-fluorouracil-loaded nanoparticles (BLPPNPs/C + F) were prepared to enhance the treatment of hepatocellular carcinoma."3.91Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. ( Gao, X; Ji, Y; Jian, X; Li, Z; Liu, Z; Ni, W; Sun, S; Wu, L, 2019)
"Bile salts (GCDA) promoted the proliferation of hepatocellular carcinoma (HCC) cells (HepG2 and QGY-7703), and GCDA treatment reduced the chemosensitivity of 5-fluorouracil (5FU) in HepG2 and QGY-7703 cells."3.91Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. ( Jin, X; Li, X; Liao, M; Wang, C; Xiao, X; Yang, M; Zhang, Y; Zhao, J, 2019)
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)."3.88Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018)
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs."3.88Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018)
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)."3.88lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018)
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats."3.88Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018)
" We found that the downregulation or complete depletion of SND1 enhanced the apoptosis levels of HepG2 and SMMC-7721 cells upon stimulation with 5-Fu (5-fluorouracil), a chemotherapeutic drug for HCC (hepatocellular carcinoma)."3.88SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. ( Cui, X; Gao, X; Qian, B; Ren, Y; Su, C; Yang, J; Yao, X; Yao, Z; Zhao, C, 2018)
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)."3.85The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017)
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)."3.85The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017)
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism."3.83Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016)
"Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin."3.83Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. ( Farmer, RW; Li, Y; Martin, RC; Yang, Y, 2016)
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)."3.83Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016)
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China."3.83FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."3.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)."3.81Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015)
" Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells."3.81Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. ( Li, H; Liu, L; Shi, Y; Su, C; Su, R; Wang, G; Zhao, L, 2015)
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)."3.81Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015)
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)."3.81Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015)
"Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system."3.81VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015)
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)."3.81Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015)
"Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC)."3.81Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. ( Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH, 2015)
" Here, we report the effect of an APN inhibitor 4cc in enhancing sensitivity of hepatocellular carcinoma (HCC) cell lines and xenograft model in response to 5-fluorouracil (5-FU) in vivo and in vitro."3.81Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. ( Dai, G; Duan, Y; Shi, LH; Sun, ZP; Wang, XJ; Xu, WF; Zhang, J; Zhang, XR, 2015)
"Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)."3.80A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014)
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)."3.80The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014)
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo."3.80Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014)
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)."3.80Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014)
"In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma."3.80Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014)
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma."3.80Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014)
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells."3.80Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014)
"Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC."3.80Fibrolamellar hepatocellular carcinoma in children and adolescents. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Malogolowkin, MH; Newman, K; Ortega, JA; Qu, W; Quinn, JJ; Reynolds, M; Sensel, MG, 2003)
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment."3.79Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013)
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma."3.79Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013)
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable."3.79Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013)
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)."3.79Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013)
" Our study found that the expression of miR-27a was down-regulated in the multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-fluorouracil (BEL/5-FU) compared with its parental BEL-7402 cell line, while the MDR1/P-glycoprotein expression was elevated."3.79MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. ( Chen, Z; Hu, T; Huang, C; Li, J; Lv, X; Ma, T; Xu, T; Zhang, L, 2013)
"To explore the potential of iodized linoleic acid (ILA) and its 5-fluoro-deoxyuridine ester (IFU) to inhibit hepatocellular carcinoma (HCC) cells in vitro and tumors in vivo."3.79[A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer]. ( Dai, ZY; Jiang, YB; Kuang, CX; Li, KC; Zeng, XY, 2013)
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease."3.79Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013)
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)."3.79MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013)
"Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits."3.79Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013)
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)."3.79[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013)
"Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients."3.79The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. ( Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S, 2013)
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)."3.78Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012)
" Swiss mice inoculated with hepatoma HepA(22) or sarcoma 180 (S(180)) cells were treated with ShD or 5-fluorouracil (5Fu)."3.78Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice. ( BaoJie, G; GuangZhi, Y; LiHua, L; Long, S; Wei, X; Yang, Z; YanYong, H; YingLi, W, 2012)
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro."3.78Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012)
"5-Fluorouracil (5-FU) chemotherapy is the first choice treatment for advanced hepatocellular carcinoma (HCC), and resistance is the major obstacle to successful treatment."3.78Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. ( Kasamatsu, A; Kobayashi, E; Sakurada, T; Sato, N; Sunaga, M; Tanzawa, H; Uchibori, K; Ueda, S; Uzawa, K; Yokota, S; Yoshikawa, M, 2012)
"The aim of the present study was to design a targeted delivery system of 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."3.78Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. ( Hassanzadeh, F; Khadem, M; Sadeghi, H; Varshosaz, J, 2012)
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma."3.78Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012)
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols."3.78Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012)
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma."3.78Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012)
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy."3.77Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011)
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings."3.77Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011)
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)."3.77Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011)
" We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC)."3.77Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. ( Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H, 2011)
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)."3.77Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011)
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."3.77Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011)
"Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro."3.77Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011)
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches."3.77Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC)."3.77Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. ( Jung, G; Kim, BH; Kim, JS; Kim, NY; Lee, KJ; Park, SJ; Park, YM; Yeon, JW; Yun, HK, 2011)
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms."3.77Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011)
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization."3.77Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011)
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)."3.77[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011)
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms."3.76Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010)
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases."3.76Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010)
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells."3.76Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010)
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)."3.76Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010)
" However, it has also been reported that 5-fluorouracil (5-FU) exacerbates liver damage in patients with liver cirrhosis (LC)."3.76Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Shinohara, M; Shizawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2010)
" Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL."3.76ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. ( Barilà, D; Giaccari, D; Mingardi, M; Santini, S; Stagni, V, 2010)
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)."3.76MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010)
"We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)."3.76[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010)
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."3.75Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009)
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)."3.75Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009)
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)."3.75Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009)
"The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the prognosis of the patients with hepatocellular carcinoma (HCC)."3.75Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamamoto, H, 2009)
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis."3.75Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009)
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)."3.75Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009)
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo."3.74[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."3.74[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)."3.74Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007)
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis."3.74Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007)
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration."3.74Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007)
"To evaluate the effect of combined antisense oligonucleotides targeting midkine (MK-AS) and chemotherapeutic drugs [cisplatin(DDP), 5-fluorouracil (5-FU) and adriamycin (ADM)] on inhibition of HepG2 cell proliferation, and to analyze the efficacy of MK-AS used in combined ADM in in situ human hepatocellular carcinoma (HCC) model."3.74Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma. ( Dai, LC; He, JF; Lu, YL; Ping, JL; Wang, X; Yao, X, 2007)
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil."3.74Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007)
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003."3.74[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007)
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor."3.74Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007)
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results."3.74Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007)
"To investigate the multicellular resistance of human hepatocellular carcinoma HepG2 cells in three-dimensional culture to delisheng, 5-fluorouracil and adriamycin, and the possible molecular mechanisms of delisheng."3.74Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. ( Cui, J; Guo, YH; Nan, KJ; Tian, T; Wang, L; Zhao, N, 2007)
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis."3.74Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."3.74Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007)
" Here, we examined the role p53 plays in the antitumour effect of combination treatment with pegylated interferon (PEG-IFN)-alpha and 5-fluorouracil (5-FU), which has been shown to effectively treat advanced hepatocellular carcinoma (HCC)."3.74Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. ( Fukuta, N; Hagiwara, S; Hayakawa, S; Kimura, M; Kudo, M; Munakata, H; Nagashima, M; Nakatani, T; Sakaguchi, Y, 2007)
"To observe changes of sensitivity to 5'-deoxy-5-fluorouridine (5'-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP)."3.74[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]. ( Fan, J; Liu, YK; Sun, RX; Tang, ZY; Xiao, YS; Ye, SL; Zhao, Y; Zhou, J, 2007)
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)."3.74Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008)
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma."3.73Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005)
"The effect of tacrolimus (FK506) and 5-fluorouracil (5-FU) on hepatocellular carcinoma remains elusive."3.73Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. ( Cao, XW; Ding, GS; Fu, ZR, 2005)
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches."3.73Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005)
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)."3.73Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005)
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)."3.73[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005)
"This study was designed to reveal whether the apoptosis induced in human hepatocellular carcinoma (HCC) cell lines by 5-fluorouracil (5-FU) could be enhanced by transfecting Bcl-2 small interfering RNA (siRNA)."3.73Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. ( Arai, M; Imazeki, F; Kanda, T; Saisho, H; Yokosuka, O, 2005)
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line."3.73Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006)
"Interferon (IFN) combined with 5-Fluorouracil (5-FU) treatment has recently been reported to show beneficial effects in patients with advanced hepatocellular carcinoma."3.73Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. ( Iwasaki, Y; Koike, K; Sakaguchi, K; Shiraha, H; Shiratori, Y; Suzuki, M; Takaki, A; Tatsukawa, M, 2006)
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated."3.73The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006)
" Anti-proliferative effects of single treatment with IFN-alpha subtypes or 5-fluorouracil (FU), and of combined treatment with each IFN-alpha subtype and 5-FU were examined on three hepatocellular carcinoma cell lines, HepG2, HLE and PLC/PRF/5."3.73Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. ( Arai, N; Ariyasu, H; Ariyasu, T; Fujioka, N; Fukuda, S; Ikeda, M; Ikegami, H; Kurimoto, M; Ohta, T; Tanimoto, T; Yamamoto, S, 2006)
"The use of 5-fluorouracil, topotecan, or gemcitabine was tested for enhancement of the effects of low dose rate (LDR) irradiation in an in vitro model for hepatocellular carcinoma."3.73Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. ( de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C, 2006)
"This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF)."3.72Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. ( Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J, 2003)
"To study the effect of wild type (wt) p53 gene transfection on drug resistant human hepatocellular carcinoma (HCC) cells induced by 5-Fluorouracil (5-FU)."3.72Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. ( Li, YX; Lin, ZB; Tan, HR, 2004)
"We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases."3.72[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004)
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression."3.72Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004)
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival."3.72Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004)
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use."3.72A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."3.72Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis."3.72Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004)
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma."3.72Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004)
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination."3.72[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004)
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)."3.72[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004)
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)."3.72Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004)
" In 25 patients with HCC, in vitro chemosensitivity to 5-fluorouracil (5-FU), epirubicin (EPI), and cisplatin (CDDP) was examined by CD-DST, and 5-FU, EPI, and paclitaxel (PTX) were examined in 38 patients with breast cancer."3.72[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]. ( Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K, 2004)
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)."3.71Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002)
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously."3.71[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002)
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU."3.71Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002)
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)."3.71[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001)
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)."3.71Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002)
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)."3.71[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002)
"Between 1990 and 1997, 227 patients with hepatocellular carcinoma were treated by intrahepatic arterial injection of a Lipiodol-Epirubicin-Mitomycin C emulsion followed by intermittent hepatic artery infusion of Epirubicin, Mitomycin C and 5-FU, employing an implantable subcutaneous infusion port."3.70[Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma]. ( An, M; Hamada, E; Ikawa, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takagi, S; Terakado, H; Watanabe, K, 1998)
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs."3.70Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999)
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system."3.70Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999)
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)."3.70[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999)
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies."3.70Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000)
"Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases."3.70[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000)
"A patient with advanced unresectable fibrolamellar hepatocellular carcinoma is reported, who was treated with cisplatinum, epirubicin and 5-fluorouracil combination chemotherapy."3.69Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy. ( Bower, M; Habib, N; Newlands, ES, 1996)
"Arterial infusion chemotherapy of EPF (etoposide, cisplatin, and 5-fluorouracil) or EAP (etoposide, Adriamycin, and cisplatin) was carried out in 28 cases of advanced hepatocellular carcinoma (HCC) between January 1988 and December 1990, and assessment was made of the anticancer efficacy of each treatment method."3.68Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. ( Midorikawa, H; Saito, Y; Sasaki, T; Takekawa, SD; Tarusawa, K; Yodono, H, 1992)
" Regarding HAI, transcatheter hepatic arterial embolization (TAE) was applied in two cases (hepatocellular carcinoma: 1; metastasis: 1) and 5-fluorouracil (continuous) combined with leucovorin (one shot) therapy (LV + 5-FU) was given to one metastatic case."3.68[Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy]. ( Arai, K; Iwasaki, Y; Kitamura, M; Miyashita, K; Mori, T; Okamoto, A, 1991)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg."3.67[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma."3.67[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984)
"An investigation was carried out into the effects of lipiodol-transcatheter arterial chemoembolization (L-TACE) therapy on hepatocellular carcinoma (HCC) and metastatic liver cancer, as well as the effects of oral 5-fluorouracil administration after L-TACE."3.67Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms. ( Hashimoto, N; Inoue, J; Kawai, S; Makino, M; Masuzawa, M; Mikuriya, S; Oda, T; Shimamura, Y; Takahashi, A; Yumoto, Y, 1989)
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma."3.67Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989)
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system."3.67Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989)
"UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined."3.67[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989)
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels."3.67[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989)
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation."3.67[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987)
"Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)."3.67[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988)
"Fifty-four patients with unresectable malignant liver tumors (14 of hepatocellular carcinoma, 40 of metastasis to the liver from gastric or colo-rectal cancer) were treated with intra-hepato-arterial (IHA) injections of cis-diamminedichloroplatinum (II) (CDDP) plus 5-fluorouracil (5-FU)."3.67[Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeda, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T; Wakatsuki, T, 1988)
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia."3.67Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985)
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)."3.67Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987)
" An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs."3.66[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)]. ( Gerok, W; Holstege, A; Keppler, D; Pausch, J, 1981)
"The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors."3.66[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983)
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0."3.66[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982)
"Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined."3.66[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982)
"Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)."3.65Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976)
"The case of a young man with hypogonadism, who was treated for five years withmethyltestosterone and who developed hepatocellular carcinoma, is discussed."3.65Hepatocellular carcinoma in association with androgen therapy. ( Goodman, MA; Laden, AM, 1977)
"The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage."3.30Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. ( Cheng, S; Guo, W; Huo, L; Jiang, D; Lau, WY; Liu, C; Mao, F; Shi, J; Sun, J; Zhang, F; Zhou, L, 2023)
"Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development."3.01Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. ( Iwamoto, H; Kawaguchi, T; Niizeki, T; Shimose, S; Shirono, T, 2023)
" We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC)."3.01Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. ( Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021)
"Arginine is an important nutrient for hepatocellular carcinoma (HCC)."3.01Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. ( Abou-Alfa, GK; Akce, M; Bomalaski, JS; Chen, YY; Cohen, SA; El Dika, I; Feng, YH; Harding, JJ; Ho, CL; Huang, WT; Johnston, A; Lee, DW; Lim, HY; Meyer, T; O'Reilly, EM; Qin, S; Ryoo, BY; Sarker, D; Tan, B; Yang, TS; Yen, CJ, 2021)
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed."2.90All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019)
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited."2.87Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018)
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy."2.80Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015)
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15."2.79A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014)
"To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC)."2.78[Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience]. ( Bao, LW; Jiang, XF; Jin, XJ; Lin, JJ; Lu, LJ; Wu, W, 2013)
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)."2.77Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012)
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection."2.75Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010)
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."2.73Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007)
"To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C (MMC)."2.71Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. ( Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK, 2003)
" Pharmacokinetic parameters were studied during the first cycle of dose levels 1 and 2 (500 mg/m2."2.71A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ( Brown, G; Chak, K; Chan, AT; Johnson, P; Leung, TW; Mok, TS; Moyses, C; Wong, H; Yeo, W, 2004)
"Over 80% of hepatocellular carcinoma (HCC) patients are HBV carriers; however, the incidence of HBV reactivation during CT has not been well-reported."2.71Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. ( Chan, AT; Chan, PS; Ho, WM; Johnson, PJ; Lam, KC; Leung, TW; Ma, B; Mo, FK; Mok, TS; Wong, WL; Yeo, W; Zee, B, 2004)
"Thirty-eight unresectable small hepatocellular carcinoma patients with diameter 2.71[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xia, JL; Yang, BW; Yie, SL; Zhang, BH, 2004)
"The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor."2.70Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002)
"Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis."2.70[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002)
"Pravastatin was administered at a daily dose of 40 mg."2.70Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001)
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients."2.70A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001)
"The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy."2.69[Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999)
"Four cases of gigantic hepatocellular carcinoma, considered by surgeons to be inoperable, were treated with repeated transcatheter chemoembolization (TOCE) until the serum alfafetoprotein reduced to normal or less than half of the original level or until the tumor reduced to less than half of the original size documented by CT scan and angiogram."2.69Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection. ( Eurvilaichit, C; Kanjanapitak, A; Leopairut, J, 2000)
"2 of the 7 (29%) patients with hepatoma responded."2.68Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995)
"Unresectable hepatocellular carcinoma is related to a poor prognosis."2.68Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997)
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity."2.67Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992)
"Hepatocellular carcinoma is known to have a doubling time of approximately 41 days."2.66194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. ( Fishman, EK; Guse, C; Klein, JL; Leibel, SA; Leichner, PK; Order, SE; Stillwagon, GB, 1989)
"Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU."2.66Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987)
"Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2."2.55Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017)
"Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population."2.53Progress in systemic therapy of advanced hepatocellular carcinoma. ( Gong, XL; Qin, SK, 2016)
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation."2.50Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014)
"The majority of primary liver cancer is hepatocellular carcinoma (HCC)."2.44Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. ( Nagai, H; Sumino, Y, 2008)
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity."2.44[Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007)
"Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting."2.44[Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007)
"Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy."2.42[Chemotherapy for hepatocellular carcinoma]. ( Ikeda, M; Okusaka, T; Ueno, H, 2004)
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor."2.41[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002)
"Hepatocellular carcinoma is a rapidly fatal disease in most patients."2.37Medical treatment of hepatocellular carcinoma. ( Friedman, M; Nerenstone, S, 1987)
"Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%."2.36[Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978)
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer."1.91Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023)
"Molecular targeted therapy combined with immunotherapy significantly improves the prognosis of patients with advanced liver cancer."1.91Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. ( Gao, W; Guo, Z; Li, H; Li, M; Liu, C; Liu, D; Mu, H; Si, T; Xing, W; Yang, X; Yu, H; Zhang, K; Zhang, W; Zou, Q, 2023)
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage."1.91MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023)
" The primary endpoint was overall survival (OS), while the secondary endpoints were progression-free survival and adverse effects."1.72Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study. ( Hibi, T; Ishii, M; Itano, O; Itano, S; Iwamoto, H, 2022)
"5-Fluorouracil (5-FU) has been widely applied in treating cancers."1.72CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022)
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu."1.72Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022)
"Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease."1.72Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. ( Akce, M; Draper, A; El-Rayes, B; Guadagno, J; Kang, S; Magliocca, J; Pectasides, M; Roccaro, G; Sellers, M; Zheng, W, 2022)
" We analysed the pharmacokinetic profile of the less toxic photoform ("ring-closed" dithienylethene) of the compound in tumors, plasma, and healthy liver."1.72Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data. ( Afonin, S; Babii, O; Borysko, P; Dovbynchuk, T; Dziubenko, N; Garmanchuk, LV; Gorbach, O; Khranovska, N; Komarov, IV; Kuznietsova, H; Schober, T; Shtanova, LY; Tolstanova, G; Ulrich, AS; Veselsky, SP; Yanchuk, PI, 2022)
"Hazard ratios for overall survival and disease progression were 0."1.72A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. ( Cheng, S; Gu, J; Jiang, D; Lau, WY; Liu, C; Mao, F; Shen, L; Shi, J; Sun, J; Wang, N; Zhou, L, 2022)
"Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment."1.72The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022)
"To evaluate the clinical efficacy of targeted therapy and immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX and lipiodol embolization in the treatment of unresectable hepatocellular carcinoma."1.72Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma. ( Chen, D; Chen, Y; Hu, XL; Huang, DB; Li, XQ; Lin, ZP; Xu, SX; Zhang, J; Zhong, H; Zou, XG, 2022)
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents."1.62Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021)
"5-Fluorouracil (5-FU) is a broad-spectrum anticancer drug, but its clinical application is limited due to drug resistance and toxic side effects."1.56Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent. ( Fang, X; Shen, A, 2020)
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure."1.56Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020)
"Liver cancer is a major threat to human life and health, and chemotherapy has been the standard non-surgical treatment for liver cancer."1.56Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. ( Dong, C; Jiang, K; Li, R; Lv, J; Sun, R; Wang, L; Wang, Q; Yin, Z; Zhang, J; Zhou, Y, 2020)
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug."1.56CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020)
"Efficient hepatocellular carcinoma (HCC) therapy remains a significant challenge due to the unsatisfactory targeting efficiency of nanoparticles (NPs) with either a passive targeting or a single active targeting property."1.56Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy ( He, DX; Huang, C; Huang, W; Liu, Y; Long, J; Tan, XW; Tang, S; Wei, H; Xiang, Y; Yu, CY; Zhou, Y, 2020)
"IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT."1.56INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020)
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC."1.56Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020)
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level."1.56Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020)
"This paper discussed the synergistic anti-tumor effect of Shuangdan Capsules combined with 5-fluorouracil(5-FU) on human liver cancer cell line Huh-7 and tumor bearing mice."1.56[Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice]. ( Chen, XW; Ding, WB; Ning, Q; Song, J; Xia, Z; Zhou, XW, 2020)
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed."1.51Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019)
"Patients with advanced hepatocellular carcinoma (HCC) have a poor oncologic outcome."1.51Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. ( Cho, CW; Lee, BH; Lee, DS; Yun, SS, 2019)
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu."1.51Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019)
"5-Fluorouracil (5-FU) is a widely used antitumor drug."1.51Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019)
"We reported a patient survived more than 7years after undergoing hepatectomy accompanied by tumor thrombectomy in the main trunk of the portal vein after preoperative hepatic arterial chemotherapy for hepatocellular carcinoma combined with tumor thrombus in the main portal vein."1.48[A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein]. ( Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R, 2018)
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity."1.48Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018)
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor."1.48Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap ( Hatano, E; Uemoto, S; Yamamoto, M; Yamaue, H, 2018)
"This study investigated the anti-hepatoma activity of different extracts from A."1.46Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract. ( Cao, YZ; Chen, JW; Chen, Y; Chen, YY; Li, FQ; Li, X; Lu, JH; Peng, CX; Zhu, XL, 2017)
"Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression."1.46A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017)
" In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)."1.46Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017)
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties."1.43Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016)
"The treatment efficacy of unresectable hepatocellular carcinoma (HCC) is still not promising."1.43Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. ( Bao, Y; Dai, Y; Dong, X; Feng, W; Shen, J; Tang, C; Zhang, J; Zheng, Y, 2016)
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer."1.43Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016)
"Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%."1.43Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016)
"BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every year, especially in Asia."1.43Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. ( He, B; Hu, X; Liu, J; Liu, S; Wang, H, 2016)
"Dioscin is a natural steroid saponin that presents in various plants."1.43Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016)
"Liver cancer is one of the most drug-resistant cancer types, and cancer stem cells are related to drug resistance."1.42JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. ( Ahn, YH; Jee, HG; Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, JH; Lee, M; Park, SY; Yoon, JH; Yu, SJ, 2015)
"A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007."1.42Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. ( Dvorak, J; Ferko, A; Kamaradova, K; Krajina, A; Melichar, B, 2015)
"The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0."1.42Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015)
"To investigate the cooperative effect of Bifidobacteria lipoteichoic acid (BLTA) combined with 5-fluorouracil on tumor cells growth and apoptosis in mice bearing H22."1.42Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. ( Guo, B; Wang, Y; Xie, N, 2015)
" The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients."1.42Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015)
"Nineteen hepatic cancer cell lines, 50 cases of adjacent tissue and 149 cases of HCC samples were employed."1.42Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. ( Brock, MV; Guo, M; Herman, JG; Li, X; Liang, P; Tao, Q; Yu, J, 2015)
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence."1.42MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015)
" Compared with either agent alone, a low dose of Dox combined with eAFP-VISA-BikDD induced better antitumor effect and prolonged longer survival of mice in two orthotopic liver cancer xenograft models."1.42Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. ( Chen, HY; Dai, HY; Hung, MC; Lai, WC; Li, LY, 2015)
"Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma."1.42Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. ( Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015)
"Luteolin may inhibit tumor angiogenesis and tumor cell proliferation by down-regulation of LFA- 3 and PCNA and up-regulation of ICAM-1 in tumor tissue of tumor-bearing mice, thereby achieving its anti-tumor effect."1.42Effect of luteolin on gene expression in mouse H22 hepatoma cells. ( Bao, LD; Gan, HM; Guo, HP; Niu, JX; Ren, JJ, 2015)
"HUVEC and human hepatoma cells (MHCC97H) were cultured, respectively, and then the MHCC97H cells were co-cultured with conditioned medium from HUVEC (EC-CM) with Transwell system."1.42[Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells]. ( Feng, C; Luo, Q; Song, G; Sun, J; Yang, X, 2015)
"Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability."1.40Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014)
" This study aimed to improve the bioavailability of TFU by preparing TFU-loaded lipid-based nanosuspensions (TFU-LNS) and perform a preclinical evaluation."1.40Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice. ( Li, M; Liu, Y; Liu, Z; Wang, L; Zhang, J; Zhang, N, 2014)
" A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer."1.40Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. ( Cai, H; Chen, YR; Guo, TK; He, J; Li, W; Yang, XJ; Yuan, Y, 2014)
"Irinotecan (CPT-11) was used as a chemotherapeutic agent in 24 patients, gemcitabine (GEM) in 24 and doxorubicin in 59."1.40Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY, 2014)
"To observe the antitumor effect of Stihopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells, and study the mechanism."1.40[Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells]. ( Chen, D; Dai, H; Song, Y, 2014)
" Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared."1.40Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. ( Li, X; Luo, X; Tsauo, J; Wang, X; Wang, Z; Zhang, H; Zhao, H, 2014)
"For locally unresectable hepatocellular carcinoma (HCC) patients, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment."1.40Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. ( Choi, JS; Han, KH; Kim, JK; Kim, JW; Kim, KS; Lee, IJ; Park, YN; Seong, J, 2014)
"To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism."1.40[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014)
"The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection."1.39Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013)
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor."1.39Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013)
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor."1.39PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013)
"The growth of H22 hepatoma transplantation tumor was inhibited more obviously in the combination group and the 5-Fu group than in the control group (P <0."1.39[Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma]. ( Jia, Q; Wang, ZP; Wang, ZX; Wu, LC; Zhang, WD; Zhang, YY; Zheng, AH, 2013)
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma."1.39Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013)
"Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port."1.39Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013)
"Here, we used the chitosan and hepatoma cell-specific binding molecule, glycyrrhetinic acid (GA), to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS)."1.39Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. ( Chen, H; Cheng, M; Gao, X; Han, J; He, B; Li, Y; Wang, Y; Xu, H; Zhang, Z, 2013)
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor."1.39Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013)
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection."1.39Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013)
"A 44-year-old man with advanced hepatocellular carcinoma (HCC) was admitted to our institution."1.39[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk]. ( Kanbara, Y; Tai, K; Terai, S, 2013)
"Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy."1.39Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013)
"The only drug that improves survival in hepatocellular carcinoma is sorafenib."1.38Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012)
"The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option."1.38Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012)
"Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy."1.38Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012)
"To investigate the therapeutic efficacy of lipoteichoic acid of Bifidobacterium (BLTA) in combination with 5-fluorouracil (5-FU) treatment on the mice bearing inoculated hepatoma-22 (H(22)) cells and the effects of BLTA on immunological regulation of organism, and explore its mechanisms."1.38Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression. ( Guo, B; Li, FR; Wang, Q; Wang, Y; Xie, N, 2012)
"5-fluorouracil (5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir."1.38Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? ( Fujita, K; Imajo, K; Kato, S; Kirikoshi, H; Kobayashi, N; Kubota, K; Maeda, S; Mawatari, H; Nakajima, A; Saito, S; Suzuki, K; Yoneda, M, 2012)
"Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels."1.38Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012)
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice."1.38Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012)
"Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups."1.38Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012)
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy."1.38Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012)
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU."1.385-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012)
"The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes."1.38How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012)
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC."1.38Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."1.38[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain."1.37Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011)
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus."1.37Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011)
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL."1.37Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011)
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil."1.37Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011)
" A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity."1.37Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. ( Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011)
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways."1.36Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010)
"Established human hepatocellular carcinoma adriamycin (ADM) multi-drug resistant cell sub-lines models Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS by three methods of in vitro concentration gradient increased induction, nude mice liver-implanted induction and subcutaneous-implanted induction respectively."1.36Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. ( Gong, R; Meng, X; Xiong, M; Zhong, X, 2010)
"5-fluorouracil was used as a positive control."1.36Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010)
"To observe the effects of the anti-liver cancer pharmacodynamic action of the Rougan Jiedu formula through the experiments of inhibiting cell proliferation of the tumour cell in vitro."1.35[The study of Rougan Jiedu formula anti-liver cancer in vivtro]. ( Li, H; Wu, CJ, 2008)
"Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed."1.35Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. ( Codecà, C; Di Maria, G; Fazio, N; Ferrari, D; Fiore, J; Foa, P; Luciani, A; Maggioni, M; Oldani, S, 2008)
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)."1.35Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008)
"Tree 1-7 on human hepatoma cell line HepG2 cultured in vitro."1.35[Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2]. ( Cai, XL; Gao, JP; Li, Q; Lin, YC; She, ZG; Wen, L, 2008)
" The life prolongation rate, toxic reactions of chemotherapy, WBC count, the body weight, tumor weight, thymus index and spleen index, and phagocytic function of intra-abdominal macrophages were investigated in the H22 tumor-bearing mice."1.35The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice. ( Dai, Z; Diao, Y; Ji, Z; Kang, H; Liu, L; Liu, X; Wang, X, 2008)
"There were upper gastrointestinal hemorrhage in 3 cases, hepatic failure in 4, pulmonary embolism in 1, cholecystitis in 4, hepatic encephalopathy in 2, gastric perforation in 1, and intrahepatic biloma in 2 cases."1.35[Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. ( Feng, B; Liang, SN; Liu, LL; Su, HY; Xu, K; Zhao, GS, 2008)
" Transcatheter arterial chemoembolization is a standard treatment option for patients with unresectable HCC, especially when combined with other therapies."1.35A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. ( Liu, J; Sui, J; Tian, G, 2009)
"Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18."1.35[Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009)
"To determine the influence of HBx gene RNA interference combined with chemotherapy on stable hepatocellular carcinoma cells growth and its apoptosis mechanism."1.35[Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells]. ( He, X; He, Y; Lei, J; Sun, H; Wang, W, 2009)
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options."1.35Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009)
"To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE)."1.35[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. ( Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009)
"A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT."1.35[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009)
"However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear."1.35Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008)
"We developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter to investigate the biological efficacy of Flt3L in combination with chemotherapeutical drug, 5-FU, in eliciting an effective anti-cancer immunity in mouse hepatoma and colon cancer model systems."1.34Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. ( Dai, J; Fan, X; Guo, Y; Hou, S; Kou, G; Li, B; Li, J; Lin, B; Ma, J; Qian, W; Wang, H; Wu, M; Zhang, D; Zhao, J, 2007)
"Two different hepatoma cell lines were incubated for 48h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy."1.34Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. ( Arce, F; Brenes, O; Díaz, C; Gätjens-Boniche, O, 2007)
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC."1.34Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007)
"Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF)."1.34[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]. ( Fan, XY; Iwaki, K; Kai, S; Kitano, S; Ohta, M; Shibata, K; Uchida, H, 2007)
"A non-invasive orthotopic hepatocellular carcinoma (HCC) model was created with human HCC cells (HepG-Luc) constitutively expressing luciferase (Luc) in nude mice."1.34Bioluminescent imaging of hepatocellular carcinoma in live mice. ( Peng, J; Sun, Z; Wang, Y; Zhan, L, 2007)
"Case 1 was a 71-year-old woman with a hepatocellular carcinoma (HCC), 45 mm in diameter, with liver cirrhosis."1.34[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. ( Hirashita, T; Nakashima, K; Sakai, I; Sakai, M, 2007)
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy."1.34Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007)
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2."1.34Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007)
"The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor."1.33Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. ( Aoyama, K; Ishikawa, T; Kawaguchi, K; Kimura, T; Kurokawa, F; Okita, K; Omori, K; Sakaida, I; Tajima, K; Takami, T; Terai, S; Tsuchiya, M; Yamasaki, T; Yokoyama, Y, 2005)
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor."1.33[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005)
"A 72-year-old man who had multiple hepatocellular carcinoma underwent eight times intrahepatic arterial chemotherapies of SMANCS and two times percutaneous ethanol injection (PEIT) therapies over three years, but new diffuse lesions appeared in the liver."1.33[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU]. ( Arima, T; Horino, K; Inoue, M; Kimura, M; Kuhara, H; Nishimura, T; Uemura, K; Yamada, K, 2005)
"Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory."1.33The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005)
"An in situ human hepatocellular carcinoma model was established in mice livers orthotopically."1.33Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005)
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation."1.335-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005)
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected."1.33Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005)
"While 5-Fu causes mainly apoptosis in hepatoma cells, the anticancer mechanism of paclitaxel is predominantly through induction of necrosis."1.33[Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study]. ( He, JB; Ji, MF; Li, XL; Yu, YL, 2005)
"Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis."1.335-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005)
"Diffused hepatoma was involved in the posterior lobe, and tumor thrombus extended into the main portal vein (Vp4)."1.33[A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)]. ( Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, N; Hasuike, Y; Hayashi, N; Izumiyama, K; Kida, H; Koshino, T; Sakita, I; Tsujie, M; Yoshida, T, 2005)
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33."1.33[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005)
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis."1.33[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006)
" 3DCRT was given with the field covering the tumor with a generous margin."1.33[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma]. ( Chen, Z; Cheng, WW; Jiang, GL; Lin, JH; Liu, LM; Meng, ZQ; Zhang, XJ; Zhou, ZH, 2006)
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal."1.33[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006)
"Recently, we reported the beneficial effects of intra arterial 5-FU infusion chemotherapy combined with interferon-alpha (IFN-alpha/5-FU combined chemotherapy) for advanced hepatocellular carcinoma (HCC)."1.33[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H, 2006)
"We report a case of advanced hepatocellular carcinoma (HCC)."1.33[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL]. ( Amano, M; Fujita, M; Hayashida, H; Higaki, N; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M; Yamashita, S, 2006)
"A syngeneic rat model of hepatocellular carcinoma was used."1.32[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003)
"The prognosis of advanced hepatocellular carcinoma remains poor."1.32Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2003)
"Human hepatoma HepG2 cells were treated with 5-Fu at the concentrations of 1X10(-1), 1X10(-2), 1X10(-3), 1X10(-4), 1X10(-5) mol/L and for 1, 2, 4, 8, 16, 24 hours, respectively."1.32Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil. ( Yang, LY; Yi, TB, 2003)
"Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy."1.32[Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy]. ( Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kitamura, S; Masuda, F; Masutani, S; Obana, T; Ohnishi, H; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M, 2003)
"The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor."1.32[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha]. ( Danno, M; Dono, K; Hatanaka, T; Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Monden, M; Nagano, H; Nakamori, S; Naoi, Y; Ohshima, S; Sakon, M; Tsujie, M; Umeshita, K; Yamamoto, H, 2003)
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used."1.32The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004)
"5-fluorouracil (5-FU) that has no carbonyl group was used as control."1.32[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)]. ( Cao, DL; Tang, DN; Wang, J; Yang, XD, 2003)
"To study the anti-tumor effect of resveratrol and in combination with 5-FU on murine liver cancer."1.32Effect of resveratrol and in combination with 5-FU on murine liver cancer. ( Meng, KW; Pan, CE; Qin, XL; Sun, ZJ; Wu, SL; Yu, L, 2004)
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein."1.32Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004)
"To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence."1.32[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004)
" The sensitivity of H22 cells to 5-FU can be markedly enhanced: The IC(50) dosage of 5-Fu can be decreased from 0."1.31The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo. ( Li, Z; Liu, J; Qi, S; Wang, T; Zhang, J; Zhu, H, 2002)
"Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)."1.31[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002)
"The prognosis of patients with advanced hepatoma is grim."1.31Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. ( Goto, T; Hoshida, Y; Kato, N; Moriyama, M; Omata, M; Otsuka, M; Seki, N; Shiratori, Y; Taniguchi, H, 2002)
"A case of hepatocellular carcinoma (HCC) complicated by tumor thrombosis of the main trunk is presented."1.31Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2000)
"Capecitabine may inhibit the growth and metastasis of HCC."1.31[The expression of platelet-derived endothelial cell growth factor in liver cancer]. ( Fan, J; Tang, Z; Zhou, J, 2000)
"We reported a case of hepatocellular carcinoma (HCC) with multiple lymph node metastases."1.31[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases]. ( Beppu, T; Fujiyama, S; Hirota, M; Ishiko, T; Ishiodori, H; Matsuda, T; Ogawa, M; Omuraya, M; Yamashita, Y, 2001)
"Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary."1.31Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002)
"If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD."1.31Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002)
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor."1.31Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002)
"For 6 patients with advanced hepatocellular carcinoma (HCC) in whom TAE was inefficacious, we tried hepatic arterial infusion chemotherapy."1.30[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)]. ( Aoyama, H; Asano, T; Fukunaga, T; Isono, K; Iwasaki, K; Kenmochi, T; Kobayashi, S; Kouno, T; Matsuzaki, H; Nakagouri, S; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1998)
"Five different human hepatoma cell lines, Hep G2, Hep G2."1.30Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. ( Jiang, S; Kim, SJ; Lee, MO; Park, JH; Shin, EC; Song, MJ, 1999)
"The innate drug resistance of human hepatocellular carcinoma (HCC) Bel7402 cell line was studied in vitro."1.30The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. ( Huang, M; Liu, G, 1999)
"AFP gene expression in human hepatoma cells was determined by avidin-biotin-peroxidase complex (ABC) immunocytochemical method."1.30Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth. ( Wang, X; Xie, H; Zhang, R, 1999)
"Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy."1.29[Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994)
"A-68-year-old man had hepatocellular carcinoma (HCC) in the area of S6 segment which was resected surgically."1.29[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer]. ( Fukuzawa, Y; Ikeda, H; Kato, K; Murata, K; Sawada, T; Tagaya, T; Takahashi, K; Takiya, S, 1996)
"In seven patients with advanced primary hepatocellular carcinoma the same therapeutic regime was used."1.28Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma. ( Cuan-Orozco, F; Kalk, JF; Koussouris, P; Mercado, MA; Paquet, KJ; Siemens, F, 1992)
" After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990."1.28[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992)
"Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma."1.28[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992)
"Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery."1.28[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report]. ( Gotoda, A; Kamiyama, T; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Saito, M; Sato, N; Uchino, J; Une, Y, 1991)
"Chemosensitivity of hepatocellular carcinoma tissues from 72 patients to 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test."1.28Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. ( Akazawa, K; Kanematsu, T; Maehara, Y; Matsumata, T; Shirabe, K; Sugimachi, K, 1991)
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)."1.28[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990)
" Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma."1.28[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990)
"Two patients had primary hepatocellular cancer (HCC)."1.28Repeated dearterialization of hepatic tumors with an implantable occluder. ( Bengmark, S; Ekberg, H; Jeppsson, B; Lundstedt, C; Persson, BG; Tranberg, KG, 1990)
"Human hepatoma and melanoma tumor cells and normal melanocytes, keratinocytes, and fibroblasts were incubated for 2, 24, and 48 h with graded concentrations of cis-platinum (0."1.28Rapid chemosensitivity assay with human normal and tumor cells in vitro. ( Babich, H; Borenfreund, E; Martin-Alguacil, N, 1990)
"Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy."1.28[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children]. ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989)
"In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia."1.28[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro]. ( Fujise, K; Hasumura, S; Homma, S; Kameda, H; Matsuura, T; Nagamori, S; Niiya, M; Shimizu, K; Sujino, H, 1989)
"Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks."1.28[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989)
"In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy."1.28[Hepatic arterial infusion chemotherapy of hepatocellular carcinoma]. ( Amioka, K; Hara, H; Iga, C; Ishibashi, T; Isozaki, H; Morita, S; Nakata, E; Nishimura, J; Okajima, K; Tanimura, M, 1989)
"Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease."1.28[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1989)
"Nineteen patients with primary hepatocellular carcinoma (7 were at Stage III and 11 were at Stage IV) and 14 patients with metastatic liver tumors (4 were at H2 and 9 were at H3 stages) received this newly developed anticancer methodology."1.28[The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer]. ( Naito, A; Nakase, A; Tamura, K; Tarumi, T; Yamamoto, T; Yano, S, 1989)
"A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments."1.27Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984)
"Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin."1.27[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984)
"Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response."1.27Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983)
"A 9-year-old boy with non-resectable hepatocellular carcinoma was treated with irradiation and intra-hepatic arterial infusion of antitumor agents."1.27[HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery]. ( Hamawaki, M; Ito, Y; Iwata, K; Kikkawa, K; Kubonishi, S; Kuroiwa, Y; Matsuoka, K; Ohmura, T; Okano, K, 1983)
"Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz."1.27[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985)
"Thirty-two patients with inoperable hepatic cancer underwent intra-arterial hepatic infusion using mitomycin C (MMC) and 5-fluorouracil (5-FU) or intra-arterial hepatic chemoembolization using heated albumin microspheres containing MMC with an average diameter 45 +/- 8 micron."1.27Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. ( Endoh, F; Fujimoto, S; Miyazaki, M; Morimoto, Y; Okui, K; Takahashi, O, 1985)
"Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU)."1.27Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J, 1988)
"5-fluorouracil was effective only in patients without cirrhosis, with an overall response rate of 22%."1.27Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. ( Audisio, R; Bignami, P; Bonfanti, G; Bozzetti, F; Colombo, M; Doci, R; Gennari, L, 1988)
"Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%."1.27[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1988)
"A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage."1.27Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985)
"All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls."1.27Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985)
"407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy."1.27[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985)
"Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil."1.27Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985)
"5-Fluorouracil was injected by a fine needle under ultrasound guidance."1.27Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance. ( Livraghi, T; Ravetto, C; Solbiati, L; Suter, F, 1986)
"A 69-year-old man with a large hepatoma of the right lobe extending in part to the medial segment of the left lobe was treated by ligation of the right hepatic artery combined with continuous infusion of a total dose of 5500 mg og 5-fluorouracil (5-FU) into the left hepatic artery."1.26A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival. ( Hiraoka, T; Konno, T; Nakakuma, K; Tashiro, S; Yokoyama, I, 1981)
"5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma."1.26Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982)
"One patient with hepatocellular carcinoma had compete disappearance of all disease with chemotherapy alone."1.26Preoperative chemotherapy for unresectable primary hepatic malignancies in children. ( Siegel, MM; Siegel, SE; Stanley, P; Weinblatt, ME; Weitzman, JJ, 1982)
"N1-S1/FdUrd Novikoff hepatoma cells, which lack thymidine kinase activity, are resistant to 5-fluorouracil (FUra) as well as 5-fluorodeoxyuridine (FdUrd), suggesting that the pathway, FUra leads to FdUrd leads to FdUMP, is utilized for the conversion of FUra to FdUMP."1.26Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. ( Crumley, J; Wilkinson, DS, 1977)
" Maintenance therapy was carried out by the administration of these drugs at induction dosage alternated each week as a single 24 hourly intravenous infusion."1.26Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. ( Das, B; Jaiswal, MS; Misra, NC; Singh, RV, 1977)
"Oral fluorouracil was administered weekly to 12 consecutive patients with unresectable hepatoma."1.26Oral fluorouracil therapy of hepatoma. ( Kennedy, PS; Lane, M; Lehane, DE; Smith, FE, 1977)
"The podophyllotoxin derivative VP 16-213 was used as monotherapy in 6 patients and combined with 5-fluorouracil in another 6."1.26[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)]. ( Brunner, KW; Cavalli, F; Gerber, A; Ryssel, HJ; Sonntag, RW; Tschopp, L, 1977)
" Comparison of the effects of single vs fractionated dosage was made on 2 types of experimental solid tumour with different growth, cell kinetic, histological and metastasizing properties."1.26Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. ( Hopkins, HA; Looney, WB; Macleod, MS, 1978)
"A case of hepatocellular carcinoma in a young female is presented in which the apparent etiology was the use of oral contraceptives for 5 1/2 years."1.26Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. ( Gattanell, PN; Holland, JF; Perloff, M, 1978)
"A 45-year-old man with hepatocellular carcinoma who developed intravascular coagulation following complete tumor regression by chemotherapy is described."1.26Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report. ( Harada, T; Makisaka, Y; Nishimura, H; Okuda, K, 1978)
"A case of hepatocellular carcinoma associated with erythrocytosis is described."1.26Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy. ( Arima, M; Hattori, N; Kimura, K; Okazaki, N; Ozaki, H, 1979)
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma."1.26Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979)
"Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts."1.25Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975)

Research

Studies (1,089)

TimeframeStudies, this research(%)All Research%
pre-1990211 (19.38)18.7374
1990's115 (10.56)18.2507
2000's294 (27.00)29.6817
2010's369 (33.88)24.3611
2020's100 (9.18)2.80

Authors

AuthorsStudies
El-Far, M1
Elmegeed, GA1
Eskander, EF1
Rady, HM1
Tantawy, MA1
Tuncbilek, M1
Guven, EB1
Onder, T1
Cetin Atalay, R1
Yu, HY1
Zhang, XQ1
Li, X16
Zeng, FB1
Ruan, HL1
Fu, J1
Liu, L10
Huang, Z2
Lai, Y1
Ji, H1
Peng, S1
Tian, J2
Zhang, Y20
Dai, M2
Yuan, X2
Kang, J1
Zhu, ZJ2
Yue, RC1
Yuan, H1
Chen, BY1
Zhang, WD3
Liu, RH2
Sun, QY2
Zhang, H13
Zhu, P1
Liu, J15
Yang, X11
Xu, S1
Yao, H1
Jiang, J2
Ye, W2
Wu, X9
Xu, J3
Shaaban, S2
Negm, A2
Ashmawy, AM2
Ahmed, DM1
Wessjohann, LA2
Bai, ZT1
Wu, ZR1
Xi, LL1
Chen, P2
Wang, FQ1
Meng, WB1
Zhou, WC1
Wu, XA1
Yao, XJ1
Zhang, M5
Tian, JL1
Yao, GD1
Wang, YX2
Gao, PY1
Wang, D2
Li, LZ1
Lin, B2
Huang, XX1
Song, SJ1
Hawash, MM1
Kahraman, DC1
Eren, F1
Cetin Atalay, R1
Baytas, SN1
Zhang, B4
Wang, N4
Zhang, C5
Gao, C1
Zhang, W8
Chen, K5
Wu, W4
Chen, Y12
Tan, C1
Liu, F4
Jiang, Y2
Zhang, L8
Zheng, C1
Wang, Y22
Nie, X1
Shi, D1
Wei, G1
Wang, J19
Chen, YY2
Cao, YZ1
Li, FQ1
Zhu, XL1
Peng, CX1
Lu, JH1
Chen, JW2
Ling, Y1
Gao, WJ1
Ling, C1
Meng, C1
Qian, J1
Liu, S8
Gan, H1
Wu, H1
Tao, J1
Dai, H2
Ding, Y2
Li, S9
Ge, W1
Liu, Z11
Zhang, X12
Wang, M2
Chen, T1
Zhang, Q4
Qiu, J2
Zhou, Q4
Guan, M1
Zou, Y3
Huang, X4
Zhao, Y6
Chen, W4
Gu, X1
Tawfik, HO1
Petreni, A1
Supuran, CT1
El-Hamamsy, MH1
Yue, K1
Hou, X2
Jia, G1
Zhang, J22
Tan, L1
Wang, X14
Zhang, Z8
Li, P1
Xu, W2
Suzuki, H2
Niizeki, T6
Shirono, T3
Koteda, Y1
Kinjyo, Y1
Mizukami, N2
Koda, M1
Ota, S1
Nakano, M4
Okamura, S3
Iwamoto, H8
Shimose, S4
Noda, Y2
Kamachi, N2
Kajiwara, A1
Suda, K1
Akiba, J1
Yano, H5
Kuromatsu, R5
Koga, H4
Torimura, T6
Pan, Y4
Mei, J4
Chen, J6
Zhang, D5
Yi, M1
Zhou, Z4
Chen, M8
Guo, R7
Xu, L10
Chen, S5
Xu, B1
Wu, Z4
Wang, P3
Yu, W2
Wu, Y4
Li, T3
Guo, W3
Zhu, J3
Sidaway, P2
Lyu, N5
Li, JB3
Lai, JF1
Chen, QF1
Li, SL2
Deng, HJ1
He, M7
Mu, LW1
Zhao, M6
Yu, H2
Qin, L2
Jia, Z1
Ni, C1
Feng, GY1
Cheng, Y4
Shi, ZR1
Hou, Z2
Jin, Z1
Qiu, G1
Xie, Q3
Mi, S1
Huang, J5
Ishii, M1
Itano, O1
Hibi, T1
Itano, S4
Pu, Y2
Yan, D4
Tu, L2
Cheng, L4
Yu, J11
Li, Z11
Zheng, X3
Sütcüoğlu, O1
Ulaş Kahya, B1
Özdemir, N1
Yazıcı, O1
Liu, N1
Wang, Q8
Hu, J1
Yang, A1
Wu, Q2
Chen, Q2
Yang, J8
Li, H10
Tao, Y2
Wang, A1
Sun, Y6
Ouyang, H1
He, D1
Liu, D4
Chen, H9
Pan, W1
Li, Q16
Xie, W1
Yu, C2
Kang, S1
Magliocca, J1
Sellers, M1
Roccaro, G1
Zheng, W1
Pectasides, M1
Draper, A1
Guadagno, J1
El-Rayes, B1
Akce, M2
Guo, J3
Huang, L2
Komarov, IV1
Tolstanova, G1
Kuznietsova, H1
Dziubenko, N1
Yanchuk, PI1
Shtanova, LY1
Veselsky, SP1
Garmanchuk, LV1
Khranovska, N1
Gorbach, O1
Dovbynchuk, T1
Borysko, P1
Babii, O1
Schober, T1
Ulrich, AS1
Afonin, S1
Yu, S4
Sathiyaseelan, A1
Saravanakumar, K1
Wang, MH1
Tiu, YC1
Gong, L1
Luo, J1
Yang, Y6
Tang, Y2
Lee, WM1
Guan, XY2
Narita, H1
Kawaratani, H1
Shibamoto, A1
Takeda, S1
Ozutsumi, T1
Tsuji, Y1
Fujinaga, Y1
Kitagawa, K1
Nishimura, N1
Hokuto, D1
Sho, M1
Yoshiji, H2
Lai, Z3
Bu, X3
Xu, Y1
Huang, Y4
Wen, D3
Wei, W5
Kan, A3
Shi, M10
Liu, X2
Liu, Q3
Bao, X1
Oranratnachai, S1
Rattanasiri, S1
Sirachainan, E1
Tansawet, A1
Raunroadroong, N1
McKay, GJ1
Attia, J1
Thakkinstian, A1
Sun, J7
Liu, C12
Shi, J3
Jiang, D2
Mao, F2
Gu, J3
Zhou, L2
Shen, L2
Lau, WY5
Cheng, S3
Huang, P1
Zhou, Y8
Yang, G1
Sun, Q1
Shi, G1
Liu, Y16
Qiao, Y1
Zhou, M4
Lin, Y4
Li, W4
An, C1
Li, C4
Xue, L1
He, J2
Ren, C1
Fu, X1
Lin, X3
Li, SH2
Wang, QX2
Fang, CK2
Lei, QC2
Huang, HK2
Cao, MR2
Luo, R2
Deng, JD2
Jiang, YC2
Zhao, RC2
Lu, LH2
Zou, JW2
Deng, M3
Lin, WP2
Guan, RG2
Wen, YH2
Zheng, L4
Guo, ZX2
Ling, YH2
Chen, HW2
Zhong, C2
Guo, RP2
Kawaguchi, T1
MasodKhooy, MJ1
Farasat, M1
Salehi Salmi, M1
Mirzaei, H1
Abdel-Hamid, NM2
ElNakeeb, NA1
El-Senduny, FF1
Fu, Y1
Peng, W1
Yang, Z5
Hu, Z3
Pang, Y1
Hu, D1
Du, Z1
Shen, J4
Yang, F4
Min, Y1
Shi, L5
Liu, M3
Wang, K5
Ke, S1
Gong, Y1
Lin, ZP1
Hu, XL1
Chen, D5
Zou, XG1
Zhong, H1
Xu, SX1
Li, XQ1
Huang, DB1
Shao, H1
Li, A1
Ma, L2
Zhang, K1
Gao, W1
Si, T1
Zou, Q1
Guo, Z1
Li, M5
Mu, H1
Xing, W1
Ji, S1
Xu, M2
Cai, C1
He, X3
Shi, Y5
Ma, J5
Chen, KE1
Chen, B2
Liang, H5
Lu, Y2
Yang, C2
Hamaya, S1
Oura, K1
Morishita, A1
Masaki, T3
Zhang, F1
Huo, L1
Brañes, A1
Karanicolas, P1
Asahina, Y2
Takatori, H3
Nio, K3
Okada, H4
Hayashi, T6
Hashiba, T2
Suda, T2
Nishitani, M1
Sugimoto, S1
Honda, M5
Kaneko, S7
Yamashita, T10
Wang, S1
Qiu, Z1
Zhu, C3
Zhao, S2
Qiu, W1
Lv, J2
Qi, W1
Wei, H3
Pan, J2
Chen, Z7
Pan, D1
Gao, T1
Huang, M3
Ou, M1
Zhong, W1
Lee, BH1
Lee, DS1
Cho, CW1
Yun, SS1
Yao, Y1
Fang, Z2
Miao, QR3
Ye, M2
Jin, X2
Li, B6
Wang, C6
Liao, M2
Hu, X5
Yang, M4
Varshosaz, J2
Fard, MM1
Mirian, M1
Hassanzadeh, F2
Li, F1
Wu, N1
Wei, N1
Wen, X1
Ling, S2
Shan, Q1
Liu, P2
Wei, X3
Ding, W1
Teng, X1
Xu, X4
Palmieri, LJ1
Dermine, S1
Coriat, R2
Kumar, P1
Agarwal, A1
Singh, AK1
Gautam, AK1
Chakraborti, S1
Kumar, U1
Kumar, D1
Bhattacharya, B1
Panda, P1
Saha, B1
Qidwai, T1
Maity, B1
Saha, S1
Wang, Z9
Gu, C1
Lang, Y1
Zhu, X2
Yang, H1
Ma, X3
Qiu, Y2
Zhu, L2
Ma, D1
Qin, Z1
Sun, C1
Shen, X1
Han, L1
Fang, X1
Shen, A1
Sun, R2
Dong, C4
Li, R4
Chu, H1
Hao, D1
Zhao, B2
Wang, L16
Alanazi, SA2
Harisa, GI3
Badran, MM3
Haq, N1
Radwan, AA1
Kumar, A2
Shakeel, F1
Alanazi, FK3
Hori, A1
Ohira, R1
Nakamura, T3
Kimura, Y3
Ueda, S3
Torii, M1
Kennoki, N1
Hori, S2
Terashima, T3
Toyama, T1
Shimakami, T1
Shimizu, R1
Arai, K3
Kawaguchi, K2
Kitamura, K1
Sakai, Y1
Mizukoshi, E2
Mao, J1
Ding, J1
Wang, G3
Xiang, DC1
Yang, JY1
Xu, YJ1
Zhang, S5
Zhang, CL1
Cao, W3
Noordam, L1
Verstegen, MMA1
Ma, B3
Wang, W7
Bolkestein, M1
Doukas, M1
Ma, Z1
Bruno, M1
Sprengers, D1
Kwekkeboom, J1
van der Laan, LJW1
Smits, R1
Peppelenbosch, MP1
Pan, Q2
Jiang, K1
Yin, Z1
Ding, H3
Shigesawa, T1
Maehara, O2
Suda, G2
Natsuizaka, M2
Kimura, M4
Shimazaki, T1
Yamamoto, K7
Yamada, R2
Kitagataya, T1
Nakamura, A1
Suzuki, K8
Ohara, M1
Kawagishi, N1
Umemura, M1
Nakai, M3
Sho, T2
Morikawa, K1
Ogawa, K3
Ohnishi, S2
Sugiyama, M1
Mizokami, M1
Takeda, H3
Sakamoto, N2
Owen, D1
Lukovic, J1
Hosni, A1
Crane, CH1
Hong, TS1
Dawson, LA1
Velec, M1
Lawrence, TS2
Jia, Y2
Peng, L1
Xiang, Y1
Huang, W3
Huang, C10
Long, J1
Tang, S2
He, DX3
Tan, XW2
Yu, CY3
Basu, A1
Dydowiczová, A1
Trosko, JE1
Bláha, L1
Babica, P1
Goto, Y1
Hisaka, T2
Sakai, H1
Takagi, K1
Fukutomi, S1
Akagi, Y1
Okuda, K10
Song, X1
He, Y5
Han, M1
Shao, Z1
Kobayashi, K6
Higai, K1
Mukozu, T3
Matsui, D3
Amanuma, M1
Yoshimine, N1
Ogino, Y1
Matsui, T5
Wakui, N4
Shinohara, M3
Momiyama, K7
Daido, Y1
Nagai, H11
Igarashi, Y5
Liu, KC1
Hao, YH1
Lv, WF1
Jia, WD1
Ji, CS1
Zhou, CZ1
Cheng, DL1
Xu, SB1
Gao, ZG1
Su, MX1
Shi, CS1
Jilek, JL1
Tu, MJ1
Yu, AM1
Xu, D2
Wu, J4
Xie, M1
Tang, R1
Cheng, C1
Chen, L4
Lin, S1
Luo, X5
Zheng, J2
Changou, CA1
Shiah, HS1
Chen, LT1
Luh, F1
Liu, SH2
Cheng, YC2
Yen, Y2
Yu, Z1
Sun, D5
Bhat, SS1
Mukherjee, D1
Sukharamwala, P1
Dehuri, R1
Murali, A1
Teja, BV1
Mei, N1
Zhao, N2
Tian, T2
Jiao, M1
Ding, WB1
Ning, Q3
Xia, Z1
Song, J3
Zhou, XW1
Chen, XW1
Zhu, Y1
Ke, KB1
Xia, ZK1
Li, HJ1
Su, R3
Zhou, FM1
Chen, R2
Wu, SG1
Zhao, H2
Gu, P1
Leung, KS1
Wong, MH1
Lu, G1
Zhang, JY1
Jiang, BH1
Qiu, JG1
Shi, XN1
Lin, MC1
Hu, B1
Sun, YF1
Huang, XW2
Cheng, JW1
Huang, A1
Zeng, HY1
Qiu, SJ1
Cao, Y1
Fan, J9
Zhou, J9
Yang, XR1
Hsu, SJ1
Chen, MP1
Zhao, ZY1
Yin, X2
Ge, NL4
Wang, YH3
Luo, JF1
Ren, ZG4
Chen, RX2
Elzayat, E1
Alomrani, AH1
Al Meanazel, OT1
Al Meanazel, AT1
Gottlieb, S1
O'Grady, C1
Gliksberg, A1
Kent, P1
Zhu, Q1
Hu, H2
Zhu, H4
Yang, B3
He, Q1
Yu, L4
Zeng, S2
Han, S1
Choi, HJ2
Beom, SH1
Kim, HR3
Lee, H1
Lee, JS1
Lee, HW3
Park, JY13
Kim, SU6
Kim, DY10
Ahn, SH11
Han, KH16
Seong, J10
Won, JY2
Kim, BK5
Qin, S5
Ren, Z4
Xiong, J1
Meng, Z1
Zou, J1
Cao, J2
Gui, S1
Chu, X1
Han, X1
Li, J16
Lai, J1
Deng, H4
Wang, H10
Hu, Y3
Zhao, Z2
Xie, Y3
Liu, H1
Jin, M1
Kong, L2
Han, Y1
Shiohira, H1
Fukunaga, K2
Tayag, JCS1
Tamashiro, Y1
Mushiroda, T1
Nakamura, K5
Harding, JJ2
Yang, TS5
Feng, YH2
Yen, CJ1
Ho, CL1
Huang, WT2
El Dika, I1
Tan, B1
Cohen, SA1
Meyer, T3
Sarker, D1
Lee, DW1
Ryoo, BY1
Lim, HY3
Johnston, A2
Bomalaski, JS1
O'Reilly, EM2
Abou-Alfa, GK2
Nagamatsu, H4
Ogo, E1
Ikeda, M7
Okusaka, T5
Sato, Y5
Furuse, J2
Mitsunaga, S1
Ueno, H5
Morizane, C4
Inaba, Y1
Kobayashi, T4
Arai, Y2
Nanda, A1
Suyila, Q1
Xian, L1
Xiulan, S1
Grbčić, P1
Tomljanović, I1
Klobučar, M1
Kraljević Pavelić, S1
Lučin, K1
Sedić, M1
Luo, N2
Tian, Y3
Yin, H2
Xiao, C1
Sheng, J1
Li, Y15
Tang, B4
Babaei, M1
Abnous, K1
Taghdisi, SM1
Amel Farzad, S1
Peivandi, MT1
Ramezani, M1
Alibolandi, M1
Yang, S4
Wang, XQ1
Thongkum, A1
Wu, C1
Li, YY1
Wangpaichitr, M1
Navasumrit, P1
Parnlob, V1
Sricharunrat, T1
Bhudhisawasdi, V2
Ruchirawat, M1
Savaraj, N1
Kong, Y4
Mu, L3
Pan, T2
Lin, A1
Wu, P4
Yuan, XF1
Li, ZZ1
Bao, SQ1
Zhang, XL2
Yang, YY1
Fan, DM1
Zhang, YZ1
Wu, CX1
Guo, HX1
Zhang, YJ1
Ye, Z1
Xiong, DS1
Oishi, N1
Sunagozaka, H2
Hara, Y2
Yoshida, M1
Shirasaki, T1
Miyanouchi, K1
Lian, Y1
Gu, L1
Gao, Z6
Lee, EJ1
Yang, SH1
Kim, KJ2
Cha, H1
Lee, SJ3
Kim, JH5
Chun, KH1
Hsiao, JH1
Tsai, CC1
Liang, TJ1
Chiang, CL1
Liang, HL3
Chen, IS1
Chen, YC3
Chang, PM1
Chou, NH1
Wang, BW1
Miyauchi, Y1
Yasuchika, K2
Fukumitsu, K2
Ishii, T2
Ogiso, S2
Minami, T1
Kojima, H1
Yamaoka, R1
Katayama, H2
Kawai, T2
Yoshitoshi-Uebayashi, EY1
Kita, S2
Yasuda, K2
Sasaki, N1
Uemoto, S3
Song, JE1
Jung, KS1
Song, K1
He, C1
Jing, Z1
Xie, J1
Ma, W1
Guo, XL3
Hu, F3
Fang, JM1
Zhu, ZΖ1
Wei, LΧ1
Xu, Q1
Kuramoto, K1
Beppu, T5
Nitta, H2
Imai, K3
Masuda, T2
Miyata, T2
Koga, Y1
Kitano, Y1
Kaida, T1
Nakagawa, S2
Okabe, H2
Hayashi, H5
Hashimoto, D1
Yamashita, YI2
Chikamoto, A3
Kikuchi, K1
Baba, H6
Kodama, K1
Kawaoka, T9
Aikata, H10
Uchikawa, S1
Nishida, Y1
Inagaki, Y2
Hatooka, M4
Morio, K4
Nakahara, T3
Murakami, E3
Tsuge, M2
Hiramatsu, A8
Imamura, M6
Kawakami, Y7
Masaki, K2
Honda, Y3
Mori, N6
Takaki, S8
Tsuji, K5
Kohno, H10
Moriya, T4
Nonaka, M2
Hyogo, H3
Aisaka, Y2
Kimura, T5
Nagata, Y1
Chayama, K10
Cai, X1
Fujisaki, S1
Takashina, M1
Tomita, R1
Sakurai, K3
Takayama, T3
Dong, L3
Bai, C1
Long, H1
Lin, Z1
Duan, B1
Guo, Y5
Zhou, R1
Bie, B1
Ettrich, TJ1
Ebert, M1
Lorenzen, S1
Moehler, M2
Vogel, A1
Witkowski, L1
Seufferlein, T1
Reinacher-Schick, A1
Liu, T1
Lu, W1
Zheng, F2
Long, Q1
Qiu, H1
Ge, Q1
Yu, X1
Luo, M2
Deng, W2
Li, L1
Ji, DG1
Guan, LY1
Ma, F1
Liu, HY1
Jia, QA1
Kadel, D1
Zhang, XF1
Zhang, QB1
Li, JW1
Huang, CZ1
Li, JH2
Yuan, JH1
Chen, QH1
Zhang, WF1
Xu, ZS1
Liu, YP1
Zhan, MX1
Lu, LG1
Ke, M1
Dong, J1
Lv, Y1
Wu, R1
Kobayashi, S15
Shiba, S1
Yoshida, Y4
Yamada, I1
Iwadou, S1
Horiguchi, S2
Takahashi, H4
Suzuki, E2
Moriguchi, M1
Otsuka, T1
Asagi, A1
Kojima, Y2
Takada, R1
Mizuno, N1
Ueno, M1
Awai, K2
Waki, K6
Nagaoki, Y2
Tamura, T1
Amano, H1
Katamura, Y3
Do, RK1
Dika, IE1
Hollywood, E1
Uhlitskykh, K1
Valentino, E1
Wan, P1
Hamilton, C1
Feng, X1
Bomalaski, J1
Li, CF1
Choi, JH1
Chung, WJ5
Bae, SH11
Song, DS3
Song, MJ6
Kim, YS5
Yim, HJ6
Jung, YK1
Suh, SJ2
Cho, SB3
Hatano, E2
Yamaue, H1
Yamamoto, M3
Wu, L4
Pan, C2
R Ebrahim, A1
El-Mesery, M1
El-Karef, A1
Eissa, LA1
Cheng, J1
Qian, D1
Ding, X2
Song, T1
Cai, M1
Zhao, J5
Pang, Q1
Hao, X2
Yuan, Z1
Cui, X1
Zhao, C3
Yao, X4
Qian, B1
Su, C4
Ren, Y1
Yao, Z2
Gao, X3
Ni, W1
Ji, Y2
Sun, S1
Jian, X1
Xiao, X1
Cui, R1
Miao, R1
Dong, Y3
Fan, H1
Ren, L1
Niu, W1
Qu, K2
Liu, YF1
Ye, PJ2
Gao, P2
Li, ZP2
Tang, SY1
Tang, SS2
Xiao, D1
Zhan, P1
AlQahtani, SA1
AlGhamdi, KM1
Salem-Bekhit, MM1
Ahmad, SF1
Byun, HK1
Kim, HJ1
Im, YR1
Imamura, YU1
Fukubayashi, K1
Ishiko, T3
Yao, J2
Pan, Z1
Cui, ZG1
Zakki, SA1
Feng, Q1
Sun, L1
Feril, LB1
Inadera, H1
Liu, XY2
Liu, ZH1
Chai, Z1
Asano, A1
Nakagawa, K3
Kobayashi, M11
Zou, R1
Fang, W1
Tan, G1
Le, Y1
Goyal, L1
Qadan, M1
Zhu, AX2
Burki, TK1
Sung, PS1
Yang, K2
Oh, JS2
Chun, HJ6
Nam, HC1
Jang, JW5
Choi, JY9
Yoon, SK9
Dou, C1
Roberts, L1
Xiao, Z1
Ko, HL1
Goh, EH1
Wang, B3
Ren, EC1
Sakabe, T1
Tsuchiya, H1
Kanki, K1
Azumi, J1
Gonda, K1
Mizuta, Y1
Yamada, D2
Wada, H27
Shomori, K1
Nagano, H45
Shiota, G1
Katsura, Y1
Murakami, M8
Akita, H3
Hama, N2
Kawamoto, K4
Marubashi, S25
Eguchi, H19
Tanemura, M10
Umeshita, K35
Doki, Y16
Mori, M17
Shan, L1
Tan, Y2
Qian, X1
Xia, J2
Wang, R2
Chen, C2
Yang, Q2
Miele, L1
Ran, L1
Fushiya, N1
Takagi, I1
Nishino, H1
Akizuki, S1
Ohnishi, A1
Lin, JJ1
Jiang, XF1
Jin, XJ1
Lu, LJ1
Bao, LW1
Kanekawa, T3
Kanayama, M7
Ishii, K4
Sumino, Y10
El Bouzidi, L1
Mahiou-Leddet, V1
Bun, SS1
Larhsini, M1
Abbad, A1
Markouk, M1
Fathi, M1
Boudon, M1
Ollivier, E1
Bekkouche, K1
Miao, L1
Lv, C1
Sun, H2
Wei, S1
Jiao, B1
Wu, K1
Yan, W1
Hu, L1
Yuan, J2
Jing, K1
Guo, M2
Walter, H1
Thomas, AL1
Kaseb, AO1
Shindoh, J1
Patt, YZ7
Roses, RE1
Zimmitti, G1
Lozano, RD3
Hassan, MM3
Hassabo, HM1
Curley, SA4
Aloia, TA1
Abbruzzese, JL1
Vauthey, JN4
Abdel-Rahman, O1
Abdel-Wahab, M1
Shaker, M1
Abdel-Wahab, S1
Elbassiony, M1
Ellithy, M1
Ahn, JS1
Jeon, JR1
Yoo, HS1
Park, TK1
Park, CK1
Sinn, DH1
Paik, SW1
Zheng, AH1
Wang, ZP3
Wang, ZX1
Wu, LC1
Jia, Q3
Zhang, YY1
Zhao, L6
Sha, YY1
Zhao, Q2
Zhu, BB1
Lu, ZJ1
You, QD2
Guo, QL2
Deng, L1
Shen, H2
He, SL1
Sun, XJ1
Zhu, XJ1
Liu, LM2
Dong, JC1
Lee, SW1
Kim, HY2
Lee, YJ2
Lee, HG1
Sinn, M1
Nicolaou, A1
Ricke, J1
Podrabsky, P1
Seehofer, D1
Gebauer, B1
Pech, M1
Neuhaus, P1
Dörken, B1
Riess, H1
Hildebrandt, B1
Yeh, CT4
Liang, KH3
Lin, CC3
Chang, ML3
Hsu, CL1
Hung, CF1
Bai, Y2
Thongprasert, S1
Chao, Y4
Kang, WK2
Lee, JH4
Jiang, H2
Dong, Q1
Shi, B2
Gao, H1
Kong, J1
Nouso, K3
Miyahara, K2
Uchida, D2
Kuwaki, K5
Izumi, N1
Omata, M5
Ichida, T2
Kudo, M4
Ku, Y3
Kokudo, N1
Sakamoto, M2
Nakashima, O1
Matsui, O2
Matsuyama, Y1
Ma, T1
Lv, X1
Xu, T1
Hu, T2
Li, KC1
Zeng, XY1
Kuang, CX1
Jiang, YB1
Dai, ZY1
Tan-Shalaby, J1
Yoon, EL1
Yeon, JE1
Lee, HJ3
Kang, SH1
Kang, K1
Yoo, YJ1
Byun, KS1
Cheng, M3
He, B5
Xu, H6
Han, J6
Witort, E1
Lulli, M1
Carloni, V1
Capaccioli, S1
Fan, F1
Geng, L1
Zhu, M1
Tsao, SW2
Man, K1
Feng, Y2
Oh, MJ1
Lee, SH2
Gu, W3
Fang, FF2
Huang, F1
Cheng, BB3
Tanaka, K5
Yabushita, Y1
Kumamoto, T2
Matsuo, K2
Taguri, M1
Endo, I2
Pascal, J1
Ashley, CE1
Brocato, TA1
Butner, JD1
Carnes, EC1
Koay, EJ1
Brinker, CJ1
Cristini, V1
Nakadai, E1
Tonouchi, A1
Fujita, Y1
Nakamura, J1
Miyazaki, M2
Brandi, G1
de Rosa, F1
Agostini, V1
di Girolamo, S1
Andreone, P1
Bolondi, L1
Serra, C1
Sama, C1
Golfieri, R1
Gramenzi, A1
Cucchetti, A1
Pinna, AD1
Trevisani, F1
Biasco, G1
Takeda, K2
Nojiri, K1
Mori, R2
Taniguchi, K1
Matsuyama, R1
Ueda, M3
Akiyama, H1
Ichikawa, Y1
Ota, M1
Tanaka, S2
Matsumura, S1
Murakata, A1
Ban, D1
Ochiai, T2
Irie, T2
Kudo, A1
Nakamura, N1
Tanabe, M1
Arii, S4
Tsuda, Y1
Tomimaru, Y8
Terai, S3
Tai, K1
Kanbara, Y1
Qin, Y1
Bao, H1
Yin, M1
Wu, S3
Yan, C1
Fan, D1
Xiong, D1
Cheng, Z1
Jin, Y2
Liang, X1
Dai, Z2
Lee, JE1
You, YK1
Lee, MA1
Zhang, SS2
Zhao, QD2
Zong, C1
Ye, F2
Guo, SW1
Zhang, JW1
Wu, MC2
Wei, LX2
Zha, Y1
Gan, P1
Yao, Q1
Ran, FM1
Tan, J1
Calderaro, J1
Azoulay, D1
Zafrani, ES1
Okur, A1
Eser, EP1
Yilmaz, G1
Dalgiç, A1
Akdemir, ÜÖ1
Oğuz, A1
Karadeniz, C1
Akyol, G1
Demiroğullari, B1
Boyunağa, Ö1
Pinarli, FG1
Sui, W1
Wang, PP1
Xu, DJ2
Wang, WP1
Xu, WK1
Dangi, R1
Hurkat, P1
Jain, A2
Shilpi, S1
Gulbake, A1
Jain, SK1
Tang, J1
Tao, ZH1
Wan, JL1
Liu, DL1
Cui, JF1
Sun, HC2
Wu, WZ2
Ogasawara, S2
Chiba, T2
Ooka, Y1
Kanogawa, N1
Motoyama, T1
Tawada, A1
Kanai, F2
Yokosuka, AO1
Tang, H4
Zhang, P2
Xiang, Q5
Yin, J5
Lei, X7
Wang, F4
Dai, W3
Shen, M1
Cheng, P1
Zheng, Y4
Lu, J3
Zhu, R1
Guo, C3
Tsai, WL1
Lai, KH2
Hsu, PI2
Chan, HH1
Chen, WC1
Yu, HC2
Tsay, FW1
Wang, HM1
Tsai, HC1
Cheng, JS2
Cui, W1
Jiang, JX1
Gao, S2
Pan, YZ1
Sun, CY1
Wang, SS1
Xie, X2
Wong, CS1
Choi, Y1
Fung, MC1
Zhang, N1
Ren, M1
Ye, L1
Ren, S1
Xu, K2
Jang, JY1
Park, SY3
Yang, JM1
Wang, JX1
Zhang, LY1
Wang, DM1
Yuan, Y2
Cai, H1
Yang, XJ1
Guo, TK1
Chen, YR1
Song, L1
Zhao, DY1
Guo, B3
Song, Y3
Goldstein, R1
Yu, D1
Gillmore, R1
Thirlwell, C1
O'Donoghue, P1
Mayer, A1
Liang, J2
Liang, L1
Wu, G2
Rau, KM1
Jian, Z1
Magata, H1
Kondo, K1
Otani, K1
Yano, K1
Yonei, A1
Akasu, I1
Marutsuka, H1
Fukushima, G1
Kataoka, H1
Hua, HW1
Jiang, F1
Huang, Q1
Liao, ZJ1
Ding, G1
Lin, CL1
Chien, RN1
Yeh, C1
Hsu, CW2
Tsauo, J1
Jia, K1
Feng, T1
Xu, F1
Lee, IJ2
Kim, JW4
Kim, JK5
Kim, KS2
Choi, JS4
Park, YN2
Wang, T3
Pan, X3
Kim, JB2
Ahn, YH1
Jee, HG1
Yu, SJ1
Lee, HS2
Lee, M2
Yoon, JH2
Kim, YJ2
Hu, XY1
Liang, JY1
Guo, XJ1
Guo, YB1
Hirata, H1
Sugimachi, K7
Takahashi, Y1
Sakimura, S1
Uchi, R1
Kurashige, J1
Takano, Y1
Nanbara, S1
Komatsu, H1
Saito, T1
Shinden, Y1
Iguchi, T1
Atsumi, K1
Sakamoto, K2
Doi, T1
Hirakawa, M1
Honda, H2
Mimori, K2
Melichar, B1
Dvorak, J1
Ferko, A1
Kamaradova, K1
Krajina, A1
Liu, W2
Song, W1
Zuo, CH1
Xia, M1
Liu, JS1
Qiu, XX1
Xu, RC1
Liu, HC1
Li, JL1
Li, YG1
Li, QL1
Xiao, H1
Hong, Y1
Wang, XH1
Zhu, HZ2
Wu, QF1
Burns, M1
Yan, Z3
Qu, P1
Yuan, P2
Xing, J1
Zhao, XL1
Shang, SQ1
Shen, HQ1
Chen, X6
Um, SH3
Hwang, JS5
Eun, JR2
Huang, WJ1
Wang, HY1
Wang, YF1
Peng, BG2
Yan, Y1
Hou, N1
So, S2
Kido, M1
Fukumoto, T2
Takebe, A1
Tanaka, M11
Kinoshita, H4
Kuramitsu, K1
Tsugawa, D1
Fukushima, K1
Urade, T1
Yoshida, T8
Asari, S1
Okazaki, T1
Shinzeki, M1
Matsumoto, I1
Ajiki, T1
Xie, N2
Onishi, H2
Nakamura, S3
Katsui, K1
Wada, N2
Morimoto, Y3
Takeuchi, Y3
Yasunaka, T1
Miyake, Y2
Shiraha, H5
Takaki, A4
Kobayashi, Y2
Sakaguchi, K3
Kanazawa, S1
Yoshitoshi, EY1
Mizumoto, M1
Xie, XY1
Le, F1
Li, LX2
Gan, YH3
Zhang, JB2
Xue, TC1
Xia, JL3
Zhang, BH2
Ye, SL5
Ogino, YU1
Yu, F1
Brock, MV1
Tao, Q1
Herman, JG1
Liang, P1
Saeki, I1
Yamasaki, T3
Tanabe, N1
Iwamoto, T1
Matsumoto, T1
Urata, Y1
Hidaka, I1
Ishikawa, T3
Takami, T2
Yamamoto, N2
Uchida, K1
Sakaida, I2
Zhao, RL1
Chen, MJ1
Zhao, FM1
Xu, DQ1
Zhou, KF1
Liao, B1
Morio, R1
Fukuhara, T1
Naeshiro, N2
Miyaki, D3
Takahashi, S9
Shakado, S3
Iwata, K3
Tsuchiya, N1
Kunimoto, H2
Yotsumoto, K2
Fukunaga, A2
Kuno, S1
Tanaka, T4
Iwashita, H2
Hirano, G2
Yokoyama, K2
Morihara, D2
Nishizawa, S1
Takeyama, Y2
Irie, M2
Sohda, T2
Kora, S1
Yoshimitsu, K1
Sakisaka, S2
Mukouzu, T1
Seo, JH1
He, LQ1
Wu, YX1
Wang, XS2
Zu, X2
Peng, C1
Dai, HY1
Chen, HY1
Lai, WC1
Hung, MC1
Li, LY1
Zhang, YF1
Yang, HY1
Xu, HF2
Lu, X2
Sang, XT1
Zhong, SX1
Mao, YL1
Motawi, TK1
El-Boghdady, NA1
El-Sayed, AM1
Helmy, HS1
Fujita, N1
Nishie, A1
Asayama, Y1
Ishigami, K1
Ushijima, Y1
Takayama, Y1
Okamoto, D1
Morita, K1
Shirabe, K2
Koto, K1
Kubo, Y2
Oda, Y1
Gu, YJ1
Li, HD1
He, WB1
Rui, L1
Zheng, HC1
Su, RJ1
Zhang, PJ1
Guo, JH1
Yang, RJ1
Qiao, M1
Zhao, X2
Cai, D1
He, K1
Chang, S1
Tong, D1
Lee, S1
Park, KW1
Seo, CJ1
Yun, DY1
Kim, MK1
Kim, BS2
Han, YS1
Oh, HK1
Lee, CH1
Yuan, S1
He, S2
Niu, JX1
Guo, HP1
Gan, HM1
Bao, LD1
Ren, JJ1
Gao, Q2
Shen, G2
Sun, ZP1
Shi, LH1
Zhang, XR1
Duan, Y1
Xu, WF1
Dai, G1
Wang, XJ1
Bi, T1
Qian, L1
Sumie, S8
Tajiri, N1
Aino, H2
Satani, M1
Matsugaki, S1
Kurogi, J3
Kajiwara, M2
Maeno, H1
Kawamoto, S1
Munechika, T1
Yonemitsu, K1
Nomi, M1
Okamoto, T1
Nagao, S1
Yanagisawa, J1
Long, F1
Liang, R3
Shao, S1
Kim, BH2
Kim, HK1
Shin, JK1
Hong, HJ1
Park, H1
Hwang, SG1
Rim, KS1
Qi, H1
Sun, MZ1
Feng, C1
Luo, Q1
Song, G1
Farmer, RW1
Martin, RC1
Kataoka, J1
Sawahara, H1
Nagahara, T1
Iwamuro, M1
Morimoto, H1
Yagi, T1
Teryukova, NP1
Pogodina, ON1
Ivanov, VA1
Lv, G1
Li, E1
Yamashita, M1
Ogawa, H1
Noda, T13
Asaoka, T1
Gotoh, K1
Fan, L1
Qi, F1
Ou, S1
Yi, X1
Ni, B1
Zheng, Z1
Ma, Y1
Zou, X1
Lei, L1
Wu, D2
Tang, C1
Feng, W1
Bao, Y1
Dong, X1
Dai, Y1
Wu, WR1
Zhang, R5
Shi, XD1
Yi, C1
Xu, LB2
Lin, JW1
Huang, YH1
Han, Z1
Yuan, F1
Qiao, T1
Shen, Q1
Peng, F1
Han, DH1
Joo, DJ1
Kim, MS2
Choi, GH1
Kim, SI1
Deng, G1
Qu, Y1
Qi, J1
Gou, Y1
Lee, P1
Du, B2
Yang, XY1
Yang, W1
Pan, F1
Wen, F1
Wen, S1
Feng, D1
Zang, Q1
Li, G1
Guo, X3
Gong, XL1
Qin, SK1
van Doorn, L1
Veelenturf, S1
Binkhorst, L1
Bins, S1
Mathijssen, R1
Zhang, G1
Zeng, X1
Zang, J1
Gan, R1
Kato, S2
Ohnishi, H2
Mehdizadeh, A1
Somi, MH1
Darabi, M1
Farajnia, S1
Akbarzadeh, A1
Montazersaheb, S1
Yousefi, M1
Bonyadi, M1
Yang, L6
Zheng, H1
Sun, G1
Yang, T2
Kou, P1
Shao, W1
Lan, X1
Lu, S1
Fan, X2
Wu, F2
Tu, J1
Ji, J1
Li, NM1
Xiang, L1
Su, Y2
Xia, Q2
Lacouture, ME1
Reilly, LM1
Gerami, P1
Guitart, J1
Sieben, M1
Herzer, K1
Zeidler, M1
Heinrichs, V1
Leuchs, B1
Schuler, M1
Cornelis, JJ1
Galle, PR2
Rommelaere, J1
Akiyama, M1
Miyaaki, H1
Miuma, S1
Shibata, H1
Fujimoto, M1
Takeshita, S1
Ozawa, E1
Ichikawa, T1
Nakao, K1
Eguchi, K1
Wu, CJ1
Ferrari, D1
Di Maria, G1
Fazio, N1
Codecà, C1
Fiore, J1
Luciani, A1
Oldani, S1
Maggioni, M1
Foa, P1
Iwasa, S1
Hagihara, A1
Sagawa, T1
Yamada, Y4
Takahashi, M4
Kobune, M1
Takimoto, R1
Fukaura, J1
Iyama, S1
Sato, T3
Miyanishi, K1
Matsunaga, T1
Kato, J1
Sasaki, K2
Hamada, H2
Niitsu, Y1
Ishida, K1
Hirooka, M2
Hiraoka, A1
Kumagi, T1
Uehara, T1
Hiasa, Y2
Horiike, N2
Onji, M4
Huang, S1
Yin, Y1
Saletti, P1
Sessa, C1
Cavalli, F2
Doh, KO1
Tang, HH1
Liang, G1
Yamaguchi, F1
Kamitori, K1
Sanada, K1
Horii, M1
Sui, L1
Tokuda, M1
Nagano, Y1
Numata, K1
Kunisaki, C1
Shimada, H2
Cai, XL1
Gao, JP1
Wen, L1
She, ZG1
Lin, YC2
Ji, Z1
Kang, H1
Diao, Y1
Luo, K1
Takeda, Y18
Dono, K23
Nakayama, M1
Shima, T1
Wakasa, K7
Monden, M31
Liang, SN1
Liu, LL1
Su, HY1
Feng, B1
Zhao, GS1
Xiao, YP1
Xiao, EH1
Luo, JG1
Bian, DJ1
Li, MQ1
He, Z1
Shang, QL1
Liang, B1
Xu, Z1
Yao, M1
Yata, Y2
Nakayama, Y1
Hirano, K4
Tokimitsu, Y1
Kudo, H1
Kawai, K1
Kajiura, S1
Yasumura, S1
Minemura, M1
Takahara, T1
Sugiyama, T1
Tian, G3
Zhou, JS1
Yan, F1
Wang, XM1
Sui, J1
Azakami, T1
Kenjo, M1
Toyota, N4
Ito, K6
Cafferata, EG1
Macció, DR1
Lopez, MV1
Viale, DL1
Carbone, C1
Mazzolini, G1
Podhajcer, OL1
Chen, GG4
Chan, UP1
Bai, LC1
Fung, KY1
Tessier, A1
To, AK1
Merchant, JL1
Lai, PB6
Patiutko, IuI1
Pylev, AL1
Sagaĭdak, IV1
Kotel'nikov, AG1
Finn, RS1
Takemasa, I2
Yoshioka, S2
Matsuura, N1
Matsubara, K1
Lei, J1
Mao, CY1
Hua, HJ1
Yu, DC1
Teng, LS1
Lee, JO2
Lee, KW1
Oh, DY2
Im, SA2
Kim, TY2
Bang, YJ2
Mohan, P1
Sukumar, R1
Surendran, R1
Sathyabhama, C1
Jayanthi, V1
Qi, Q1
Mu, R1
Kanda, D1
Takeuchi, S1
Hatanaka, T2
Iesaki, K1
Yoshinaga, T1
Kubota, J1
Higuchi, T1
Yoo, BK1
Gredler, R2
Vozhilla, N1
Su, ZZ1
Forcier, T1
Shah, K2
Saxena, U1
Hansen, U1
Fisher, PB2
Sarkar, D2
Xiong, YQ1
Zhu, XD1
Zhuang, PY1
Qin, LX1
Tang, ZY6
McIntosh, A1
Hagspiel, KD1
Al-Osaimi, AM1
Northup, P1
Caldwell, S1
Berg, C1
Angle, JF1
Argo, C1
Weiss, G1
Rich, TA1
Cao, LQ2
Wang, XL1
Xue, P1
Jiao, XY1
Peng, HP2
Lu, HW2
Zheng, Q1
Chen, XL1
Huang, XH1
Fu, XH1
Chen, JS3
Sun, HW1
Chen, LH1
Wei, CJ1
Zheng, XK1
Li, QS1
Guan, J1
Zhong, JL1
Xue, X1
Yue, P1
Qu, X2
Woo, HY3
Choi, BG3
Im, HU1
Cheong, JY3
Cho, SW2
Jang, BK4
Kim, SG2
Seo, YS2
Doi, Y1
Shimmura, T1
Kuribayashi, H1
Tanaka, Y2
Kanazawa, Y1
Yamamoto, H7
Sun, B1
Lu, Z2
Meng, Y1
Wu, M7
Rose, M1
Saif, MW3
Chu, E1
Foo, A1
Jiang, Z1
Su, T1
Sharma, A2
Upadhyay, AK1
Bhat, MK2
Wu, FY2
Huang, GS2
Jiang, JW2
Xu, XD2
Peng, DY2
Sun, HQ1
He, XE1
Wang, WL1
Lei, JH1
Moon, HJ1
Kim, TN1
Chang, JC1
Koehler, BC1
Urbanik, T1
Vick, B1
Boger, RJ1
Heeger, S1
Schuchmann, M1
Schulze-Bergkamen, H2
Hatano, H2
Tomokuni, A2
Ishikawa, M2
Hieda, M1
Kakizawa, H2
Koizumi, Y1
Kisaka, Y1
Abe, M4
Murakami, H1
Matsuura, B1
Yamagami, T1
Yoshimatsu, R1
Miura, H1
Tanaka, O1
Nishimura, T3
Ming, ZJ1
Qiu, YH1
Cao, L1
Zhang, XG1
Hsu, CH2
Hsu, C1
Toh, HC2
Epstein, RJ1
Hsiao, LT1
Chen, PJ1
Lin, ZZ1
Chao, TY1
Cheng, AL2
Morsy, MA1
Shizawa, K1
Watanabe, M5
Iida, K1
Han, SW1
Ma, SH2
Yip, J1
Nakamoto, Y2
Takamura, H1
Tani, T2
Zen, Y1
Hiraki, M1
Yoshida, H5
Sata, M11
Troisi, RI1
Van Huysse, J1
Berrevoet, F1
Vandenbossche, B1
Sainz-Barriga, M1
Vinci, A1
Ricciardi, S1
Bocchetti, T1
Rogiers, X1
de Hemptinne, B1
Lee, DY5
Lee, KH3
Xia, Y1
Xi, T1
Shen, F1
Ueshima, K1
Takita, M1
Nagai, T1
Tatsumi, C1
Ueda, T2
Kitai, S1
Ishikawa, E1
Yada, N1
Inoue, T1
Hagiwara, S3
Minami, Y2
Chung, H1
Shao, ZL1
Xiao, JB1
Xia, T1
Haraguchi, N1
Ishii, H1
Tanaka, F1
Ohkuma, M1
Kim, HM1
Takiuchi, D1
Barnard, GF1
Zhong, X1
Xiong, M1
Meng, X1
Gong, R1
Lin, CY1
Wu, CL1
Fang, JL1
Tsao, CJ1
Mir, O1
Cessot, A1
Brezault, C1
Ropert, S1
Durand, JP1
Cacheux, W1
Chaussade, S1
Goldwasser, F1
Song, XR1
He, G1
Luo, YF1
He, ZY2
Li, SZ1
Li, JM1
Hou, SX1
Wei, YQ1
Stagni, V1
Mingardi, M1
Santini, S1
Giaccari, D1
Barilà, D1
Mahavorasirikul, W2
Viyanant, V2
Chaijaroenkul, W2
Itharat, A1
Na-Bangchang, K2
Chon, YE1
Cha, J1
Chon, CY4
Shin, SK1
Ye, C1
Leung, BC1
Ho, RL2
Yuan, YF1
Chan, TH1
Zheng, BJ1
Ozaki, I1
Hamajima, H1
Iwane, S1
Kawaguchi, Y2
Eguchi, Y1
Mizuta, T1
Kasai, K2
Ushio, A2
Kasai, Y2
Sawara, K2
Miyamoto, Y2
Oikawa, K2
Kuroda, H2
Takikawa, Y2
Hashimoto, Y1
Sun, W1
Sohal, D1
Haller, DG1
Mykulowycz, K1
Rosen, M1
Soulen, MC1
Caparro, M1
Teitelbaum, UR1
Giantonio, B1
O'Dwyer, PJ1
Shaked, A3
Reddy, R1
Olthoff, K1
Mete, E1
Gul, HI1
Cetin-Atalay, R1
Das, U1
Sahin, E1
Gul, M1
Kazaz, C1
Dimmock, JR1
de Lima Lopes, G1
Dicksey, JS1
Peters, WP1
Palalay, M1
Chang, AY1
Ang, SF1
Tan, SH1
Poon, DY1
Ong, SY1
Foo, KF1
Choo, SP1
Hashimoto, O1
Inoue, K2
Kuwahara, R1
Kerbel, RS1
Ueno, T2
Kim, JD1
Zhong, Y1
Luo, CL1
An-Jun, Z1
Kang, SS1
Cho, HA1
Kim, JS4
Kang, WJ1
Lee, JD1
Xie, F1
Deng, B1
Mao, H1
Chuma, M1
Taguchi, H1
Yamamoto, Y1
Shimizu, S1
Nakanishi, M1
Horimoto, H1
Terashita, K1
Sakuhara, Y1
Abo, D1
Tsukuda, Y1
Tsunematsu, S1
Hige, S1
Kato, M1
Shirato, H1
Asaka, M1
Long, S1
GuangZhi, Y1
BaoJie, G1
YanYong, H1
YingLi, W1
LiHua, L1
Seki, A1
Yun, M1
Yoon, HI1
Cho, HJ1
Huang, HY1
Niu, JL1
Zhao, LM1
Lu, YH1
Liao, WJ1
Mei, MH1
Qin, LL1
Yuan, SG1
Osuga, K2
Lee, J2
Park, SH2
Park, JO1
Park, YS1
Yim, DS1
Fang, F1
Qin, W1
Gallant, JN1
Katz, SI1
Dolloff, NG1
Smith, CD1
Abdulghani, J1
Allen, JE1
Dicker, DT1
Hong, B1
Navaraj, A1
El-Deiry, WS1
Tomuleasa, C3
Soritau, O3
Fischer-Fodor, E1
Pop, T2
Susman, S3
Mosteanu, O2
Petrushev, B3
Aldea, M3
Acalovschi, M1
Irimie, A3
Kacso, G3
Park, YM3
Kim, NY1
Yun, HK1
Lee, KJ2
Park, SJ1
Yeon, JW1
Jung, G2
Ning, W1
Xiao-Juan, G1
Cai-Hong, Z1
Jin-Hua, J1
Fang, M1
Qing-Duan, W1
Zang, Y1
Zou, W1
Shen, ZY1
Liao, D1
Zhu, B1
Chien, SY1
Kuo, SJ1
Chen, YL1
Chen, DR1
Cheng, CY1
Su, CC1
Petrini, I1
Lencioni, M1
Ricasoli, M1
Iannopollo, M1
Orlandini, C1
Oliveri, F1
Bartolozzi, C1
Ricci, S1
Tani, S1
Murata, S1
Tamura, M2
Morita, M1
Hirata, Y1
Iida, H1
Kakuno, A1
Nishigami, T1
Yamanaka, N1
Choi, SB1
Park, MS2
Liu, B1
Ou, Q1
Tian, L1
Sheng, XF1
Cao, JG1
Poggi, G1
Montagna, B1
Melchiorre, F1
Quaretti, P1
Delmonte, A1
Riccardi, A1
Tagliaferri, B1
Sottotetti, F1
Di Cesare, P1
Stella, MG1
Villani, L1
Zorzetto, M1
Greco, G1
Cornalba, G1
Bernardo, G1
Ma, K1
Fei, Q1
Niu, D1
Sakai, A1
Koganemaru, M1
Abe, T3
Iwamoto, R1
Nonoshita, M1
Yoshida, S1
Uchiyama, D1
Hayabuchi, N1
Uchibori, K1
Kasamatsu, A1
Sunaga, M2
Yokota, S1
Sakurada, T1
Kobayashi, E1
Yoshikawa, M2
Uzawa, K1
Tanzawa, H1
Sato, N5
Tong, SW1
Yang, YX1
Hu, HD1
An, X1
Hu, P1
Ren, H2
Zhang, DZ1
Kishimoto, T1
Jiao, J1
Hong, S1
Shen, B1
Sahara, S1
Kawai, N1
Sato, M4
Ikoma, A2
Nakata, K2
Sanda, H1
Minamiguchi, H1
Shirai, S1
Sonomura, T1
Kawaguchi, A1
Kakuma, T1
Sadeghi, H1
Khadem, M1
Li, D1
Song, JR1
Deng, WJ1
Sun, K1
Xie, XQ1
Song, YJ1
Uchino, K1
Obi, S2
Tateishi, R2
Sato, S4
Kanda, M2
Arano, T1
Enooku, K1
Goto, E1
Masuzaki, R1
Nakagawa, H2
Asaoka, Y1
Kondo, Y1
Yamashiki, N1
Goto, T2
Shiina, S2
Koike, K2
Berindan, I1
Cristea, V2
Youn, JM1
Cha, JH1
Kim, HL1
Li, FR1
Ge, N1
Gan, Y1
Ye, S1
Kirikoshi, H1
Yoneda, M1
Mawatari, H1
Fujita, K1
Imajo, K2
Kobayashi, N1
Kubota, K1
Maeda, S2
Nakajima, A2
Saito, S1
Shao, YY1
Huang, CC1
Lin, SD1
Chen, XZ1
Cao, ZY1
Chen, TS1
Zhang, YQ1
Liu, ZZ1
Su, YT1
Liao, LM1
Du, J1
Yadunandam, AK1
Yoon, JS1
Seong, YA1
Oh, CW1
Kim, GD1
Liang, RR1
Qi, JA1
Wang, ZD1
Liu, PJ1
Le, XF1
Li, ZF1
Srivastava, J1
Siddiq, A1
Emdad, L1
Santhekadur, PK1
Shen, XN1
Robertson, CL1
Dumur, CI1
Hylemon, PB1
Mukhopadhyay, ND1
Bhere, D1
Ahmad, R1
Giashuddin, S1
Stafflinger, J1
Subler, MA1
Windle, JJ1
Orza, A1
Dudea, M1
Florea, A1
Pall, E1
Berindan-Neagoe, I1
Li, N1
Yan, S1
Jiang, X1
Fang, P1
Gao, Y1
Ding, CR1
Cui, F1
Jiao, SC1
Seki, H1
Ozaki, T1
Ooi, H1
Wan, T3
Zha, B2
Ye, T3
Rangwala, F1
Williams, KP1
Smith, GR1
Thomas, Z1
Allensworth, JL1
Lyerly, HK1
Diehl, AM1
Morse, MA1
Devi, GR1
Nishiofuku, H1
Anai, H1
Sueyoshi, S1
Masada, T1
Kichikawa, K1
Zhu, W1
Zhou, H1
Jia, L1
Lu, F1
Hou, YQ1
Yuan, ZJ1
Rong, C1
Antoniou, E1
Mantas, D1
Paraskeva, P1
Dimitroulis, D1
Smyrnis, A1
Nikitakis, N1
Labadariou, A1
Tsavaris, N1
Vernicos, P1
Kostakis, A1
Cheng, MR1
Chen, HX1
Yang, FX1
Xu, HZ1
Zha, BB1
Kong, WD1
Cao, JM1
Xu, TT1
Lu, GM1
Huang, XE1
Ling, CQ2
Yue, XJ1
Yu, XH1
Brito, AF1
Abrantes, AM1
Pinto-Costa, C1
Gomes, AR1
Mamede, AC1
Casalta-Lopes, J1
Gonçalves, AC1
Sarmento-Ribeiro, AB1
Tralhão, JG1
Botelho, MF1
Hua, XD1
Zhou, S1
Duan, X1
Kim, JY1
Yoo, EJ1
Kwon, JH3
Kay, CS1
Itamoto, T2
Nakahara, H2
Tashiro, H1
Haruta, N2
Asahara, T2
Naito, A2
Qi, S1
Ando, E8
Yamashita, F6
Yutani, S1
Fukumori, K6
Yano, Y6
Boucher, E1
Corbinais, S1
Brissot, P1
Boudjema, K1
Raoul, JL3
Katsuramaki, T1
Furuhata, T1
Yamaguchi, K1
Ohmura, T2
Hata, F1
Mukaiya, M2
Hirata, K2
Akçali, Z1
Akin, E1
Ozyilkan, O1
Jin, J3
Wei, HL1
Liu, GT1
Sakon, M25
Seong, JS1
Youn, YH1
Moon, YM2
Kamiyama, T5
Matsushita, M3
Kurauchi, N3
Nakagawa, T3
Kamachi, H3
Kondo, M10
Ito, T2
Ogata, T2
Nishikawa, M1
Todo, S3
Yi, J2
Liao, X2
Brown, TD3
Ellis, LM2
Hoshida, Y3
Moriyama, M2
Otsuka, M2
Kato, N2
Taniguchi, H4
Shiratori, Y3
Seki, N1
Shao, ZX1
Cheng, ZG1
Pulatov, DA1
Kamiyama, H1
Toyama, N1
Mori, Y1
Miyazaki, K2
Nagano, M1
Yamada, S1
Suminaga, Y1
Konishi, F1
Katzenstein, HM2
Krailo, MD2
Malogolowkin, MH2
Ortega, JA2
Qu, W1
Douglass, EC5
Feusner, JH2
Reynolds, M4
Quinn, JJ2
Newman, K2
Finegold, MJ2
Haas, JE2
Sensel, MG2
Castleberry, RP2
Bowman, LC2
Komorizono, Y1
Kohara, K1
Oketani, M1
Maeda, M2
Shibathou, T1
Shigenobu, S1
Hiramine, Y1
Yamasaki, N1
Arima, T3
Kazuaki, I1
Yang, LY2
Yi, TB2
Yang, JQ1
Uygur-Bayramiçli, O1
Gemici, C1
Yang, FC1
Zheng, SS1
Li, MW1
Zeng, QL1
Jiang, GP1
Xie, HY1
Zhou, T1
Zhai, L1
Xing, L1
Nanashima, A1
Yamaguchi, H1
Shibasaki, S1
Morino, S1
Yoshinaga, M1
Sawai, T1
Nakagoe, T1
Ayabe, H1
Teramoto, K1
Kawamura, T1
Mori, A1
BOOTH, BA1
SARTORELLI, AC1
MCBRIDE, TJ1
NOBLE, LC1
CARR, MA1
HULL, K1
OLESON, JJ1
MORSE, PA1
POTTER, VR1
Stippel, DL1
Töx, U1
Gossmann, A1
Beckurts, KT1
Hölscher, AH1
Pan, DY1
Qiao, JG1
Huo, YC1
Zhou, YK1
Shi, HA1
Masutani, S2
Shimizu, J3
Tatsuta, M1
Masuda, F1
Imamura, H1
Ishida, H2
Furukawa, H3
Tomotsu, K1
Yura, M1
Obana, T1
Kitamura, S1
Saeki, N1
Inoue, Y2
Takamura, M1
Nakanishi, K2
Ota, H11
Yamamoto, T10
Nakamura, M12
Miyamoto, A15
Nakamori, S16
Murakami, T3
Nakamura, H5
Iijima, S2
Kikkawa, N1
Kurokawa, E1
Kato, T1
Tsujie, M2
Ohshima, S1
Naoi, Y2
Danno, M1
Tamesa, T4
Okada, T1
Takemoto, N1
Tangoku, A4
Oka, M5
Lai, YC1
Shih, CY1
Jeng, CM1
Yang, SS1
Hu, JT1
Sung, YC1
Liu, HT1
Hou, SM1
Wu, CH1
Chen, TK1
Wu, ZQ2
Xiao, YS3
Shi, YH1
Li, XM1
Sun, QM2
Liu, YK3
Kogure, T1
Ueno, Y1
Iwasaki, T2
Shimosegawa, T1
Yang, XD1
Tang, DN1
Cao, DL1
Li, YX1
Lin, ZB1
Tan, HR1
Li, JT1
Ou, QJ1
Wu, YC1
Kawashima, R1
Haisa, M1
Takaoka, M1
Shirakawa, Y1
Uetsuka, H1
Gunduz, M1
Nagai, N1
Tanaka, N1
Naomoto, Y1
Zhang, ZL1
Zou, WG1
Luo, CX1
Li, BH1
Wang, JH1
Sun, LY1
Qian, QJ1
Fukuda, Y1
Fujio, N1
Tsukazaki, T1
Terakura, M1
Mayumi, K1
Koyama, I1
Tsukazaki, Y1
Osugi, H1
Qiu, F1
Lambert, B2
De Ridder, L2
Slegers, G2
De Gelder, V2
Dierckx, RA1
Thierens, H2
Xue, Q1
Ganten, TM1
Haas, TL1
Sykora, J1
Stahl, H1
Sprick, MR1
Fas, SC1
Krueger, A1
Weigand, MA1
Grosse-Wilde, A1
Stremmel, W1
Krammer, PH2
Walczak, H1
Mazzanti, R1
Giallombardo, AL1
Mini, E1
Nobili, S1
Neri, B1
Arena, U1
Pantaleo, P1
Fabbroni, V1
Ghilardi, M1
Gattai, R1
Bandettini, L1
Zhao, JG1
Feng, GS1
Kong, XQ1
Li, MH1
Cheng, YS1
Chang, HK1
Liau, CT1
Chang, WC1
Chang, UI2
Nam, SW2
Mok, TS5
Leung, TW6
Brown, G1
Moyses, C1
Chan, AT5
Yeo, W5
Wong, H1
Chak, K1
Johnson, P1
El-Saadani, MA1
Aguayo, A2
Nooka, AK1
Schnirer, II1
Wolff, RA1
Charnsangavej, C3
Hamada, A1
Yamakado, K1
Nakatsuka, A1
Takaki, H1
Akeboshi, M1
Yamamoto, S3
Tomita, Y1
Iizuka, N1
Aozasa, K1
Wu, SL1
Sun, ZJ1
Meng, KW1
Qin, XL1
Pan, CE1
Kurokawa, Y1
Matoba, R1
Ueno, N1
Ishii, S1
Kato, K2
Kawabe, T1
Noguchi, T3
Tanimoto, K1
Shimokuni, T1
Ukon, K1
Tsujimoto, H1
Fukushima, M1
Kawahara, K2
Hiyama, K1
Nishiyama, M1
Jin, CD1
Arai, I2
Kishin, R1
Xing, X1
Lam, KC3
Zee, B3
Chan, PS1
Mo, FK3
Ho, WM3
Wong, WL1
Johnson, PJ5
Matsumoto, G1
Tsuruta, K1
Okamoto, A2
Endo, M1
Sonoyama, T1
Kikuchi, S2
Ichikawa, D1
Fujiwara, H1
Okamoto, K1
Sakakura, C1
Ueda, Y1
Otsuji, E1
Hagiwara, A1
Yamagishi, H1
Damdinsuren, B9
Li, HH1
Duan, ZH1
Zhang, HW1
Yie, SL1
Yang, BW1
Yagita, H1
Kwon, KM2
Park, KS2
Cho, KB2
Kim, GC2
Kim, YH2
Nakata, S1
Tomoda, K3
Watanabe, K3
Taguchi, K1
Tsukahara, M1
Nakajima, H1
Kamiyama, N1
Khor, LW1
Abumiya, K1
Kobayashi, H1
Takezako, Y1
Wang, HE1
Wu, HC1
Kao, SJ1
Tseng, FW1
Wang, YS1
Yu, HM1
Chou, SL1
Yen, SH2
Chi, KH1
Kurokawa, F1
Aoyama, K1
Tajima, K1
Yokoyama, Y2
Omori, K1
Tsuchiya, M1
Okita, K1
Dou, J1
Iwashita, Y1
Sasaki, A2
Kai, S2
Hirano, S1
Ohta, M2
Kitano, S3
Hiraoka, N1
Hwang, JY1
Horino, K1
Inoue, M1
Kuhara, H1
Uemura, K1
Yamada, K1
Ocker, M1
Alajati, A1
Ganslmayer, M1
Zopf, S1
Lüders, M1
Neureiter, D1
Hahn, EG1
Schuppan, D1
Herold, C1
Sheng, Z1
Ruan, YB1
Guang, Y1
Yang, ML1
Zhang, ZH1
Ma, LW1
Song, SB1
Xiu, DR1
Wang, JJ1
Yang, XX1
Jia, YM1
Li, CP2
Lin, CP1
Lo, GH1
Lin, CK1
Chen, HH1
Lo, CC1
Tseng, HH1
Yin, XY3
Lü, MD2
Liang, LJ2
Lai, JM1
Li, DM2
Kuang, M1
Sugimoto, K1
Shiraki, K1
Yamanaka, Y1
Murata, K2
Nakano, T1
Rong, LF1
Li, YH1
Guo, L1
Xu, SY1
Kountouras, J1
Zavos, C1
Chatzopoulos, D1
Cao, XW1
Fu, ZR1
Ding, GS1
Cheng, SC2
Lin, RX1
Tuo, CW1
Lü, QJ1
Wang, SQ1
Haruno, M1
Shimamura, R1
Ogawa, Y2
Tanaka, H2
Sakai, K3
Araki, K1
Hillemann, A1
Brandenburg, B1
Schmidt, U1
Roos, M1
Smirnow, I1
Lemken, ML1
Lauer, UM1
Hildt, E1
Zheng, JF1
Wang, HD1
Niguma, T1
Mimura, T1
Tutui, N1
Yu, YL1
Ji, MF1
He, JB1
Li, XL1
Lin, ZY1
Shen, YF1
Yu, ZJ1
Yu, JW1
Cai, W1
Yuan, HX1
Li, XY1
Chen, JP1
Wu, XY1
Yao, DF1
Kanda, T2
Tada, M1
Imazeki, F2
Yokosuka, O2
Nagao, K1
Saisho, H3
Kurokohchi, K2
Takaguchi, K1
Kita, K1
Kuriyama, S2
Dai, J3
Koh, J2
Yu, SC3
Hui, P2
Wong, HT1
Tang, A1
Enjoji, M1
Morizono, S1
Kotoh, K1
Kohjima, M1
Miyagi, Y1
Yoshimoto, T1
Nakamuta, M1
Anami, Y1
Oguma, S2
Matsuda, Y2
Yamaki, T1
Sazawa, Y1
Komiya, H1
Izai, J1
Ota, T1
Ciccolini, J1
Mercier, C1
Dahan, L2
Evrard, A1
Boyer, JC1
Richard, K1
Dales, JP1
Durand, A1
Milano, G1
Seitz, JF2
Lacarelle, B1
Kida, H1
Hasuike, Y2
Fukuchi, N1
Fujiwara, S1
Hayashi, N1
Ebisui, C1
Sakita, I1
Fujimoto, T1
Koshino, T1
Izumiyama, K1
Uchida, S1
Nokita, H1
Horiuchi, H1
Ishikawa, H1
Kawashima, Y1
Fujishita, M1
Aoyagi, S4
Shirouzu, K1
Kato, H1
Bazarragchaa, D1
Poh, SB1
Bai, LY1
Chen, PM1
Arai, M1
Gao, WB1
Han, JD1
Du, M1
Lee, Y1
Han, SH1
Kwon, SY1
Kwon, OS1
Kim, SS1
Park, YH1
Lee, JN1
Bang, SM1
Cho, EK1
Shin, DB1
Wang, MQ1
Shao, RH1
Ye, HY1
Wang, ZQ1
Liu, FY1
Quek, R1
Lim, ST1
Ong, S1
Diasio, R1
Lim, TY1
Sim, SJ1
Choi, SJ1
Choi, JW1
Kwon, HC1
Lee, KM1
Won, JH1
Yoo, BM1
Hahm, KB1
Toune, R1
Unuma, T2
Teratani, T1
Oh, HJ1
Lee, SY1
Kim, CW1
Cha, SB1
Byun, JY1
Zhang, YN1
Kojiro, S1
Momosaki, S1
Takemoto, Y1
Nishida, N1
Kojiro, M3
Berretta, M1
Lleshi, A1
Di Benedetto, F1
Bearz, A1
Spina, M1
Tirelli, U1
Ni, H1
Terakawa, N1
Satoi, S1
Takai, S1
Yanagimoto, H1
Takahashi, K2
Komiyama, Y1
A-Hon, K1
Kamiyama, Y1
Zorzi, D1
Abdalla, EK1
Pawlik, TM1
Zhou, ZH1
Cheng, WW1
Meng, ZQ1
Lin, JH1
Zhang, XJ1
Jiang, GL1
Chau, GY1
Lui, WY1
Tsay, SH1
King, KL1
Wu, CW1
Cui, YL1
Juzi, JT1
Qian, BY1
Hao, XS1
Ohsuga, K1
Kim, T1
Tatsukawa, M1
Suzuki, M1
Iwasaki, Y3
Lei, XY1
Zhong, M1
Feng, LF1
Zhu, BY1
Liao, DF1
Oie, S2
Ono, M2
Maruyama, Y2
Terada, T2
Kuwano, M2
Fujioka, N1
Ariyasu, T1
Arai, N1
Ariyasu, H1
Tanimoto, T1
Ikegami, H1
Ohta, T1
Fukuda, S5
Kurimoto, M1
Dai, LC2
Lu, YL2
Ping, JL2
He, JF2
Zhou, JJ1
Chen, RF1
Tang, QB1
Zhou, QB1
Shitara, K1
Munakata, M1
Kudo, T1
Muto, O1
Okada, R1
Mitobe, S1
Sakata, Y2
Ishii, E1
Yabu, K1
Yanase, K1
Ikenaka, Y1
Noguchi, R1
Kitade, M1
Kaji, K1
Yoshii, J1
Namisaki, T1
Yamazaki, M1
Asada, K1
Tsujimoto, T1
Akahane, T1
Uemura, M1
Fukui, H1
Yabuuchi, S1
Katayose, Y1
Rikiyama, T1
Oikawa, M1
Onogawa, T1
Muto, M1
Unno, M1
Yamashita, S1
Niinobu, T1
Amano, M1
Nishikawa, Y1
Hayashida, H1
Higaki, N1
Fujita, M1
Mizumoto, T1
Okabe, K1
Baba, Y1
Takamori, H1
Kanemitsu, K1
Hiroto, M1
De Vos, F1
Van de Wiele, C1
Higami, K2
Okano, N1
Matsumaru, K1
Miki, K2
Enoki, T1
Kitada, K1
Harada, E1
Noshima, S1
Hamano, K1
Hou, S1
Kou, G1
Qian, W1
Brenes, O1
Arce, F1
Gätjens-Boniche, O1
Díaz, C1
Imai, Y5
Fukuda, K1
Matsumoto, H2
Zhao, QZ1
Dou, KF1
Naganuma, A1
Toyoda, M1
Hamada, T1
Yanagisawa, M1
Kosone, T1
Arai, H1
Takagi, H2
Miao, J1
Yun, JP1
Chun, SY1
Zheng, ZZ1
Chak, EC1
Xia, NS1
Yoon, YJ1
Kuroda, M1
Urawa, N1
Mifuji, R1
Araki, J1
Horiike, S1
Itani, T1
Furjita, N1
Konishi, M1
Iwasa, M1
Kaito, M1
Adachi, Y1
Chan, SL1
Leung, NW2
Lam, WY1
Tang, JW1
Chan, PK1
Fan, XY1
Uchida, H1
Iwaki, K1
Shibata, K1
Sun, Z1
Peng, J1
Zhan, L1
Hirashita, T1
Nakashima, K5
Sakai, M1
Sakai, I1
Fukushima, H1
Hosoi, F1
Deguchi, A1
Himoto, T1
Yoneyama, H1
Maeta, T1
Kiuchi, T1
Kohi, F1
Miyoshi, H1
Taminato, T1
Chung, C1
Park, SG1
Joh, JW1
Blanchard, P1
Huguet, F1
André, T1
Boige, V1
Pignon, JP1
Bouché, O1
Blanc, JF1
Jouve, JL1
Dupouy, N1
Ducreux, M1
Cui, J1
Nan, KJ1
Guo, YH1
Imai, M1
Kamimura, H1
Tsuchiya, A1
Togashi, T1
Seki, K1
Ohta, H2
Kamimura, T1
Uka, K3
Miki, D3
Jeong, SC2
Kodama, H1
Shirakawa, H1
Song, TY1
Lin, HC1
Yang, NC1
Hu, ML1
Meric, JB1
Nakatani, T2
Sakaguchi, Y1
Nagashima, M1
Fukuta, N1
Hayakawa, S1
Munakata, H1
Tejani, MA1
Sun, RX1
Jia, F2
Wei, L2
Takahashi, T7
Mamada, Y1
Taniai, N1
Mizuguchi, Y1
Shimizu, T2
Kakinuma, D1
Ishikawa, Y1
Akimaru, K1
Sugisaki, Y1
Tajiri, T1
Jiang, JM1
Liu, JY1
Zhu, JR1
Le, C1
Di Lorenzo, G1
Rea, A1
Carlomagno, C1
Pepe, S1
Palmieri, G1
Labianca, R1
Chirianni, A1
De Stefano, A1
Esposito, V1
De Placido, S1
Montesarchio, V1
Shao, ZY1
Zhai, BJ1
Zhao, CL1
Hu, K1
Shen, DM1
Hu, WJ1
Tomonaga, T1
Ebara, M1
Nomura, F1
Ikehara, T1
von Delius, S1
Lersch, C1
Mayr, M1
Stock, K1
Schulte-Frohlinde, E1
Schmid, RM1
Eckel, F1
August, DA1
Han, CJ1
Shim, JH1
Park, JW1
Nam, BH1
Lee, WJ1
Kim, CM1
Saneto, H1
Chunhu, Z1
Suiyu, H1
Meiqun, C1
Guilin, X1
Yunhui, L1
Ma, H1
Zheng, D1
Yuan, JN1
Lee, WP1
Lee, RC1
Chang, FY1
Lee, SD1
Whang-Peng, J1
Albaugh, JS1
Keeffe, EB1
Krippaehne, WW1
Falkson, G6
MacIntyre, JM2
Moertel, CG6
Johnson, LA1
Scherman, RC1
Balch, CM2
Urist, MM2
Shiraishi, K1
Majima, Y1
Sato, K1
Sakemi, T1
Sakai, T2
Hirai, K3
Ninomiya, F1
Tanikawa, K5
Akiharu, W1
Higashi, T1
Nakatsukasa, H1
Fujiwara, M1
Shiota, T1
Yamauchi, Y1
Nagashima, H2
Ueoka, H1
Kuroda, S1
Ohnoshi, T1
Kimura, I1
Numoto, A1
Hino, I1
Tsuji, M1
Heinrich, UE1
Bolkenius, M1
Daum, R1
Oppermann, HC1
Mehls, O1
Brandeis, WE1
Ohya, T1
Sheen, MC1
Huang, TJ1
Sheen, PC1
Ho, YH1
Sheu, HM1
Ou, SC1
Chen, CY1
Wu, CC1
Moser, K1
Dittrich, C1
Pirich, P1
Schneeweiss, B1
Choi, TK1
Lee, NW1
Wong, J1
Schlager, SI1
Ohanian, SH4
Oon, CJ1
Chua, EJ1
Foong, WC1
Tan, LK1
Yo, SL1
Chang, CH1
Ho, ST1
Seah, CS1
Friedman, MA2
Volberding, PA1
Cassidy, MJ1
Resser, KJ1
Wasserman, TH1
Phillips, TL2
Pausch, J2
Holstege, A1
Keppler, D2
Gerok, W2
Nakakuma, K1
Tashiro, S1
Hiraoka, T1
Konno, T1
Yokoyama, I1
Czerwiński, W2
Young, D1
Vine, E1
Ghanbarpour, A1
Shani, J2
Siemsen, JK1
Wolf, W2
Evans, AE1
Land, VJ1
Newton, WA1
Randolph, JG1
Sather, HN1
Tefft, M1
Weinblatt, ME1
Siegel, SE1
Siegel, MM1
Stanley, P1
Weitzman, JJ1
Joishy, SK1
Bennett, JM1
Balasegaram, M1
Moertel, C2
Carbone, PP2
Penalba, C1
Larouze, B1
Mechali, D1
Saimot, G1
Coulaud, JP1
Cedermark, BJ1
Gunven, P1
Hammarberg, C1
Anttila, MI1
Sotaniemi, EA1
Kairaluoma, MI1
Mokka, RE1
Sundquist, HT1
Niederhuber, JE1
Ensminger, WD1
Ramming, KP2
Kuroiwa, Y1
Kikkawa, K1
Kubonishi, S1
Hamawaki, M1
Okano, K1
Ito, Y3
Matsuoka, K1
Fujii, M2
Murakami, N2
Matsuka, Y2
Ejiri, T2
Asano, K2
Yamashita, Y3
Kanaoka, M1
Ohta, Y4
Hattori, M2
Munehisa, T1
Tajima, H1
Goto, M1
Muro, T1
Kohno, K1
Sato, A1
Furukawa, R1
Ogino, T1
Washtien, WL1
Steele, G1
Osteen, RT1
Wilson, RE1
Brooks, DC1
Mayer, RJ1
Zamcheck, N1
Ravikumar, TS2
Ellis, PA1
Norman, A1
Hill, A1
O'Brien, ME1
Nicolson, M1
Hickish, T1
Cunningham, D1
Brucker, C1
Weiss, M1
Schweiberer, L1
Genz, T1
Maassen, V1
Debus-Thiede, G1
Guyader, D1
Bretagne, JF1
Duvauferrier, R1
Bourguet, P1
Bekhechi, D1
Deugnier, YM1
Gosselin, M1
Lygidakis, NJ1
Kosmidis, P1
Ziras, N1
Parissis, J1
Kyparidou, E1
Tetef, M1
Doroshow, J1
Akman, S1
Coluzzi, P1
Leong, L1
Margolin, K1
Morgan, RJ1
Raschko, J1
Shibata, S1
Somlo, G1
Aramaki, M3
Kawano, K2
Kim, YI5
Yanagi, I3
Koga, A4
Aso, K3
Nishio, T2
Shirotani, T2
Kodama, T1
So, H2
Shibata, J4
Nagashima, J2
Nakao, A2
Nabeyama, A1
Okada, Y1
Sakagami, K1
Salminen, E1
Nikkanen, V1
Kelm, C1
Henneking, K1
Zimmermann, T1
Vollerthun, M1
Padberg, W1
Yoffe, B1
Pazdur, R1
Fischer, H1
Cleary, K2
Roh, M2
Smith, R1
Noonan, CA1
Levin, B1
Takenaka, K4
Yoshida, K1
Nishizaki, T1
Korenaga, D1
Hiroshige, K1
Ikeda, T1
Su, J1
Zhen, YC1
Qi, CQ1
Hu, JL1
Vaughn, D1
Treat, J1
Olthoff, KM2
Rosove, MH2
Shackleton, CR2
Imagawa, DK2
Farmer, DG2
Northcross, P2
Pakrasi, AL2
Martin, P2
Goldstein, LI2
Colleoni, M2
Gaion, F1
Liessi, G2
Mastropasqua, G1
Nelli, P2
Manente, P2
Iwama, T1
Mishima, Y1
Komesu, I1
Ohgami, N1
Sou, H1
Kumabe, T1
Motohara, T1
Ozawa, Z1
Morita, S2
Pizzorno, G1
Bodden, W1
Marsh, J1
Strair, R1
Pollack, J1
Hendler, R1
Hanna, J1
D'Andrea, E1
Maruhashi, Y1
Hirose, S1
Satomura, Y1
Hayakawa, Y1
Demachi, H1
Miwa, A1
Nakanuma, Y1
Iwamiya, T2
Sawada, S2
Yasui, M1
Nonami, T1
Kurokawa, T1
Harada, A1
Hashimoto, S1
Kajikawa, M1
Hiraoka, E1
Suto, T1
Moriya, N1
Watanabe, Y2
Sasaki, D1
Yodono, H4
Takekawa, SD2
Tarusawa, K4
Ikami, I2
Kanehira, J3
Saito, Y3
Sasaki, T4
Nishi, N2
Yakushiji, H1
Kitahara, K1
Sasatomi, E1
Tsutsumi, N1
Hirohashi, Y1
Iwanaga, A1
Iyama, A1
Fukagawa, H1
Wen, YJ1
Xu, HB1
Yan, XQ1
Finegold, M2
Cantor, AB1
Glicksman, A2
Sitzmann, JV1
Abrams, R1
Bismuth, H1
Chiche, L1
Adam, R1
Castaing, D1
Itsubo, M1
Lai, RQ1
Uchino, J5
Une, Y5
Gondo, H1
Nakajima, Y5
Toyoda, H2
Nakano, S2
Takeda, I2
Kumada, T2
Sugiyama, K2
Osada, T2
Kiriyama, S2
Suga, T2
Oki, H1
Ijuin, H1
Ban, S1
Sakata, K1
Ono, N1
Noguchi, H1
Itobayashi, E1
Shimauchi, A1
Lynes, AC1
Stuart, K1
Tessitore, J1
Huberman, M1
Mughal, TI1
Koriech, OM1
Sugahara, K1
Tobe, T1
Takiya, S1
Sawada, T2
Tagaya, T1
Fukuzawa, Y1
Ikeda, H1
Link, KH1
Pillasch, J1
Weindel, M1
Leder, G1
Beger, HG1
Matuo, H1
Nakayama, T3
Nakano, H1
Sasaki, Y3
Imaoka, S3
Ishikawa, O3
Kabuto, T2
Kameyama, M1
Hiratsuka, M1
Ohigashi, H2
Yasuda, T2
Iwanaga, T1
Blesing, CH1
Kerr, DJ1
Busuttil, RW1
Bower, M1
Newlands, ES1
Habib, N1
Ishimura, H1
Mastrapasqua, G1
Vicario, G1
Sgarbossa, G1
Pancheri, F1
Ono, T3
Nagasue, N3
Uchida, M1
Yukaya, H1
Yamanoi, A2
Takao, T4
Nishida, M2
Maeda, Y5
Takao, K1
Sawamura, A1
Kim, R1
Takashima, I1
Miyahara, E1
Aogi, K1
Yamaguchi, Y1
Noma, K1
Hihara, J1
Toge, T1
Jibiki, M1
Taniguchi, Y1
Matsuo, T1
Ikari, H1
Ishibashi, T2
Sugamura, Y1
Kunizaki, T1
Hirao, K1
Takayama, W1
Asano, T1
Nakagouri, S1
Kenmochi, T1
Okazumi, S1
Takeda, A1
Fukunaga, T1
Iwasaki, K1
Shutou, K1
Matsuzaki, H1
Aoyama, H1
Shinotou, K1
Kouno, T1
Isono, K1
Kato, O1
Fukuda, H1
Kusaba, T1
Mathurin, P1
Rixe, O1
Carbonell, N1
Bernard, B1
Cluzel, P1
Bellin, MF1
Khayat, D1
Opolon, P1
Poynard, T1
Miura, T5
An, M1
Matsumoto, Y3
Terakado, H1
Murata, M2
Takagi, S1
Ikawa, M1
Hamada, E1
Nakasato, S1
Jiang, W1
Diasio, RB1
Jiang, S1
Shin, EC1
Lee, MO1
Kim, SJ1
Park, JH1
Murakami, K1
Matsuura, T2
Sano, M1
Hashimoto, A1
Yonekura, K1
Sakukawa, R1
Saiki, I1
Liu, G1
Yamamitsu, S1
Tsuji, A1
Shirasaka, T1
Oikawa, I1
Kimura, H3
Denno, R1
Hoque, A1
Ellis, L1
Lozano, R1
Carrasco, CH1
Imamoto, E1
Naito, Y1
Minami, M1
Boku, Y1
Inuma, S1
Masuyama, M1
Yoshikawa, T1
Ho, SK1
Liew, CT1
Tang, AM2
Seno, H1
Kojima, K1
Nakajima, N1
Kohashi, T1
Katayama, S1
Fukuda, T1
Yano, M1
Katayama, K1
Dohi, K1
Nisida, M2
Kishimoto, S1
Eurvilaichit, C1
Kanjanapitak, A1
Leopairut, J1
Eichhorst, ST1
Müller, M1
Li-Weber, M1
Angel, P1
Takayasu, Y1
Ikeda, J1
Tominaga, M1
Takamatsu, M1
Tsuchida, S1
Sendou, H1
Suzuki, Y2
Kuroda, Y1
Shirasawa, H1
Luo, D1
Habib, NA1
Sarraf, CE1
Mitry, RR1
Havlík, R1
Nicholls, J1
Kelly, M1
Vernon, CC1
Gueret-Wardle, D1
El-Masry, R1
Salama, H1
Ahmed, R1
Michail, N1
Edward, E1
Jensen, SL1
Tang, Z1
Naitoh, M1
Hara, F1
Mitunaga, S1
Ikeda, E1
Moriyama, S1
Tuji, T1
Furutani, S1
Nawa, S1
Ohtuka, K1
Kashiyama, Y1
Guo, WJ1
Yu, EX1
Kawata, S3
Yamasaki, E1
Nagase, T1
Inui, Y1
Ito, N1
Inada, M1
Tamura, S2
Noda, S2
Matsuzawa, Y1
Guseinov, E1
Horák, D1
Titova, M1
Adamyan, A1
Kokov, L1
Kubishkin, V1
Vishnevskii, V1
Skuba, N1
Trostenyuk, N1
Nazmy El Assal, O1
Llovet, JM1
Ruff, P1
Tassopoulos, N1
Castells, L1
Bruix, J1
El-Hariry, I1
Peachey, M1
Onishi, Y1
Yajima, Y1
Hayashi, C1
Aoki, C1
Takahashi, N1
Miyazaki, A1
Eda, Y1
Ohira, S1
Oikawa, H1
Xie, H1
Omuraya, M1
Matsuda, T1
Ishiodori, H1
Hirota, M1
Fujiyama, S1
Ogawa, M2
Tsujinaka, T1
Furukawa, S1
Ito, S1
Hatakeyama, K1
Maruyama, T1
Nozue, M1
Aoyagi, H1
Sakamoto, T1
Fukue, M1
Matsui, S1
Kodaira, Y1
Monma, E1
Takada, Y1
Shidara, S1
Ikezawa, K1
Shimakura, S1
Okada, S2
Kuriyama, H1
Urabe, T1
Imamura, I1
Eriguchi, N1
Yamada, A1
Nakazaki, H2
Takita, W1
Hasebe, Y2
Tokura, N1
Seo, A1
Kurihara, A1
Takada, M1
Saito, N1
Shirasaka, K1
Benson, AB1
Mitchell, E1
Abramson, N1
Klencke, B1
Ritch, P1
Burnhan, JP1
McGuirt, C1
Bonny, T1
Levin, J1
Hohneker, J1
Liu-Mares, W1
Qin, C1
Zhang, A1
Cheb, S1
Tang, W1
Zuo, G1
Shen, W1
Gopalakrishnan, TV1
Thompson, EB1
Segerling, M3
Borsos, T3
Abe, I1
Suzuki, T2
Ono, H2
Nakase, A5
Honjo, I2
Inokuchi, K1
Iwaki, A1
Kono, K1
Yamaguchi, T1
Mayr, AC1
Holton, CP1
Burrington, JD1
Hatch, EI1
Oberfield, RA3
Shiu, MH1
Fortner, JG1
Brookhart, W1
Allen, R1
Looney, W1
Hopkins, H1
Kovacs, C1
Morris, H1
Kovacs, CJ6
Hopkins, HA9
Simon, RM1
Looney, WB8
Murad, F1
Wilkinson, DS4
Tlsty, TD1
Hanas, RJ1
Fujii, S1
Okuda, H1
Akazawa, A1
Yasuda, Y1
Terui, S1
Keczkes, K1
Barker, DJ1
Bast, RC1
Greene, SL1
Zbar, B1
Rapp, HJ1
Kirsch, WM2
Van Buskirk, JJ2
Schulz, DW1
Tabuchi, K1
Sparks, FC1
Eilber, FR1
Holmes, EC1
Morton, DL1
McBride, CM2
Schaffner, JG2
Trefil, JS2
Wakefield, JA2
Crumley, J2
Goodman, MA1
Laden, AM1
Misra, NC1
Jaiswal, MS1
Singh, RV1
Das, B1
Kennedy, PS1
Lehane, DE1
Smith, FE1
Lane, M1
Link, JS1
Bateman, JR1
Paroly, WS1
Durkin, WJ1
Peters, RL1
Kurihara, M1
Shirakabe, H1
Izumi, T1
Miyasaka, K1
Ariyama, J1
Ritenour, R1
Greenberg, N1
Schumm, DE1
Webb, TE1
Fegiz, G1
Rosati, D1
Tonelli, F1
Donfrancesco, A1
Cochrane, AM1
Murray-Lyon, IM1
Brinkley, DM1
Williams, R2
Tret'iakov, AV1
Riazanov, EM1
Filov, VA1
Cory, JG1
Grady, ED1
Nolan, TR1
Crumbley, AJ1
Rosen, AR1
Ryan, R1
Metman, EH1
Oberfield, R1
Glouse, M1
Baker, LH1
Saiki, JH1
Jones, SE1
Hewlett, JS1
Brownlee, RW1
Stephens, RL1
Vaitkevicius, VK2
Tschopp, L1
Gerber, A1
Sonntag, RW1
Ryssel, HJ1
Brunner, KW1
Habs, M1
Habs, G1
Schmähl, D1
Macleod, MS1
Schlesinger, T1
Atkins, HL1
Bradley-Moore, PR1
Casella, V1
Fowler, JS1
Greenberg, D1
Ido, T1
Lambrecht, RM1
MacGregor, R1
Mantescu, C1
Neirinckx, R1
Som, P1
Wolf, AP1
Wodinsky, I1
Meaney, K1
Gattanell, PN1
Perloff, M1
Holland, JF1
Harada, T1
Makisaka, Y1
Nishimura, H1
Senzer, NN1
Terrell, W1
Pratt, CB2
Lavin, P1
Pretorius, FJ1
Watanabe, A2
Hobara, N2
Wellwood, JM1
Cady, B1
Okazaki, N4
Ozaki, H1
Arima, M1
Hattori, N2
Kimura, K1
Schilling, A1
Gewiese, B1
Berger, G1
Boese-Landgraf, J1
Fobbe, F1
Stiller, D1
Gallkowski, U1
Wolf, KJ1
Kajanti, M1
Pyrhönen, S1
Mäntylä, M1
Rissanen, P1
Smith, FW1
Heys, SD1
Evans, NT1
Roeda, D1
Gvozdanovic, D1
Eremin, O1
Mallard, JR1
Paquet, KJ1
Kalk, JF1
Cuan-Orozco, F1
Siemens, F1
Koussouris, P1
Mercado, MA1
Ito, J1
Tanzawa, Y1
Toda, N1
Okamoto, M1
Taniguchi, M1
Uta, Y1
Tagawa, K1
van Eeden, H1
Burger, W1
Ansell, SM1
Giovannini, M1
Kanai, T2
Gotoh, M2
Tarui, T1
Monden, T1
Mori, T3
Abe, K2
Sugata, F2
Takizawa, K2
Yoshiba, M2
Takagi, T2
Kuniyasu, Y2
Okada, K3
Iwao, Y2
Aikawa, H1
Kuramoto, S1
Maeda, T1
Hanawa, S1
Yanagita, K1
Yoshio, T1
Cantor, A1
Morioka, N1
Tanigawa, N1
Okuda, Y1
Hashimoto, M1
Kawasaki, H1
Midorikawa, H2
Otani, Y1
Tsukui, M1
Goto, K1
Makuuchi, H1
Tajima, T1
Mitomi, T1
Nose, H1
Yoshimori, M1
Aoki, K1
Dhir, V1
Swaroop, VS1
Mohandas, KM1
Dinshaw, KA1
Desai, DC1
Nagral, A1
Sharma, V1
Jagannath, P1
Desouza, LJ1
Nagabuchi, E2
Ogasawara, K2
Saito, M2
Gotoda, A2
Takeda, M1
Mizuguchi, N1
Ohyama, Y1
Suzuki, S1
Itoh, M2
Mukojima, T1
Kumagai, T1
Iwasaki, H1
Tada, I3
Mori, K2
Takeyama, M1
Matsuoka, S2
Kitamura, M1
Miyashita, K1
Higashi, S1
Yokomori, K1
Hori, T1
Asoh, S1
Tuji, A1
Takemura, T1
Kajanti, MJ1
Pyrhönen, SO1
Staines, A1
Cullen, S1
Guiney, EJ1
Fitzgerald, RJ1
Breatnach, F1
Kanematsu, T5
Maehara, Y2
Matsumata, T3
Akazawa, K1
Stillwagon, GB2
Order, SE3
Guse, C2
Leibel, SA3
Asbell, SO1
Klein, JL3
Leichner, PK3
Order, S1
Pajak, T1
Leibel, S1
Asbell, S1
Leichner, P1
Ettinger, D1
Stillwagon, G1
Herpst, J1
Haulk, T1
Kopher, K2
Fujii, N1
Akimura, R1
Nakamura, Y2
Watanabe, T4
Izumi, R3
Shimizu, K3
Miyazaki, I1
Tomida, A1
Krakamp, B1
Schmitz, R1
Knöpfle, G1
Leidig, P1
Ohashi, I1
Oohigashi, H1
Fukuda, I2
Persson, BG1
Jeppsson, B1
Ekberg, H1
Tranberg, KG1
Lundstedt, C1
Bengmark, S1
Ng, TB1
Yeung, HW1
Borenfreund, E1
Babich, H1
Martin-Alguacil, N1
Hatta, Y1
Endo, Y2
Sassa, T1
Yoshikawa, N1
Hirose, N1
Funatomi, H1
Taguchi, S1
Fujimoto, S1
Endoh, F1
Takahashi, O1
Okui, K1
O'Connell, MJ2
Hahn, RG1
Rubin, J2
Fuchimoto, S1
Yasui, Y1
Gouchi, A1
Hamada, F1
Sanada, E1
Urakubo, M1
Okura, M1
Akamatsu, Y1
Orita, K2
Hashimoto, N1
Kawai, S1
Mikuriya, S1
Oda, T2
Inoue, J1
Shimamura, Y1
Takahashi, A1
Masuzawa, M1
Yumoto, Y1
Makino, M1
Muraoka, A1
Tokiwa, T1
Sato, J1
Strohmeyer, G1
Porschen, R1
Sasaki, F1
Hata, Y1
Sawada, H1
Saito, H1
Kanda, Y2
Akazawa, S1
Futatsugi, K1
Fujiki, T1
Saifuku, K1
Suzuki, F1
Nakajima, T1
Muraoka, M1
Hasumura, S1
Nagamori, S1
Fujise, K1
Homma, S1
Sujino, H1
Niiya, M1
Kameda, H1
Yano, S2
Tarumi, T3
Tamura, K2
Shimada, M1
Ling, HY1
Wang, NZ1
Shiga, T1
Nishimaki, K1
Kajikawa, S1
Horigome, N1
Hanasaki, K1
Adachi, W1
Kinosita, T1
Sodeyama, H1
Kuroda, T1
Iida, F1
Okajima, K1
Isozaki, H1
Nakata, E1
Nishimura, J1
Iga, C1
Amioka, K1
Tanimura, M1
Hara, H1
Haida, K2
Mitarai, Y1
Shibata, T1
Hurukawa, H1
Yabushita, K2
Horichi, H1
Kitabayashi, K1
Urade, M2
Iyobe, T1
Segawa, M1
Nagafuchi, E1
Misawa, K1
Takekawa, S1
Ye, WJ1
Bedenne, L1
Chauffert, B1
Lorcerie, B1
Faivre, J1
Hillon, P1
Klepping, C1
Martin, F1
Hamazaki, K1
Mimura, H1
Fishman, EK1
Soga, K1
Turuya, T1
Toshima, M1
Shibasaki, K1
Matugi, H1
Kawai, C1
Asakura, H1
Recchia, F1
Passalacqua, G1
Rodorigo, C1
Belli, L1
Morgante, A1
Rabitti, G1
Higashi, H2
Ogita, S3
Tokiwa, K3
Suenaga, M2
Lin, DY1
Liaw, YF1
Lee, TY1
Lai, CM1
Nerenstone, S1
Friedman, M1
Hannigan, JF1
Carter, SK1
Zaniboni, A1
Simoncini, E1
Marpicati, P1
Marini, G1
Doci, R1
Bignami, P1
Bozzetti, F1
Bonfanti, G1
Audisio, R1
Colombo, M1
Gennari, L1
Herlin, T1
Norup, K1
Storm, K1
Fujimura, T1
Ohhori, I1
Yonemura, Y1
Tsuda, M1
Nishioka, S1
Yataka, I1
Onoyama, Y1
Kanno, T1
Nakatsuka, H1
Hamazoe, R1
Koga, S2
Shimizu, N1
Sawata, T1
Ishiguro, M1
Wakatsuki, T2
Murakami, A2
Kusumoto, T1
Al-Idrissi, HY1
Ibrahim, EM1
Abdel Satir, A1
Satti, MB1
Al-Kasem, S1
Al-Qurain, A1
Green, AA1
Wrenn, E1
Champion, J1
Shipp, M1
Ohtsuki, T1
Obata, H1
Tomimatsu, M1
Hasegawa, H1
Ohnishi, K1
Rao, A1
O'Connell, TX1
Kagan, AR1
Steckel, RJ1
Marymont, JV1
Dakhil, SR1
Travers, H1
Housholder, DF1
Kido, C1
Kawazoe, Y1
Yamashita, K1
Kumagai, M1
Maeta, M1
Yoshioka, H1
Wang, CE1
Cao, XH1
Zhen, YY1
Kondo, H1
Fuse, M1
Naitoh, A1
Schutt, AJ1
Wieand, HS1
Glimelius, B1
Ettinger, DS1
Finney, K1
Surdyke, M1
Yamazaki, H1
Horikoshi, N1
Ueno, K1
Mukaiyama, T1
Miyaoka, K1
Iwamura, F1
Kimura, S1
Livraghi, T1
Ravetto, C1
Solbiati, L1
Suter, F1
Andersson, M1
Billström, A1
Domellöf, L1
Gustavsson, B1
Sato, R1
Ouchi, K1
Owada, Y1
Saitoh, R1
Miyoshi, S1
Tarui, S1
Imashuku, S1
Bezwoda, WR1
Weaving, A1
Kew, M1
Derman, DP1
Massey, WH2
Fletcher, WS2
Judkins, MP1
Dennis, DL2
Kanamoto, Y1
McIntire, KR1
Vogel, CL1
Princler, GL1
Patel, IR1
Weiss, JW1
Pitot, HC2
Fain, WR1
Conn, JH1
Chavez, CM1
Provan, JL1
Stokes, JF1
Edwards, D1
Kissel, P1
Bessot, M4
Duprez, A3
Geddes, EW1
Gorgun, B1
Watne, AL1
Champeau, M1
Arsac, M1
Pineau, P1
Thevenin, F1
Fays, J1
Grilliat, JP1
Anderson, JM1
Alberto, P1
Matsui, K1
Tomoe, T1
Terajima, S1
Yamasato, M1
Kondo, J1
Katsuta, K1
Hozumi, M1
Pashintseva, LP1
Krusanova, NI1
Assekritova, IV1
Ramirez, G1
Ansfield, FJ1
Curreri, AR1
Thompson, RP1
Nicholson, DC1
Farnan, T1
Whitmore, DN1
Wolberg, WH1
Sanderson, TA1
Wood, DC1
Mauuary, G1
Winsback, AM1
White, WD1
Juniper, K1
Daido, R1
Koike, A1
Nomiyama, Y1
Francis, TI1
Sugimura, M1
Ishida, M1
Iwamura, K1
Harrison, NW1
Dhru, D1
Primack, A1
Bhana, D1
Kyalwazi, SK1
al-Sarraf, M1
Go, TS1
Kithier, K1
Scott, D1
Theologides, A1
Stehlin, JS1
Hafström, L1
Greeff, PJ1
Plagemann, PG1
Erbe, J1
Schulz, D1
Young, HE1
Linder, GT1
Crook, JN1
Cohn, I1
Russell, DH1
Marton, LJ1
LeGendre, SM1
Morris, HP2
Lea, MA1
Khalil, FL1
Bullock, J1
Douglass, HO1
Mittelman, A1
Koyama, S1
Majima, S1
Matsushige, H1

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)[NCT05532319]Phase 265 participants (Anticipated)Interventional2022-02-01Recruiting
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma[NCT05609695]100 participants (Anticipated)Observational2023-03-01Not yet recruiting
A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents[NCT05718492]100 participants (Anticipated)Interventional2022-10-18Recruiting
Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma[NCT05573282]50 participants (Anticipated)Observational2022-10-16Recruiting
A Phase III Randomized Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin With Sorafenib for Patients With Barcelona-Clinic Liver Cancer (BCLC)-C Stage Hepatocellular Carcinoma[NCT03164382]Phase 3262 participants (Actual)Interventional2017-03-01Completed
A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC[NCT06041477]Phase 3540 participants (Anticipated)Interventional2023-09-30Recruiting
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After Hepatic Artery Infusion Chemotherapy (HAIC) for Locally Advanced Hepatocellular Carcinoma (HCC)[NCT05002452]150 participants (Anticipated)Observational2021-12-20Recruiting
An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope[NCT04945720]Phase 230 participants (Anticipated)Interventional2022-04-11Recruiting
A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma[NCT05231382]Phase 3426 participants (Anticipated)Interventional2022-03-28Recruiting
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: A Prospective, Phase II Clinical Study[NCT03869034]Phase 240 participants (Actual)Interventional2019-03-25Active, not recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587]Early Phase 160 participants (Anticipated)Interventional2021-07-01Enrolling by invitation
A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camreli[NCT05313282]Phase 3140 participants (Anticipated)Interventional2022-06-15Recruiting
A Prospective, Single-arm, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib-Mesylate Tablets and Camrelizumab for Injec[NCT04191889]Phase 247 participants (Anticipated)Interventional2020-04-13Recruiting
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949]Phase 1/Phase 239 participants (Anticipated)Interventional2019-12-01Not yet recruiting
Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus[NCT04025437]Phase 2/Phase 3214 participants (Anticipated)Interventional2019-03-01Active, not recruiting
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187]Phase 3247 participants (Actual)Interventional2016-05-31Completed
A Prospective, Single-armed, Multicentric, Explorative Phase II Clinical Research of Conversional Therapy With Combination of Hepatic Arterial Infusion Chemotherapy and Donafenib and Toripalimab for Unresectable Hepatocellular Carcinoma[NCT05493332]Phase 293 participants (Anticipated)Interventional2022-09-30Not yet recruiting
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375]Phase 2/Phase 3192 participants (Anticipated)Interventional2015-02-28Recruiting
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697]Phase 3290 participants (Anticipated)Interventional2016-01-31Recruiting
Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02585479]Phase 2/Phase 30 participants (Actual)Interventional2015-10-31Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma[NCT02584556]Phase 2/Phase 30 participants (Actual)Interventional2015-10-31Withdrawn
Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02534337]Phase 2/Phase 30 participants (Actual)Interventional2015-09-30Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02527772]Phase 2/Phase 30 participants (Actual)Interventional2015-09-30Withdrawn (stopped due to It doesn't meet the requirements of randomized trials)
Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT02452853]Phase 251 participants (Anticipated)Interventional2015-05-31Active, not recruiting
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study[NCT02426450]Phase 228 participants (Anticipated)Interventional2015-04-30Active, not recruiting
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment[NCT00471965]Phase 3371 participants (Actual)Interventional2007-03-31Completed
A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.[NCT00970216]160 participants (Actual)Observational2009-02-28Completed
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737]Phase 2125 participants (Anticipated)Interventional2020-01-10Recruiting
Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.[NCT00619541]Phase 246 participants (Anticipated)Interventional2007-01-31Completed
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors[NCT02404480]Phase 131 participants (Actual)Interventional2016-01-31Completed
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957]180 participants (Actual)Observational2006-02-28Completed
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427]Phase 2101 participants (Actual)Interventional2017-05-15Completed
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168]0 participants Expanded AccessNo longer available
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience[NCT02557750]35 participants (Anticipated)Observational2016-01-31Recruiting
Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498]Phase 235 participants (Anticipated)Interventional2015-06-30Completed
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809]Phase 440 participants (Anticipated)Interventional2014-01-31Recruiting
Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486]Phase 2160 participants (Actual)Interventional2011-11-14Completed
Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143]Phase 230 participants (Anticipated)Interventional2021-12-31Not yet recruiting
The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma[NCT00493402]Phase 3365 participants (Actual)Interventional2007-07-31Completed
A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083]Phase 220 participants Interventional2010-04-30Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HBV-DNA < 300 Copies/mL in 48 Weeks

(NCT00970216)
Timeframe: 48 weeks

Interventionparticipants (Number)
Chronic Hepatitis B79

Reviews

52 reviews available for fluorouracil and Hepatocellular Carcinoma

ArticleYear
Use of chemotherapy to treat hepatocellular carcinoma.
    Bioscience trends, 2022, Mar-11, Volume: 16, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2022
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
    Nature protocols, 2022, Volume: 17, Issue:8

    Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids

2022
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.
    Cancer medicine, 2023, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2023
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
    Clinical and molecular hepatology, 2023, Volume: 29, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2023
Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries.
    Current opinion in pharmacology, 2023, Volume: 70

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv

2023
Cisplatin in Liver Cancer Therapy.
    International journal of molecular sciences, 2023, Jun-29, Volume: 24, Issue:13

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Liver Ne

2023
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas

2023
Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review.
    Future oncology (London, England), 2014, Volume: 10, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Embolization, Ther

2014
[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour

2014
Progress in systemic therapy of advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Aug-07, Volume: 22, Issue:29

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Fluorourac

2016
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2016, Volume: 113, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol

2016
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ch

2017
Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy.
    Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial

2008
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2009
Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon.
    Oncology, 2010, Volume: 78 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;

2010
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluoro

2012
[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf

2002
Fibrolamellar hepatocellular carcinoma in children and adolescents.
    Cancer, 2003, Apr-15, Volume: 97, Issue:8

    Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2003
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
    Surgical endoscopy, 2003, Volume: 17, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula

2003
[The chemotherapy for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cis

2003
[Recent progress in chemotherapy for hepatocellular carcinoma].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Aug-10, Volume: 93, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2004
[Chemotherapy for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial

2004
Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
    Journal of surgical oncology, 2005, Jun-15, Volume: 90, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2005
[FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Synergism; Drug Th

2006
[The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr

2006
[Gemcitabine and digestive carcinomas].
    Bulletin du cancer, 2007, Volume: 94 Spec No Actualites

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2007
[Angiogenesis targeting in gastro-intestinal cancers].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2007
Safety of capecitabine use in patients with liver dysfunction.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:9

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate

2007
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
    The Korean journal of hepatology, 2008, Volume: 14, Issue:1

    Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabi

2008
[Hepatic tumors].
    Acta medica Austriaca, 1983, Volume: 10, Issue:4

    Topics: alpha-Fetoproteins; Angiography; Breast Neoplasms; Bronchial Neoplasms; Carcinoembryonic Antigen; Ca

1983
Update on regional treatments for hepatobiliary malignancies.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular;

1995
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 1994, Volume: 15

    Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N

1994
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
    Annals of surgery, 1995, Volume: 221, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce

1995
Medical treatment of hepatocellular carcinoma: any progress?
    Tumori, 1994, Oct-31, Volume: 80, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1994
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg

1996
Intra-hepatic arterial drug delivery.
    Journal of drug targeting, 1996, Volume: 3, Issue:5

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col

1996
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?
    Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:2

    Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Ethanol; F

1998
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
    Cancer, 2001, Jun-15, Volume: 91, Issue:12

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa

2001
Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector.
    Molecular biotechnology, 2001, Volume: 18, Issue:3

    Topics: Adenoviruses, Human; alpha-Fetoproteins; Animals; Antineoplastic Protocols; Antiviral Agents; Carcin

2001
Nonsurgical treatment of hepatocellular carcinoma.
    Seminars in oncology, 2001, Volume: 28, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli

2001
Systemic therapy for hepatocellular carcinoma.
    Seminars in oncology, 2001, Volume: 28, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco

2001
[Hepatic arterial infusion chemotherapy using 'low dose FP'].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula

2001
[Adverse reaction of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Ci

2001
[Hepatic arterial infusion chemotherapy combined with interferon-alpha for hepatocellular carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched

2001
[Chemotherapy of gastrointestinal tumors (review of the literature)].
    Onkologie, 1978, Volume: 1, Issue:6

    Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl

1978
Therapeutic approaches to hepatoma.
    Cancer treatment reviews, 1975, Volume: 2, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Drug Synergism; Drug Therapy, Com

1975
The biologic basis of malignant brain tumor therapy.
    Advances in neurology, 1976, Volume: 15

    Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm;

1976
[Selective chemotherapy of hepatocellular carcinomas].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1978, Issue:84

    Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Liver Neopla

1978
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies;

1989
[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
    Minerva medica, 1989, Volume: 80, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluatio

1989
Medical treatment of hepatocellular carcinoma.
    Gastroenterology clinics of North America, 1987, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co

1987
Systemic cytostatic drug therapy in liver cancer.
    Annales chirurgiae et gynaecologiae. Supplementum, 1986, Volume: 200

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;

1986

Trials

128 trials available for fluorouracil and Hepatocellular Carcinoma

ArticleYear
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China;

2022
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 174

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr

2022
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-01, Volume: 41, Issue:10

    Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial;

2023
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-01, Volume: 41, Issue:10

    Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial;

2023
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-01, Volume: 41, Issue:10

    Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial;

2023
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-01, Volume: 41, Issue:10

    Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial;

2023
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
    Signal transduction and targeted therapy, 2023, 09-27, Volume: 8, Issue:1

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Treatment Outcome; Tretinoin

2023
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
    The oncologist, 2021, Volume: 26, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Drugs, Chin

2021
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc

2021
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Cancer, 2021, Dec-15, Volume: 127, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2021
A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
    Japanese journal of clinical oncology, 2017, Jun-01, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; C

2017
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
    BMC cancer, 2018, Jun-04, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2018
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocel

2018
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cat

2018
All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll
    Trials, 2019, Apr-29, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Disease Progressio

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
[Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation;

2013
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepato

2013
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
    BMC gastroenterology, 2013, Aug-09, Volume: 13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2013
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
    The oncologist, 2013, Volume: 18, Issue:12

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit

2013
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin

2014
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo

2014
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo

2014
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo

2014
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo

2014
Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
    Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:12

    Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2014
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2015
Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo

2015
Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:131

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Hep

2014
Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
    World journal of gastroenterology, 2015, Sep-28, Volume: 21, Issue:36

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

2015
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl

2016
Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    Anti-cancer drugs, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2016
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2009
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenoviruses, Human; Adult; Aged; Antimetabolites, Antineoplastic; Body Fluids; Carcinoma, Hepatocel

2009
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.
    Journal of gastroenterology, 2009, Volume: 44, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod

2009
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2010
Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod

2010
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
    Anticancer research, 2009, Volume: 29, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy

2009
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    British journal of cancer, 2010, Mar-16, Volume: 102, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
    Annals of surgical oncology, 2010, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; C

2010
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
    Oncology, 2010, Volume: 78 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F

2010
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
    Cancer, 2011, Jul-15, Volume: 117, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepat

2011
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
    The Korean journal of hepatology, 2010, Volume: 16, Issue:4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2010
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate

2012
Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.
    Investigational new drugs, 2011, Volume: 29, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju

2011
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C

2012
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju

2011
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
    Cancer, 2012, Jul-01, Volume: 118, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2012
Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
    Oncology, 2011, Volume: 81, Issue:5-6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2011
Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
    Cardiovascular and interventional radiology, 2012, Volume: 35, Issue:6

    Topics: Aged; Aged, 80 and over; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hep

2012
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
    Journal of gastroenterology, 2012, Volume: 47, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2012
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined

2013
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Cancer, 2002, Aug-01, Volume: 95, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2002
Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Cohort S

2002
[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
    Taehan Kan Hakhoe chi = The Korean journal of hepatology, 2002, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Fluo

2002
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Feb-01, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2003
[Clinical study on treatment of middle-advanced stage liver cancer by combined treatment of hepatic artery chemoembolization with gan'ai no. I and no. II].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2001, Volume: 21, Issue:3

    Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Ch

2001
[Dynamics of clinical and biochemical indices in patients with primary liver cancer during endovascular chemotherapy].
    Likars'ka sprava, 2002, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2002
Fibrolamellar hepatocellular carcinoma in children and adolescents.
    Cancer, 2003, Apr-15, Volume: 97, Issue:8

    Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2003
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2003
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2003, Volume: 2, Issue:2

    Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin

2003
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    World journal of gastroenterology, 2003, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluoro

2003
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2004
A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Evaluation; Female; Fluorouracil; Human

2004
[Clinical observation on the treatment of middle-late stage liver carcinoma by combined therapy of hepato-arterial chemo-embolising and Chinese drugs for strengthening pi and regulating qi].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2004, Volume: 24, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2004
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato

2004
[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Cispla

2004
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Cancer, 2005, Feb-15, Volume: 103, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2005
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    World journal of gastroenterology, 2005, Apr-28, Volume: 11, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2005
Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.
    World journal of gastroenterology, 2005, Sep-07, Volume: 11, Issue:33

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen

2005
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
    Journal of the National Cancer Institute, 2005, Oct-19, Volume: 97, Issue:20

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2005
Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2005, Sep-28, Volume: 11, Issue:36

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fe

2005
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
    BMC cancer, 2006, Jan-05, Volume: 6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisp

2006
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
    Cancer, 2006, May-01, Volume: 106, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci

2006
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2007
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
    Pancreas, 2006, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Fem

2006
Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.
    Annals of surgical oncology, 2006, Volume: 13, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Che

2006
Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases.
    Digestive surgery, 2006, Volume: 23, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2006
Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
    World journal of gastroenterology, 2007, Jan-14, Volume: 13, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cispla

2007
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp

2007
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.
    Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C

2007
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
    British journal of cancer, 2007, Oct-08, Volume: 97, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin

2007
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
    World journal of gastroenterology, 2007, Nov-07, Volume: 13, Issue:41

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc

2007
Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
    Cancer, 2007, Dec-01, Volume: 110, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod

2007
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
    World journal of gastroenterology, 2007, Dec-28, Volume: 13, Issue:48

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2007
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2008
Primary liver cancer. An Eastern Cooperative Oncology Group Trial.
    Cancer, 1984, Sep-15, Volume: 54, Issue:6

    Topics: Adenoma, Bile Duct; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body W

1984
Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.
    Cancer, 1984, Feb-01, Volume: 53, Issue:3

    Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular

1984
Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma.
    Cancer, 1982, Sep-01, Volume: 50, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cyclophosphamide;

1982
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hep

1995
Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:11

    Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Hepatocellular; F

1994
Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 1995, Volume: 15, Issue:5

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, He

1995
5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.
    Cancer investigation, 1995, Volume: 13, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

1995
[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv

1995
[The study of continuous arterial infusion chemotherapy with CDDP and 5-FU in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

1995
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
    Cancer, 1993, Nov-01, Volume: 72, Issue:9

    Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Biomarkers; Carcinoma, Hepatocellular; Chemotherapy, Ad

1993
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
    Annals of surgery, 1995, Volume: 221, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce

1995
[The study of continuous arterial infusion chemotherapy with 5-FU and CDDP in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

1994
[Intra-arterial chemotherapy for the treatment of advanced hepatocellular carcinoma through implantable port (reservoir)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

1994
Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12

    Topics: Adenoma, Bile Duct; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1994
Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 1994, Volume: 33 Suppl

    Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Emboliza

1994
Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation?
    Transplantation proceedings, 1993, Volume: 25, Issue:1 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy

1993
Chemohormonal therapy of unresectable hepatocellular carcinoma.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato

1993
A pilot study of interferon alpha and 5-fluorouracil in hepatocellular carcinoma.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin

1996
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
    The British journal of surgery, 1996, Volume: 83, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu

1996
Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular;

1997
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
    Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

1997
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
    Anti-cancer drugs, 1998, Volume: 9, Issue:5

    Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over

1998
[Biochemical modulation of 5-FU--effect of low dose CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin

1999
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1999
Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2000, Volume: 83, Issue:5

    Topics: Adult; Angiography; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality The

2000
[Phase I study of super high-dose chemotherapy for liver cancer with percutaneous isolated hepatic perfusion (PIHP) and peripheral blood stem cell transplantation (PBSCT)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2000
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
    Human gene therapy, 2001, Feb-10, Volume: 12, Issue:3

    Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplast

2001
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
    British journal of cancer, 2001, Apr-06, Volume: 84, Issue:7

    Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplast

2001
A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato

2001
Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Human

2002
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci

2002
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy,

2002
5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases.
    Cancer, 1977, Volume: 39, Issue:5

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Adminis

1977
Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma.
    Cancer, 1977, Volume: 40, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Carcinoma, H

1977
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.
    Cancer, 1978, Volume: 42, Issue:5

    Topics: Adenoma, Bile Duct; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Clinical Trials a

1978
Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison.
    American journal of clinical oncology, 1992, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin;

1992
Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.
    American journal of clinical oncology, 1992, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy

1992
Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:1

    Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Moda

1991
A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepa

1991
194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study.
    International journal of radiation oncology, biology, physics, 1989, Volume: 17, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;

1989
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial.
    Gastroenterology, 1988, Volume: 94, Issue:2

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Emboliz

1988
Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma: experience of the Northern California Oncology Group.
    NCI monographs : a publication of the National Cancer Institute, 1988, Issue:6

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Female;

1988
[The role of antineoplastic solution in transcatheter hepatic arterial embolization--in terms of survival rates affecting anticancer agents together with gelatin sponge].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization

1988
Systemic cytostatic drug therapy in liver cancer.
    Annales chirurgiae et gynaecologiae. Supplementum, 1986, Volume: 200

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic;

1986
Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil.
    Oncology, 1987, Volume: 44, Issue:4

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinica

1987

Other Studies

912 other studies available for fluorouracil and Hepatocellular Carcinoma

ArticleYear
Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:10

    Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Ce

2009
Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
    Journal of medicinal chemistry, 2012, Apr-12, Volume: 55, Issue:7

    Topics: Adenosine; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cellular

2012
2-methoxyjuglone induces apoptosis in HepG2 human hepatocellular carcinoma cells and exhibits in vivo antitumor activity in a H22 mouse hepatocellular carcinoma model.
    Journal of natural products, 2013, May-24, Volume: 76, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpo

2013
Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
    Journal of medicinal chemistry, 2013, Jun-13, Volume: 56, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Azo Compounds; Carcinoma, Hepatocellular; Cell Line, Tumo

2013
Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
    European journal of medicinal chemistry, 2013, Volume: 69

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat

2013
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas

2014
Combinatorial synthesis, in silico, molecular and biochemical studies of tetrazole-derived organic selenides with increased selectivity against hepatocellular carcinoma.
    European journal of medicinal chemistry, 2016, Oct-21, Volume: 122

    Topics: Antineoplastic Agents; Antioxidants; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry Techniqu

2016
Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells.
    Bioorganic & medicinal chemistry letters, 2017, 02-15, Volume: 27, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Coumaric Acids; Epithelial-Mesenchymal Transition; Huma

2017
Cytotoxic clerodane diterpenoids from Croton crassifolius.
    Bioorganic & medicinal chemistry letters, 2017, 03-01, Volume: 27, Issue:5

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Croton; Diterpenes, Cler

2017
Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
    European journal of medicinal chemistry, 2017, Mar-31, Volume: 129

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Prot

2017
Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment.
    European journal of medicinal chemistry, 2017, Mar-31, Volume: 129

    Topics: Acridones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Des

2017
Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
    European journal of medicinal chemistry, 2017, May-05, Volume: 131

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line

2017
Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract.
    Bioorganic & medicinal chemistry letters, 2017, 05-01, Volume: 27, Issue:9

    Topics: Animals; Annona; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line,

2017
β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
    European journal of medicinal chemistry, 2019, Apr-15, Volume: 168

    Topics: Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prol

2019
Synthesis and biochemical studies of novel organic selenides with increased selectivity for hepatocellular carcinoma and breast adenocarcinoma.
    European journal of medicinal chemistry, 2019, Oct-01, Volume: 179

    Topics: Antineoplastic Agents; Antioxidants; Biphenyl Compounds; Breast Neoplasms; Carcinoma, Hepatocellular

2019
Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Dose-

2019
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
    European journal of medicinal chemistry, 2020, Nov-01, Volume: 205

    Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dos

2020
Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.
    European journal of medicinal chemistry, 2022, Mar-15, Volume: 232

    Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carcinoma, Hepatocellul

2022
Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.
    Bioorganic chemistry, 2021, Volume: 116

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Respons

2021
Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
    Internal medicine (Tokyo, Japan), 2022, Apr-15, Volume: 61, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorou

2022
Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Annals of surgical oncology, 2022, Volume: 29, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf

2022
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    BMC cancer, 2021, Oct-19, Volume: 21, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo

2021
[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2021, Volume: 37, Issue:10

    Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Fluorouracil; Humans; L

2021
FOLFOX-HAIC active in large HCC.
    Nature reviews. Clinical oncology, 2022, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv

2022
ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.
    Annals of surgical oncology, 2022, Volume: 29, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf

2022
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
    Journal of vascular and interventional radiology : JVIR, 2022, Volume: 33, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2022
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
    Journal of vascular and interventional radiology : JVIR, 2022, Volume: 33, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2022
HAIC-FO improves outcomes in HCC.
    Nature reviews. Clinical oncology, 2022, Volume: 19, Issue:3

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Oxaliplatin; Sorafenib

2022
Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and
    Canadian journal of gastroenterology & hepatology, 2022, Volume: 2022

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluor

2022
Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
    Oncology, 2022, Volume: 100, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arteries; Carcinoma, Hepatocellular; Cisplatin; Dise

2022
CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.
    Disease markers, 2022, Volume: 2022

    Topics: Carcinoma, Hepatocellular; Cell Line; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Fluoroura

2022
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 06-10, Volume: 40, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Flu

2022
Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.
    Molecules (Basel, Switzerland), 2022, Mar-24, Volume: 27, Issue:7

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Galactosamine; Liver Neoplasms;

2022
Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase.
    Chemico-biological interactions, 2022, Jun-01, Volume: 360

    Topics: Amphibian Venoms; Antineoplastic Agents; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation;

2022
Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
    Current pharmaceutical design, 2022, Volume: 28, Issue:25

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Del

2022
Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Oncology research and treatment, 2022, Volume: 45, Issue:7-8

    Topics: Adult; Carcinoma, Hepatocellular; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Liver Neo

2022
Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data.
    Journal of photochemistry and photobiology. B, Biology, 2022, Volume: 233

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Peptides;

2022
Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis.
    Journal of physiology and biochemistry, 2022, Volume: 78, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver

2022
Cerium oxide decorated 5-fluorouracil loaded chitosan nanoparticles for treatment of hepatocellular carcinoma.
    International journal of biological macromolecules, 2022, Sep-01, Volume: 216

    Topics: Animals; Carcinoma, Hepatocellular; Cerium; Chitosan; Fibroblasts; Fluorouracil; Liver Neoplasms; Ma

2022
GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.
    Cancer gene therapy, 2022, Volume: 29, Issue:11

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition;

2022
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
    Clinical journal of gastroenterology, 2022, Volume: 15, Issue:5

    Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Port

2022
Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
    Cancer medicine, 2023, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Leu

2023
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
    Chinese medical journal, 2022, Oct-05, Volume: 135, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Fluo

2022
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Canadian journal of gastroenterology & hepatology, 2022, Volume: 2022

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci

2022
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
    Cancer medicine, 2023, Volume: 12, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2023
Circ_0003998 upregulates ARK5 expression to elevate 5-Fluorouracil resistance in hepatocellular carcinoma through binding to miR-513a-5p.
    Anti-cancer drugs, 2022, 11-01, Volume: 33, Issue:10

    Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Fl

2022
One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
    BMC medicine, 2022, 10-31, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf

2022
Combinatorial treatment with Silybum marianum essential oil enhances the therapeutic efficacy of a 5-fluorouracil base therapy for hepatocellular carcinoma.
    Phytotherapy research : PTR, 2023, Volume: 37, Issue:5

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Mice; NF-kappa B; Oils

2023
Efficient chemosensitizing and antimetastatic combinations of a naturally occurring trans-ferulic acid with different chemotherapies on an in vitro hepatocellular carcinoma model.
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:8

    Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Fluorouraci

2023
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Journal of gastroenterology, 2023, Volume: 58, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Ind

2023
Novel Steroidal[17,16-
    Molecules (Basel, Switzerland), 2023, Mar-16, Volume: 28, Issue:6

    Topics: Androsterone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation

2023
Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2022, Volume: 73, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ethiodized Oil; Fluoroura

2022
Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:8

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance

2023
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hep

2023
MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil.
    Biochemical and biophysical research communications, 2023, 08-30, Volume: 670

    Topics: Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Move

2023
Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.
    Oncology research, 2022, Volume: 30, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorourac

2022
IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells.
    Oncology research, 2022, Volume: 30, Issue:2

    Topics: Carcinoma, Hepatocellular; Cell Line; Computational Biology; Fluorouracil; Humans; Liver Neoplasms

2022
Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?
    Annals of surgical oncology, 2024, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2024
Beta-Hydroxyisovaleryl-Shikonin Eradicates Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells by Suppressing dUTP Pyrophosphatase Expression.
    International journal of molecular sciences, 2023, Nov-14, Volume: 24, Issue:22

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial Cell Adhesion Molecule; Fluorouracil; Humans

2023
Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.
    European journal of pharmacology, 2019, Oct-15, Volume: 861

    Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Technique

2019
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    World journal of surgical oncology, 2019, Aug-15, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C

2019
Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
    Journal of proteomics, 2019, 09-30, Volume: 208

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver

2019
Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.
    Journal of cellular physiology, 2020, Volume: 235, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Flavonoids; Fluorouracil; Gene

2020
Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
    Anti-cancer agents in medicinal chemistry, 2020, Volume: 20, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cathepsin B; Chitosan; Chondroitin; Drug

2020
H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA.
    Biochemical and biophysical research communications, 2019, 11-26, Volume: 520, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzylisoquinolines; Carcinoma, Hep

2019
Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
    Digestive diseases and sciences, 2020, Volume: 65, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluo

2020
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply.
    JAMA oncology, 2019, 12-01, Volume: 5, Issue:12

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve

2019
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma.
    JAMA oncology, 2019, 12-01, Volume: 5, Issue:12

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve

2019
Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis.
    Regulatory toxicology and pharmacology : RTP, 2019, Volume: 109

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular;

2019
Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2019, Oct-29, Volume: 36, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2019
NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
    Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:2

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor;

2020
Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent.
    Pharmaceutical development and technology, 2020, Volume: 25, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoemb

2020
Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line.
    Proteomics. Clinical applications, 2020, Volume: 14, Issue:4

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Re

2020
Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.
    Current drug delivery, 2020, Volume: 17, Issue:10

    Topics: Carcinoma, Hepatocellular; Cholesterol; Drug Carriers; Fluorouracil; Hep G2 Cells; Humans; Liposomes

2020
Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma.
    The British journal of radiology, 2020, Volume: 93, Issue:1110

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2020
IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2020
Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil.
    Journal of proteomics, 2020, 05-15, Volume: 219

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver

2020
The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth.
    The Journal of international medical research, 2020, Volume: 48, Issue:3

    Topics: Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proli

2020
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway.
    Life sciences, 2020, Jul-01, Volume: 252

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation;

2020
LGR5 marks targetable tumor-initiating cells in mouse liver cancer.
    Nature communications, 2020, 04-23, Volume: 11, Issue:1

    Topics: Ablation Techniques; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; C

2020
Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux.
    Carcinogenesis, 2020, 11-13, Volume: 41, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular;

2020
CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma.
    Journal of pharmacological sciences, 2020, Volume: 143, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Differentiation; Cyc

2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Carcinogenesis, 2021, 02-11, Volume: 42, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast

2021
Challenges in Reirradiation of Intrahepatic Tumors.
    Seminars in radiation oncology, 2020, Volume: 30, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2020
Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell

2020
Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
    Molecular pharmaceutics, 2020, 09-08, Volume: 17, Issue:9

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor

2020
Ready to go 3D? A semi-automated protocol for microwell spheroid arrays to increase scalability and throughput of 3D cell culture testing.
    Toxicology mechanisms and methods, 2020, Volume: 30, Issue:8

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Proliferat

2020
Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
    Anticancer research, 2020, Volume: 40, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-

2020
INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.
    BMC surgery, 2020, Aug-01, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T

2020
Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
    Biological & pharmaceutical bulletin, 2020, Volume: 43, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Membe

2020
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellul

2020
Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
    Drug metabolism and disposition: the biological fate of chemicals, 2020, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Su

2020
MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance.
    Pharmacological research, 2021, Volume: 163

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Inducing Factor; Carcinoma, Hep

2021
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
    Molecular cancer, 2021, 01-06, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C

2021
Thiolated polymer nanocarrier reinforced with glycyrrhetinic acid for targeted delivery of 5-fluorouracil in hepatocellular carcinoma.
    Drug delivery and translational research, 2021, Volume: 11, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Fluorouracil; Glycyrrhetinic Acid; Liver Neoplasms; Polymers; Ra

2021
Biological features, gene expression profile, and mechanisms of drug resistance of two- and three-dimensional hepatocellular carcinoma cell cultures.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tum

2021
[Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2020, Volume: 45, Issue:23

    Topics: Animals; Capsules; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese H

2020
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Molecular medicine (Cambridge, Mass.), 2021, 02-12, Volume: 27, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Depe

2021
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
    Clinical and translational medicine, 2021, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bl

2021
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
    Academic radiology, 2021, Volume: 28 Suppl 1

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Humans; Infusions, Intra-Ar

2021
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
    Bioengineered, 2021, Volume: 12, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Fluorouracil; Hep G2 Cells

2021
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma.
    Oncology, 2021, Volume: 99, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child;

2021
Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
    Biochemical pharmacology, 2021, Volume: 188

    Topics: Acetylation; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dose-Response Relationship,

2021
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cispla

2021
Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer.
    International journal of nanomedicine, 2021, Volume: 16

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Carriers; Drug Liberatio

2021
Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
    Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:9

    Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Hepatic Artery; Huma

2021
Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres.
    Chemotherapy, 2021, Volume: 66, Issue:4

    Topics: Angiography; Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Carri

2021
Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability.
    Phytotherapy research : PTR, 2021, Volume: 35, Issue:10

    Topics: Apoptosis; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation;

2021
Effect of 5-fluorouracil on mRNA expression of drug metabolizing enzyme and transporter genes in human hepatoma cell lines.
    Biomedical research (Tokyo, Japan), 2021, Volume: 42, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fluoro

2021
Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.
    Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:8

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Heart Atria; Humans; Liver Neoplasms; Pulmonary Embolism; V

2022
Hepatoprotective Mongolian prescription II enhances the antitumor effects of chemotherapeutics in hepatocellular carcinoma xenografts.
    Pathology, research and practice, 2017, Volume: 213, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fluo

2017
Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
    Biochemical and biophysical research communications, 2017, 06-10, Volume: 487, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat

2017
USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
    Oncotarget, 2017, Apr-11, Volume: 8, Issue:15

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm;

2017
Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma.
    Nanomedicine (London, England), 2017, Volume: 12, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; D

2017
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
    BMC cancer, 2017, 05-19, Volume: 17, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cell-Free System; Chemoemboliza

2017
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    International journal of molecular sciences, 2017, Jun-01, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Argin

2017
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
    International journal of cancer, 2017, 10-01, Volume: 141, Issue:7

    Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antibody-Dependent Cell Cytotoxicity; Antimetabolites, An

2017
A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
    Anticancer research, 2017, Volume: 37, Issue:7

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelia

2017
GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.
    Scientific reports, 2017, 07-11, Volume: 7, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo

2017
Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma.
    Cancer research and treatment, 2018, Volume: 50, Issue:3

    Topics: Adult; Aged; Biomarkers, Tumor; Blood Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mo

2018
Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
    International journal of surgery (London, England), 2017, Volume: 45

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2017
A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
    Scientific reports, 2017, 08-29, Volume: 7, Issue:1

    Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cell Prolifer

2017
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu

2017
The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice.
    European journal of medical research, 2017, Nov-21, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Hep G2 Cells; Human

2017
Inhibition of autophagy in hepatocarcinoma cells promotes chemotherapeutic agent-induced apoptosis during nutrient deprivation.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Adenine; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepat

2018
Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, He

2018
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Oncology, 2018, Volume: 94, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Journal of hepatology, 2018, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China;

2018
[A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis.
    Oncogene, 2018, Volume: 37, Issue:20

    Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Movement; Cyclin E; Fluoroura

2018
Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 98

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; bcl-X Protein; Carcin

2018
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:6

    Topics: Adult; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Sorafenib

2018
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
    Zeitschrift fur Gastroenterologie, 2018, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Gastrointes

2018
RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 46, Issue:4

    Topics: Animals; Antigens, Nuclear; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell M

2018
Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway.
    Biochemical and biophysical research communications, 2018, 06-18, Volume: 501, Issue:1

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor;

2018
Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Medical science monitor : international medical journal of experimental and clinical research, 2018, May-03, Volume: 24

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinogenesis; Carcinoma, Hepatoc

2018
Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 104

    Topics: Antigens, CD; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil;

2018
MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
    The international journal of biochemistry & cell biology, 2018, Volume: 101

    Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Carcinoma,

2018
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Cancer science, 2018, Volume: 109, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2018
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap
    Journal of hepato-biliary-pancreatic sciences, 2018, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2018
lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
    Cell communication and signaling : CCS, 2018, 08-17, Volume: 16, Issue:1

    Topics: Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression

2018
Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats.
    Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Disease Models, Ani

2018
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
    Cell death & disease, 2018, 09-24, Volume: 9, Issue:10

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Hepatocellular; Cohort Stu

2018
SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.
    RNA biology, 2018, Volume: 15, Issue:10

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endonucleases; Fluorouracil; Gene Expressi

2018
Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
    Journal of pharmaceutical sciences, 2019, Volume: 108, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotin; Carcinoma, Hepatocellular; Curcumin

2019
Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma.
    Journal of cellular physiology, 2019, Volume: 234, Issue:7

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Surv

2019
Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:7

    Topics: Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy

2019
Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
    ACS applied materials & interfaces, 2019, Mar-20, Volume: 11, Issue:11

    Topics: ADAM17 Protein; Animals; Apoptosis; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line; C

2019
Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2019
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
    Journal of vascular and interventional radiology : JVIR, 2019, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Clini

2019
Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.
    Artificial cells, nanomedicine, and biotechnology, 2019, Volume: 47, Issue:1

    Topics: Animals; Biomimetics; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Pre

2019
Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019, Volume: 133

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemorad

2019
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
    Anticancer research, 2019, Volume: 39, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol

2019
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
    Medical science monitor basic research, 2019, Apr-08, Volume: 25

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docet

2019
Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells.
    Journal of cellular physiology, 2019, Volume: 234, Issue:11

    Topics: Aluminum Chloride; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; C

2019
Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells.
    Viruses, 2019, 04-24, Volume: 11, Issue:4

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dr

2019
Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
    Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:6

    Topics: AC133 Antigen; AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular;

2019
Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.
    JAMA oncology, 2019, 07-01, Volume: 5, Issue:7

    Topics: Carcinoma, Hepatocellular; China; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Po

2019
Hepatic arterial chemotherapy for hepatocellular carcinoma.
    The Lancet. Oncology, 2019, Volume: 20, Issue:6

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve

2019
Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2019
TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma.
    International journal of biological sciences, 2019, Volume: 15, Issue:8

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatin Immunoprecipitation; Epit

2019
Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.
    World journal of surgery, 2013, Volume: 37, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2013
hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors.
    Carcinogenesis, 2013, Volume: 34, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Hepatocel

2013
Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Car

2013
PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
    Annals of surgical oncology, 2013, Volume: 20 Suppl 3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral

2013
Efficient total synthesis and biological activities of 6-deoxyisojacareubin.
    Archiv der Pharmazie, 2013, Volume: 346, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Humans;

2013
Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma.
    Current pharmaceutical design, 2014, Volume: 20, Issue:1

    Topics: Antimetabolites, Antineoplastic; Base Sequence; Blotting, Western; Carcinoma, Hepatocellular; Cell L

2014
Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
    Future oncology (London, England), 2013, Volume: 9, Issue:4

    Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette

2013
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
    Anti-cancer drugs, 2013, Volume: 24, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C

2013
Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:124

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie

2013
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
    Pharmaceutical biology, 2013, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P

2013
Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.
    Cell death & disease, 2013, Jun-06, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Enzyme Ac

2013
Epigenetic silencing of DACH1 induces loss of transforming growth factor-β1 antiproliferative response in human hepatocellular carcinoma.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Adolescent; Adult; Aged; Azacitidine; Carcinoma, Hepatocellular; DNA Methylation; Eye Proteins; Fema

2013
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    British journal of cancer, 2013, Jun-25, Volume: 108, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Cancer, 2013, Sep-15, Volume: 119, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2013
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2013
[Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2013, Volume: 33, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Charybdotoxin; Fluorouracil; Hypoxia-Inducible

2013
Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2013, Volume: 91, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor

2013
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    BMC cancer, 2013, Jul-29, Volume: 13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell C

2013
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
    World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular

2013
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
    World journal of gastroenterology, 2013, Aug-07, Volume: 19, Issue:29

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D

2013
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
    International journal of cancer, 2014, Mar-01, Volume: 134, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F

2014
The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Cancer letters, 2014, Jan-01, Volume: 342, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinom

2014
Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
    British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce

2013
MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Cellular signalling, 2013, Volume: 25, Issue:12

    Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; beta Cate

2013
[A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Humans; Inhibitory Concentration

2013
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
    BMJ case reports, 2013, Sep-16, Volume: 2013

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fl

2013
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Journal of clinical gastroenterology, 2014, Volume: 48, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular

2014
Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
    Marine drugs, 2013, Sep-17, Volume: 11, Issue:9

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Deliv

2013
Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tum

2013
[Effect of plasmid transfected shMRE11 on the drug-resistance of BEL7402/5-FU hepatoma cells].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2013, Volume: 29, Issue:10

    Topics: Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorouracil; Humans; Li

2013
MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
    Molecular cancer, 2013, Oct-08, Volume: 12, Issue:1

    Topics: 3' Untranslated Regions; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Base Sequen

2013
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease-

2013
Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
    Oncology reports, 2014, Volume: 31, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter,

2014
Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2013, Volume: 39, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2013
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response.
    ACS nano, 2013, Dec-23, Volume: 7, Issue:12

    Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug

2013
[A case of huge advanced hepatocellular carcinoma resected after hepatic arterial infusion therapy of 5-FU/LV/CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal

2013
Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report.
    Anticancer research, 2013, Volume: 33, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Female;

2013
EpCAM-targeted therapy for human hepatocellular carcinoma.
    Annals of surgical oncology, 2014, Volume: 21, Issue:4

    Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2014
[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, The

2013
[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality

2013
SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
    Molecular medicine reports, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cysteine Endopeptidases; Drug Resistance, Neoplasm

2014
Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
    Biomaterials, 2014, Volume: 35, Issue:9

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation;

2014
SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.
    Biomaterials, 2014, Volume: 35, Issue:9

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellu

2014
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Jan-07, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2014
Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.
    Cancer letters, 2014, May-01, Volume: 346, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Benzothiazoles; Carcinoma, Hepatocellular; Ce

2014
Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2.
    Oncology reports, 2014, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatoce

2014
Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Drug Therapy; Fluorouracil;

2014
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine

2014
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
    Oncology reports, 2014, Volume: 31, Issue:5

    Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell

2014
Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines.
    Molecular medicine reports, 2014, Volume: 9, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biologic

2014
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
    Journal of microencapsulation, 2014, Volume: 31, Issue:5

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Delivery Systems; Fluorouracil; Hep

2014
MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.
    Biochemical and biophysical research communications, 2014, Apr-25, Volume: 447, Issue:1

    Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; D

2014
Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells.
    Die Pharmazie, 2014, Volume: 69, Issue:4

    Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Col

2014
The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Analysis of Variance; Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Colony-Formi

2014
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2014
Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation.
    International journal of nanomedicine, 2014, Volume: 9

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Bacterial Toxins; Carcinoma, Hepatocellular; Cell Line,

2014
Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.
    Molecular medicine reports, 2014, Volume: 10, Issue:2

    Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Down

2014
HepG2 cells recovered from apoptosis show altered drug responses and invasiveness.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2014, Volume: 13, Issue:3

    Topics: Ablation Techniques; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Dos

2014
Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
    International journal of nanomedicine, 2014, Volume: 9

    Topics: Animals; Carcinoma, Hepatocellular; Diffusion; Drug Evaluation, Preclinical; Female; Fluorouracil; H

2014
Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2014, Volume: 34, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dow

2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
The synergistic effect of organic silicone quaternary ammonium salt and 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2014, Volume: 23, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He

2014
Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:14

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif

2014
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

    Topics: Aged; Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato

2014
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
    World journal of gastroenterology, 2014, Aug-21, Volume: 20, Issue:31

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemo

2014
[Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells].
    Wei sheng yan jiu = Journal of hygiene research, 2014, Volume: 43, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Glycosaminoglycans; L

2014
Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fema

2015
Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Diagnostic and interventional radiology (Ankara, Turkey), 2014, Volume: 20, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2014
Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells.
    Molecular medicine reports, 2014, Volume: 10, Issue:6

    Topics: AMP-Activated Protein Kinases; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellu

2014
Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.
    Yonsei medical journal, 2014, Volume: 55, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Chem

2014
Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; bcl-X Protein; Binding Sites; Carcinoma, H

2015
JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Anthracenes; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Fluo

2015
5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
    Clinical and experimental pharmacology & physiology, 2015, Volume: 42, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Carcinoma, Hepatocellu

2015
Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, H

2015
Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2015, Volume: 159, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Czech Republic; Disease-Fr

2015
Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.
    Oncotarget, 2015, Feb-10, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula

2015
Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell

2015
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2015
Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:5

    Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Chemoembolization, Therapeutic; Disea

2015
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
    Current cancer drug targets, 2015, Volume: 15, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Prote

2015
Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.
    Anti-cancer drugs, 2015, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C

2015
[Long-term survival in a patient receiving multidisciplinary therapy for hepatocellular carcinoma with left iliac bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocell

2014
Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis.
    Bulletin du cancer, 2015, Volume: 102, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bifidobacterium; Carcinoma, H

2015
Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
    Hepatology international, 2015, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2015
Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jul-01, Volume: 21, Issue:13

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, T

2015
Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    World journal of gastroenterology, 2015, Apr-07, Volume: 21, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2015
VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Gene Expression Regulation, Neopla

2015
MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 35, Issue:6

    Topics: 3' Untranslated Regions; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-

2015
Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Oncotarget, 2015, May-10, Volume: 6, Issue:13

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Proli

2015
A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Ph

2015
[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2014, Volume: 37, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplati

2014
Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell

2015
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Journal of digestive diseases, 2015, Volume: 16, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carci

2015
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis Patients.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:131

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2014
Education and Imaging. Hepatobiliary and Pancreatic: Complete remission after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with decompensated cirrhosis.
    Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:1

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcino

2016
[Novel hybrids of (phenylsulfonyl)furoxan and N-benzyl matrinol as anti-hepatocellular carcinoma agents].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2015, Volume: 50, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Hep G2 Cells; Humans; Liver Neoplasm

2015
MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large.
    Molecular medicine reports, 2015, Volume: 12, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Cisp

2015
Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
    Oncotarget, 2015, Sep-15, Volume: 6, Issue:27

    Topics: Adaptor Proteins, Signal Transducing; alpha-Fetoproteins; Animals; Apoptosis Regulatory Proteins; bc

2015
The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2015, Volume: 14, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization,

2015
Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:2

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Disease Models, Animal

2016
Significance of the Signal Intensity of Gadoxetic Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma.
    Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2016, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic

2016
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma.
    Oncotarget, 2015, Oct-20, Volume: 6, Issue:32

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; CSK Tyrosine-Protein Kinase; DN

2015
Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
    European journal of pharmacology, 2015, Dec-05, Volume: 768

    Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1;

2015
MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD.
    International journal of molecular sciences, 2015, Oct-06, Volume: 16, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Dihyd

2015
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
    Molecular medicine reports, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette

2015
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:3

    Topics: Adult; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Diagnostic Errors; Doxorubicin; Dru

2015
Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.
    Molecular medicine reports, 2016, Volume: 13, Issue:1

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell

2016
Effect of luteolin on gene expression in mouse H22 hepatoma cells.
    Genetics and molecular research : GMR, 2015, Nov-19, Volume: 14, Issue:4

    Topics: Animals; Carcinoma, Hepatocellular; CD58 Antigens; Cell Line, Tumor; Cell Proliferation; Fluorouraci

2015
Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell

2016
Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 76

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13

2015
Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Blotting, Western;

2016
[New FP Therapy Was Effective for a Case of Massive Hepatocellular Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal

2015
Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
    Oncotarget, 2016, Feb-23, Volume: 7, Issue:8

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Dr

2016
[Fluoroscopy-induced Subacute Radiation Dermatitis in Patient with Hepatocellular Carcinoma].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Volume: 67, Issue:2

    Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluoroscopy; Fluorouracil; Gamma Rays; Humans;

2016
ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun.
    Oncotarget, 2016, Mar-29, Volume: 7, Issue:13

    Topics: Animals; Annexins; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumo

2016
[Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2015, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Coculture Techniques; Culture Me

2015
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
    BMC cancer, 2016, Mar-16, Volume: 16

    Topics: Carcinoma, Hepatocellular; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Epithel

2016
Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.
    Oncology reports, 2016, Volume: 35, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Core

2016
[Spontaneous cytotoxicity treated with anti-tumor drugs of splenocytes of rats on a model of hepatoma cell monolayer cultures].
    Voprosy onkologii, 2015, Volume: 61, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell

2015
Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
    Journal of experimental & clinical cancer research : CR, 2016, Apr-22, Volume: 35

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2016
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens;

2016
Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
    Journal of pharmacological sciences, 2016, Volume: 131, Issue:4

    Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepat

2016
Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Medicine, 2016, Volume: 95, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Abl

2016
Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor;

2016
Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy.
    Journal of medical virology, 2017, Volume: 89, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Drug Therapy; Female; Fluorouraci

2017
Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
    Oncotarget, 2016, Jul-19, Volume: 7, Issue:29

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepato

2016
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

2016
The Effects and Mechanisms of Periplaneta americana Extract Reversal of Multi-Drug Resistance in BEL-7402/5-FU Cells.
    Molecules (Basel, Switzerland), 2016, Jun-28, Volume: 21, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Tr

2016
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
    Yonsei medical journal, 2016, Volume: 57, Issue:5

    Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor

2016
Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.
    Journal of experimental & clinical cancer research : CR, 2016, 07-13, Volume: 35, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor

2016
Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
    Molecular pharmaceutics, 2016, 09-06, Volume: 13, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Deliver

2016
Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
    Scientific reports, 2016, 07-29, Volume: 6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models,

2016
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Co

2016
Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
    Oncology reports, 2016, Volume: 36, Issue:4

    Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorourac

2016
The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy.
    Biochemical and biophysical research communications, 2016, 09-23, Volume: 478, Issue:3

    Topics: Autophagy; Base Sequence; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; C

2016
Capecitabine and the Risk of Fingerprint Loss.
    JAMA oncology, 2017, Jan-01, Volume: 3, Issue:1

    Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil

2017
Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma.
    Medical science monitor : international medical journal of experimental and clinical research, 2016, Oct-14, Volume: 22

    Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Female;

2016
Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2016, Nov-15, Volume: 23, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associ

2016
miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5‑fluorouracil by targeting EIF4E.
    Oncology reports, 2017, Volume: 37, Issue:1

    Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Down-Regulation; Drug Resistance, Ne

2017
Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.
    Artificial cells, nanomedicine, and biotechnology, 2017, Volume: 45, Issue:8

    Topics: Carcinoma, Hepatocellular; Down-Regulation; Fluorouracil; Gene Knockdown Techniques; Hep G2 Cells; H

2017
Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell

2017
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
    Experimental cell research, 2017, 02-15, Volume: 351, Issue:2

    Topics: Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Arginase; Carcinoma, Hepatocellu

2017
In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
    Drug delivery, 2017, Volume: 24, Issue:1

    Topics: A549 Cells; Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatoce

2017
Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy.
    The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:6

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Line,

2017
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom

2008
Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.
    World journal of gastroenterology, 2008, Jun-28, Volume: 14, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Combined M

2008
Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
    Oncology reports, 2008, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2008
[The study of Rougan Jiedu formula anti-liver cancer in vivtro].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2008, Volume: 31, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif

2008
Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
    Anti-cancer drugs, 2008, Volume: 19, Issue:8

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemo

2008
Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy

2008
Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
    Hepatology (Baltimore, Md.), 2008, Volume: 48, Issue:3

    Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellula

2008
Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:9

    Topics: Absorbable Implants; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carci

2008
Down-regulation of Sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells.
    Acta biochimica et biophysica Sinica, 2008, Volume: 40, Issue:9

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Fluorouracil

2008
Commentary 2008: 25 or 50 years later?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neopl

2008
Hepatocellular carcinoma-related gene targeting using the large circular antisense library.
    Oncology reports, 2008, Volume: 20, Issue:4

    Topics: Antisense Elements (Genetics); Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Surviva

2008
[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:10

    Topics: Anticarcinogenic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatoc

2008
Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7.
    Journal of bioscience and bioengineering, 2008, Volume: 106, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Rel

2008
[A resected case of huge advanced hepatocellular carcinoma(BCC)treated with intra-arterial infusion chemotherapy combined with interferon-alpha].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorouracil; Hepatecto

2008
[Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2008, Volume: 31, Issue:6

    Topics: Antineoplastic Agents; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-R

2008
The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2008, Volume: 28, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2008
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie

2009
Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells.
    Cancer letters, 2009, Apr-18, Volume: 276, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 8;

2009
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola

2008
[Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

2008
[Comparison between pathological findings and MR diffusion-weighted imaging in primary hepatocellular carcinoma after transcatheter arterial chemoembolization].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:12

    Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Diffusion M

2008
Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
    Cancer letters, 2009, Jun-28, Volume: 279, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement

2009
[A case of hepatocellular carcinoma rapidly progressing after percutaneous radiofrequency ablation successfully treated with low-dose 5-FU and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:2

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2009
[Expression of ERK5 in multidrug-resistant hepatocellular carcinoma cell line].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:3

    Topics: Carcinoma, Hepatocellular; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoro

2009
A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenoviruses, Human; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2009
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-01, Volume: 15, Issue:9

    Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase;

2009
ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.
    Cancer letters, 2009, Sep-28, Volume: 283, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 6; Cell Cycle; Cell Death; Cell Line, Tumo

2009
[Advanced hepatic resection for malignancy].
    Khirurgiia, 2009, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce

2009
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
    British journal of cancer, 2009, May-19, Volume: 100, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols;

2009
[Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2009, Volume: 34, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C

2009
Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2009, Volume: 8, Issue:3

    Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplas

2009
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular

2009
Hepatocellular carcinoma in membranous obstruction of the inferior vena cava--a causal or a casual presentation.
    Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:2

    Topics: Adult; Angioplasty, Balloon; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Flu

2009
Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He

2010
[A case of advanced hepatocellular carcinoma effectively treated with 5-fluorouracil and high-concentration cisplatin suspended in lipiodol by short-term hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin;

2009
Identification of genes conferring resistance to 5-fluorouracil.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Aug-04, Volume: 106, Issue:31

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell L

2009
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu

2009
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
    Cancer, 2009, Nov-01, Volume: 115, Issue:21

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Moda

2009
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:9

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cyclooxygenase 2; Down-Regulation; Drug

2009
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:6

    Topics: Adult; Aged; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modal

2009
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2010
Quantitative (19)F imaging of nmol-level F-nucleotides/-sides from 5-FU with T(2) mapping in mice at 9.4T.
    Magnetic resonance in medicine, 2009, Volume: 62, Issue:5

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; F

2009
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.
    BMC cancer, 2009, Oct-12, Volume: 9

    Topics: Angiogenic Proteins; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Prolif

2009
Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.
    Cancer biology & therapy, 2009, Volume: 8, Issue:22

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carboplatin; Carcinom

2009
[Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2009
Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hep

2010
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2009
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    World journal of gastroenterology, 2009, Dec-21, Volume: 15, Issue:47

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Line, Tumo

2009
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
[A long-term survival case of hepatocellular carcinoma with lymph node metastasis on the posterior surface of the pancreas head and portal vein tumor thrombus successfully treated with hepatopancreatoduodenectomy and adjuvant interferon-alpha and 5-fluoro
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv

2009
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio

2010
Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
    AJR. American journal of roentgenology, 2010, Volume: 194, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Combin

2010
Implantation of port-catheter system for hepatic arterial infusion chemotherapy with catheter tip fixation in a patient with celiac arterial obstruction.
    Journal of vascular and interventional radiology : JVIR, 2010, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoma, Hepato

2010
Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2010, Volume: 17, Issue:8-9

    Topics: Aesculus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinom

2010
[Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances 5-FU sensitivity].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2010
Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats.
    The Journal of membrane biology, 2010, Volume: 234, Issue:1

    Topics: alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Fluorouracil; Glucosamine; Glycosaminoglycan

2010
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Cisplatin;

2010
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    American journal of clinical oncology, 2011, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate

2011
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
    Gene therapy, 2010, Volume: 17, Issue:7

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Ca

2010
Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells.
    British journal of cancer, 2010, May-11, Volume: 102, Issue:10

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, T

2010
Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
    Cancer research, 2010, Jun-01, Volume: 70, Issue:11

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2010
Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis.
    Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cause of Death; Cis

2010
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
    Surgical endoscopy, 2011, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Su

2011
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2011
Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
    Chinese journal of cancer, 2010, Volume: 29, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2010
CD13 is a therapeutic target in human liver cancer stem cells.
    The Journal of clinical investigation, 2010, Volume: 120, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; CD13 Antige

2010
Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods.
    Journal of experimental & clinical cancer research : CR, 2010, Aug-20, Volume: 29

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma,

2010
Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2011
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv

2012
Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
    Annals of surgical oncology, 2011, Volume: 18, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral

2011
Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.
    Journal of pharmaceutical sciences, 2010, Volume: 99, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug

2010
ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis.
    Carcinogenesis, 2010, Volume: 31, Issue:11

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutat

2010
Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.
    BMC complementary and alternative medicine, 2010, Sep-28, Volume: 10

    Topics: Antineoplastic Agents, Phytogenic; Atractylodes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholan

2010
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
    International journal of radiation oncology, biology, physics, 2011, Dec-01, Volume: 81, Issue:5

    Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer

2011
Susceptibility of Hep3B cells in different phases of cell cycle to tBid.
    Biochimica et biophysica acta, 2011, Volume: 1813, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting,

2011
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; DNA Primers; Drug Evaluation, Precl

2010
Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
    Gut, 2011, Volume: 60, Issue:4

    Topics: Adenoviridae; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bioma

2011
Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.
    Oncology reports, 2011, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2011
Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2011
[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2010
The design and cytotoxic evaluation of some 1-aryl-3-isopropylamino-1-propanone hydrochlorides towards human Huh-7 hepatoma cells.
    Archiv der Pharmazie, 2011, Volume: 344, Issue:5

    Topics: Acetone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Crystallography, X-Ray;

2011
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular

2012
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
    Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He

2011
Which treatment modality should we choose for advanced hepatocellular carcinoma?
    The Korean journal of hepatology, 2010, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate

2010
[Effect of bushen jianpi decoction and its disassemble recipes on tumor growth in mice with transplanted primary hepatic carcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2011, Volume: 31, Issue:2

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chinese Herbal; Fluorouracil

2011
Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.
    Archives of pharmacal research, 2011, Volume: 34, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2011
18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
    Cancer, 2011, 10-15, Volume: 117, Issue:20

    Topics: Adult; Aged; Analysis of Variance; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-

2011
Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro.
    Cancer letters, 2011, Jul-01, Volume: 306, Issue:1

    Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Calcium; Carcinoma, Hepatoce

2011
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
    Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:7

    Topics: Carcinoma, Hepatocellular; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Imm

2011
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:1

    Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; AT

2011
Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice.
    Phytotherapy research : PTR, 2012, Volume: 26, Issue:1

    Topics: Adjuvants, Immunologic; Animals; Antigens, CD19; Antineoplastic Agents, Phytogenic; Boraginaceae; Ca

2012
Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Cardiovascular and interventional radiology, 2012, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,

2012
Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
    International journal of radiation oncology, biology, physics, 2012, Mar-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Female; F

2012
Reversal effect of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2011, Sep-15, Volume: 18, Issue:12

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Chalcones; Chromatogra

2011
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
    Pharmacogenomics, 2011, Volume: 12, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma,

2011
[The inhibitory effect of RNA interference on STAT3 expression in liver cancer cell line SMMC7721].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2011, Volume: 27, Issue:6

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gene Knockdown Techni

2011
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci

2011
FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
    Cancer, 2012, Jan-01, Volume: 118, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding

2012
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Dea

2011
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
    Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:2

    Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecit

2011
Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.
    The Korean journal of hepatology, 2011, Volume: 17, Issue:2

    Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispla

2011
Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.
    Journal of biomedicine & biotechnology, 2011, Volume: 2011

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, He

2011
miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
    Oncology reports, 2012, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoma, Hepatocellular;

2012
Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells.
    Integrative cancer therapies, 2011, Volume: 10, Issue:4

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Carboplatin; Carcinoma, Hepatocellular; Caspase 3; C

2011
Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
    Molecular medicine reports, 2012, Volume: 5, Issue:1

    Topics: Abietanes; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-2-Associ

2012
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:11

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2011
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein.
    European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit Analy

2012
Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells.
    World journal of gastroenterology, 2011, Oct-14, Volume: 17, Issue:38

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspas

2011
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.
    The Journal of biological chemistry, 2012, Feb-17, Volume: 287, Issue:8

    Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Drug Resistanc

2012
Hepatic arterial infusion chemotherapy with a coaxial reservoir system using a non-braided spiral tip microcatheter.
    Japanese journal of radiology, 2012, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Catheter

2012
Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines.
    International journal of oncology, 2012, Volume: 40, Issue:4

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor;

2012
Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:5

    Topics: Adult; Aged; Annexin A3; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Re

2012
[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T

2011
Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
    Cancer letters, 2012, Jul-01, Volume: 320, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; C

2012
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
    Journal of liposome research, 2012, Volume: 22, Issue:3

    Topics: Acetone; Amines; Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Dela

2012
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:119

    Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo

2012
Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.
    Cancer letters, 2012, Jul-28, Volume: 320, Issue:2

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin

2012
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
    Journal of gastroenterology, 2012, Volume: 47, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2012
Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.
    Experimental oncology, 2012, Volume: 34, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel

2012
Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
    The Korean journal of hepatology, 2012, Volume: 18, Issue:1

    Topics: Administration, Metronomic; Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepat

2012
Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.
    Bulletin du cancer, 2012, Volume: 99, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bifidobacterium; Carcinoma, Hepatocellular;

2012
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Annals of surgical oncology, 2012, Volume: 19, Issue:11

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization

2012
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?
    World journal of gastroenterology, 2012, Apr-28, Volume: 18, Issue:16

    Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Fluorouracil; Hepatic Arter

2012
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14

    Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Mon

2012
Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Oncology reports, 2012, Volume: 28, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Proc

2012
Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells.
    International journal of oncology, 2012, Volume: 41, Issue:3

    Topics: Apoptosis; Autophagy; Calcium; Carcinoma, Hepatocellular; Caspase 12; Cell Line, Tumor; Endoplasmic

2012
Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling.
    International journal of oncology, 2012, Volume: 41, Issue:3

    Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Enzyme Inhibi

2012
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
    Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat

2012
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
    Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Prolifer

2012
Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2012
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car

2012
MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2.
    Die Pharmazie, 2012, Volume: 67, Issue:7

    Topics: 3' Untranslated Regions; Antimetabolites; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; C

2012
Reversal effect of melanoma differentiation associated gene-7/interleukin-24 on multidrug resistance in human hepatocellular carcinoma cells.
    Anatomical record (Hoboken, N.J. : 2007), 2012, Volume: 295, Issue:10

    Topics: Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Doxorubicin; Drug Resistance, Mul

2012
Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems.
    Acta radiologica (Stockholm, Sweden : 1987), 2012, Nov-01, Volume: 53, Issue:9

    Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatoc

2012
Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Lin

2012
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
    BMC cancer, 2012, Sep-10, Volume: 12

    Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting,

2012
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc

2012
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2012
5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatoce

2012
Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells.
    The international journal of biochemistry & cell biology, 2013, Volume: 45, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement

2013
TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
    Anatomical record (Hoboken, N.J. : 2007), 2013, Volume: 296, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1;

2013
Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.
    The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astragalus Plant; ATP Binding Ca

2012
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
    Transplantation proceedings, 2012, Volume: 44, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj

2012
Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
    World journal of gastroenterology, 2012, Nov-14, Volume: 18, Issue:42

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepat

2012
Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2012
Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9

    Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Asso

2012
Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
    Oncology reports, 2013, Volume: 29, Issue:3

    Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell

2013
Hepatocellular carcinoma and chemotherapy: the role of p53.
    Chemotherapy, 2012, Volume: 58, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line,

2012
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo

2012
RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy.
    Oncology reports, 2013, Volume: 29, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi

2013
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin

2013
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Radiation oncology (London, England), 2013, Jan-16, Volume: 8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiothe

2013
Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein.
    Journal of surgical oncology, 2002, Volume: 80, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

2002
The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
    Chinese medical journal, 2002, Volume: 115, Issue:5

    Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Benzylisoquinolines; Calmodulin; Carcinoma, Hep

2002
[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched

2002
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Cancer, 2002, Nov-01, Volume: 95, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F

2002
Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
    World journal of gastroenterology, 2002, Volume: 8, Issue:6

    Topics: Buthionine Sulfoximine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluorescein; Fluoroura

2002
[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combina

2002
Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
    Journal of Tongji Medical University = Tong ji yi ke da xue xue bao, 2001, Volume: 21, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

2001
Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells.
    Journal of gastroenterology, 2002, Volume: 37 Suppl 14

    Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; F

2002
Resection of hepatocellular carcinoma with tumor thrombus of the portal vein after neoadjuvant regional chemotherapy.
    Journal of hepato-biliary-pancreatic surgery, 2002, Volume: 9, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2002
[A case of advanced hepatocelluar carcinoma achieving a complete response following the hepatic arterial infusion chemotherapy and subsequent lipiodolization].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2003
Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Res

2003
[Role of caspase-8 and caspase-3 in hepatoma cells apoptosis induced by 5-fluorouracil].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2003, Volume: 11, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase

2003
Is liver disease an octreotide side effect?
    Journal of clinical gastroenterology, 2003, Volume: 37, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug

2003
[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2003, Volume: 41, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cyclo

2003
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
    Digestive diseases and sciences, 2003, Volume: 48, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; F

2003
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Hepatocellular;

2003
GROWTH INHIBITION OF A SPECTRUM OF TRANSPLANTED MOUSE TUMORS BY COMBINATIONS OF INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS AND ALKYLATING AGENTS.
    Cancer research, 1963, Volume: 23

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tumor;

1963
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl

1964
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
    Cancer research, 1965, Volume: 25

    Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv

1965
Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2003, Volume: 23, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterization, Pe

2003
Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
    AJR. American journal of roentgenology, 2003, Volume: 181, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2003
Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2003, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Caspase 9; Caspase

2003
[Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2003
[Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2003
[A case of successful treatment of advanced hepatocellular carcinoma with tumor thrombi in the major portal branches and inferior vena cava with combined intraarterial 5-fluorouracil, adriamycin and cisplatin therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi

2003
[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy

2003
[A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr

2003
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fl

2003
The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Cisplatin;

2004
[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)].
    Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12

    Topics: Aldehyde Reductase; Aldo-Keto Reductases; Antineoplastic Agents; ATP Binding Cassette Transporter, S

2003
Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
    Acta pharmacologica Sinica, 2004, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Multiple; Drug Resista

2004
[Application of arsenic trioxide in comprehensive therapy of liver carcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2003, Volume: 23, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma

2003
Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU.
    International journal of oncology, 2004, Volume: 24, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Collagen; Colonic Neop

2004
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy.
    Cell research, 2003, Volume: 13, Issue:6

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cu

2003
[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma,

2004
An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2003, Volume: 23, Issue:4

    Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line

2003
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
    Canadian journal of physiology and pharmacology, 2004, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-R

2004
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En

2004
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Cell death and differentiation, 2004, Volume: 11 Suppl 1

    Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apop

2004
Changes of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model.
    World journal of gastroenterology, 2004, May-15, Volume: 10, Issue:10

    Topics: Animals; Carbon; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Diagnost

2004
Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
    Journal of gastroenterology, 2004, Volume: 39, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F

2004
Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:5

    Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular

2004
A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma.
    Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:1

    Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bilirubin; Carcinoma, Hepatocellular; Cerulop

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors.
    Journal of vascular and interventional radiology : JVIR, 2004, Volume: 15, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, I

2004
Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
    Journal of gastroenterology, 2004, Volume: 39, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Fluorourac

2004
Effect of resveratrol and in combination with 5-FU on murine liver cancer.
    World journal of gastroenterology, 2004, Oct-15, Volume: 10, Issue:20

    Topics: Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell C

2004
Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2004
Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy.
    International journal of oncology, 2004, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dr

2004
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq

2004
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dihydrouracil De

2004
5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:3

    Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Galactosidase; Carcinoma,

2005
[Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2004
[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration

2004
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati

2004
[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi

2004
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis

2004
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin].
    The Korean journal of hepatology, 2004, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F

2004
[Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response

2004
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Collagen; Culture Med

2004
Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell.
    Biochemical pharmacology, 2005, Feb-15, Volume: 69, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Humans; Idoxuridine; Iod

2005
Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Journal of gastroenterology, 2005, Volume: 40, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2005
Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.
    Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell

2005
Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carcinoma, Hepatocellular;

2005
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2005, Volume: 45, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin;

2005
[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined

2005
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular;

2005
CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
    World journal of gastroenterology, 2005, Feb-28, Volume: 11, Issue:8

    Topics: Animals; Carcinoma, Hepatocellular; Combined Modality Therapy; CpG Islands; Fluorouracil; Genetic Th

2005
[Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju

2005
Intraarterial chemotherapy: another choice for unresectable advanced hepatocellular carcinoma?
    Journal of the Chinese Medical Association : JCMA, 2004, Volume: 67, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

2004
Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
    Journal of the Chinese Medical Association : JCMA, 2004, Volume: 67, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

2004
Images of interest. Hepatobiliary and pancreatic: Tumor thrombi in esophageal varices.
    Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Endoscopy; Eso

2005
Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.
    World journal of gastroenterology, 2005, May-07, Volume: 11, Issue:17

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Capsules; Carcinoma, Hepatocellular; Cell Line,

2005
Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2005, Volume: 4, Issue:2

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluo

2005
P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.
    Cell biology international, 2005, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel

2005
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
    Acta pharmacologica Sinica, 2005, Volume: 26, Issue:6

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA

2005
[A case of hepatocellular carcinoma with tumor thrombi in the first branch of the portal vein and hepatic vein trunks treated by transcatheter hepatic arterial chemoembolization and hepatic arterial infusion chemotherapy--two years and six months follow-u
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

2005
Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.
    Journal of hepatology, 2005, Volume: 43, Issue:3

    Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane Permeability; Cyt

2005
5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
    World journal of gastroenterology, 2005, Jul-07, Volume: 11, Issue:25

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorour

2005
Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
    Journal of hepato-biliary-pancreatic surgery, 2005, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

2005
[Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2005, Volume: 25, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocell

2005
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
    British journal of cancer, 2005, Sep-05, Volume: 93, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog

2005
[Transcatheter hepatic arterial chemoembolization on recurrent hepatocellular carcinoma after resection].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2005
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
    Oncology reports, 2005, Volume: 14, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocel

2005
Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.
    World journal of gastroenterology, 2005, Sep-14, Volume: 11, Issue:34

    Topics: Aged; Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Co

2005
Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
    Cancer gene therapy, 2006, Volume: 13, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Re

2006
[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response

2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellul

2006
[A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorouracil;

2005
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Aged; Alprostadil; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols;

2005
[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl

2005
Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2.
    DNA and cell biology, 2005, Volume: 24, Issue:12

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line,

2005
[Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2005, Volume: 25, Issue:11

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco

2005
[Investigation of bile duct injury after transcatheter arterial chemoembolization].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Carcinom

2005
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy

2006
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Clinical colorectal cancer, 2006, Volume: 5, Issue:5

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycy

2006
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2006
[Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2006, Volume: 4, Issue:3

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Do

2006
Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:1 Pt 1

    Topics: Angiogenic Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular;

2006
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capeci

2006
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
    Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:1

    Topics: Acetyltransferases; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Wes

2006
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma.
    Journal of hepato-biliary-pancreatic surgery, 2006, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa

2006
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Che

2006
Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines.
    International journal of oncology, 2006, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cas

2006
Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.
    Acta biochimica et biophysica Sinica, 2006, Volume: 38, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-X Protein; Camptothecin; Car

2006
Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Journal of hepatology, 2007, Volume: 46, Issue:1

    Topics: Antibodies; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; CASP8 and FA

2007
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
    International journal of oncology, 2006, Volume: 29, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Ce

2006
Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells.
    Biomedical research (Tokyo, Japan), 2006, Volume: 27, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Ce

2006
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
    Acta pharmacologica Sinica, 2006, Volume: 27, Issue:12

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor;

2006
[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer

2006
[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched

2006
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Oncology reports, 2007, Volume: 17, Issue:2

    Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Combined

2007
[A case of an elderly patient having advanced hepatocellular carcinoma with tumor thrombus in the inferior vena cava treated with chemo-radio-therapy--intraarterial infusion of weekly high dose 5-FU (WHF)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Aged, 80 and over; Carcinoma, Hepatocellular; Combined Modality Therapy; Fluorouracil; Humans; Infus

2006
[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Human

2006
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2006
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts,

2006
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.
    Canadian journal of physiology and pharmacology, 2006, Volume: 84, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor;

2006
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl

2007
Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:10

    Topics: Adenoviridae; Adoptive Transfer; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Carcinoma, H

2007
Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2007, Volume: 61, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3;

2007
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.
    International journal of clinical oncology, 2007, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Hepatectomy

2007
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
    Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor

2007
Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
    World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor

2007
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:9

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2007
[Anti-tumor effect of interferon for hepatocellular carcinoma-from the clinical consideration].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T

2007
[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2007
Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas.
    Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:9

    Topics: Alternative Splicing; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, He

2007
Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:74

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dose-Response Relat

2007
[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dihydro

2007
Bioluminescent imaging of hepatocellular carcinoma in live mice.
    Biotechnology letters, 2007, Volume: 29, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2007
[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2007
Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
    Journal of gastroenterology, 2007, Volume: 42, Issue:6

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Therapy,

2007
[A case of chronic hepatitis C virus-related advanced hepatocelluar carcinoma surviving more than 8 years].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr

2007
Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:8

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehydrogenase (NADP);

2007
Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology.
    World journal of gastroenterology, 2007, Aug-28, Volume: 13, Issue:32

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Medi

2007
Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation.
    Cancer science, 2007, Volume: 98, Issue:11

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Genes, Reporter; Hepatitis B virus; Human

2007
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Oncology reports, 2007, Volume: 18, Issue:4

    Topics: Angiopoietins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepato

2007
Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture.
    World journal of gastroenterology, 2007, Nov-07, Volume: 13, Issue:41

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumo

2007
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit

2007
Antiproliferative and antimetastatic effects of the ethanolic extract of Phellinus igniarius (Linnearus: Fries) Quelet.
    Journal of ethnopharmacology, 2008, Jan-04, Volume: 115, Issue:1

    Topics: Animals; Antineoplastic Agents; Basidiomycota; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mov

2008
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
    Journal of gastroenterology, 2007, Volume: 42, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi

2007
Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He

2007
[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase].
    Zhonghua yi xue za zhi, 2007, Aug-14, Volume: 87, Issue:30

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Sy

2007
Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells.
    BMC cancer, 2007, Nov-12, Volume: 7

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Gene Expressi

2007
Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:78

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; DNA, Complementary; Female; Fluoro

2007
Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice.
    World journal of gastroenterology, 2007, Dec-14, Volume: 13, Issue:46

    Topics: Animals; Antimetabolites; Apoptosis; Arginine; bcl-2-Associated X Protein; Carcinoma, Hepatocellular

2007
Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.
    Cancer biology & therapy, 2008, Volume: 7, Issue:3

    Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Fluorouracil; Humans; L

2008
Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2).
    Ultrasonics, 2008, Volume: 48, Issue:4

    Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug

2008
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
    World journal of surgery, 2008, Volume: 32, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju

2008
Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:6

    Topics: Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression

2007
Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Mon

2008
Capecitabine for treatment of advanced hepatocellular carcinoma.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:80

    Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycyti

2007
A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.
    Cancer biology & therapy, 2008, Volume: 7, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cellul

2008
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin;

2009
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
    World journal of gastroenterology, 2008, Apr-28, Volume: 14, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

2008
Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells.
    Anti-cancer drugs, 2008, Volume: 19, Issue:4

    Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell P

2008
AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
    Life sciences, 2008, Jun-06, Volume: 82, Issue:23-24

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hep

2008
Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.
    Digestive diseases and sciences, 1984, Volume: 29, Issue:8

    Topics: Adult; Carcinoma, Hepatocellular; Cholestasis, Extrahepatic; Combined Modality Therapy; Doxorubicin;

1984
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1984, Volume: 55, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru

1984
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou

1984
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:12 Pt 1

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C

1984
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:12 Pt 1

    Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched

1984
Virilizing hepatoblastoma--significance of alpha-1-fetoprotein and human chorionic gonadotropin as tumor markers in diagnosis and follow-up.
    European journal of pediatrics, 1981, Volume: 135, Issue:3

    Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Chorionic Gonadotropin; Cyclophosphamide; Doxorubicin

1981
[Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:9

    Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluor

1982
Continuous intra-arterial infusion chemotherapy of hepatoma.
    Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1983, Volume: 82, Issue:3

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Fema

1983
Tumor cell lipid composition and sensitivity to humoral immune killing. I. Modification of cellular lipid and fatty acid content by metabolic inhibitors and hormones.
    Journal of immunology (Baltimore, Md. : 1950), 1980, Volume: 124, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cardiolipins; Cattle; Cholesterol; Cytotoxicity, Immunologic; Da

1980
Adriamycin in the treatment of resectible and irresectible primary hepatocellular carcinoma.
    Annals of the Academy of Medicine, Singapore, 1980, Volume: 9, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Therapy, Combination; Fluorourac

1980
Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiation.
    Annals of the Academy of Medicine, Singapore, 1980, Volume: 9, Issue:2

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Evaluation;

1980
[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].
    Klinische Wochenschrift, 1981, Jun-15, Volume: 59, Issue:12

    Topics: Antineoplastic Agents; Asialoglycoproteins; Azo Compounds; Carcinoma, Hepatocellular; Cell Membrane

1981
A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival.
    The Japanese journal of surgery, 1981, Volume: 11, Issue:2

    Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Ligation;

1981
[Advanced liver neoplasms in children].
    Pediatria polska, 1981, Volume: 56, Issue:8

    Topics: Adolescent; Carcinoma, Hepatocellular; Child; Child, Preschool; Female; Fluorouracil; Humans; Infant

1981
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
    Nuklearmedizin. Nuclear medicine, 1982, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular

1982
Preoperative chemotherapy for unresectable primary hepatic malignancies in children.
    Cancer, 1982, Sep-15, Volume: 50, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Child, Preschool; Cyclophospham

1982
Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia: a comparison with African and American patients.
    Cancer, 1982, Sep-15, Volume: 50, Issue:6

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neopl

1982
Prolonged survival with hepatocellular carcinoma.
    Gastroenterology, 1982, Volume: 83, Issue:5

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Time Factors

1982
Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
    Journal of surgical oncology, 1983, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adult; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Th

1983
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
    Deutsche medizinische Wochenschrift (1946), 1983, Jul-01, Volume: 108, Issue:26

    Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa

1983
Pharmacokinetics of ftorafur after intravenous and oral administration.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:3

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Half-Life; Human

1983
Surgical considerations in the management of hepatic neoplasia.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Adenoma, Bile Duct; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Floxuridine;

1983
The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors.
    Seminars in oncology, 1983, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Fluorouracil; Hepati

1983
[HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Fluorouracil

1983
[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:10

    Topics: Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Fl

1982
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans

1982
[Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:2

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Colonic Neoplasms; Drug Synergism; Dru

1983
[Evaluation of chemotherapy in hepatocellular carcinoma with liver cirrhosis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;

1983
Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines.
    Cancer research, 1984, Volume: 44, Issue:3

    Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Fluorouracil; Gastrointestinal Neoplasms; Humans;

1984
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
    American journal of surgery, 1984, Volume: 147, Issue:4

    Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali

1984
[Hepatocellular carcinoma in pregnancy].
    Geburtshilfe und Frauenheilkunde, 1994, Volume: 54, Issue:5

    Topics: Adult; Carcinoma, Hepatocellular; Cesarean Section; Chemotherapy, Adjuvant; Combined Modality Therap

1994
[Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12

    Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubic

1995
Exceptional toxicity of 5-fluorouracil and interferon-alpha in a patient with hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:5

    Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Interferon-gamma; Liver Neoplasms; Male

1995
[Palliative therapy of primary liver tumors].
    Langenbecks Archiv fur Chirurgie, 1993, Volume: 378, Issue:4

    Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; alpha-Fetoproteins; Angiography; Antineoplastic Combine

1993
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
    American journal of surgery, 1995, Volume: 169, Issue:4

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che

1995
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzofurans; Biological Transport; Carc

1995
The significance of portal vein chemotherapy for liver micrometastases: an experimental study of a rat model.
    Surgery today, 1994, Volume: 24, Issue:10

    Topics: Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorouracil; Heparin; Infusions, Int

1994
[A case of poorly differentiated hepatic cell carcinoma which showed 90% decrease in size after chemotherapy with intraarterial infusion of mitomycin C and oral administration of tegafur].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:16

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula

1994
Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system.
    Cancer chemotherapy and pharmacology, 1994, Volume: 33 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D

1994
Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 1994, Volume: 33 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;

1994
Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE).
    Cancer chemotherapy and pharmacology, 1994, Volume: 33 Suppl

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1994
[A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato

1994
[Application of crossed assay design in test of drug sensitivity in vitro in combined chemotherapy of liver cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1993, Volume: 15, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D

1993
Diagnosis and therapy for primary hepatic carcinoma: transcatheter inferior phrenic arteriography and chemoembolization.
    Journal of Tongji Medical University = Tong ji yi ke da xue xue bao, 1993, Volume: 13, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

1993
Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:1

    Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

1993
Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.
    Annals of surgery, 1993, Volume: 217, Issue:2

    Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combi

1993
[The present status of chemotherapy for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:7

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino

1993
[Pathomorphological study of resected hepatocellular carcinoma after transcatheter hepatic arterial chemo-embolization].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 1993, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

1993
[The study of continuous local arterial-infusion chemotherapy with 5-FU + CDDP for patients with severely advanced HCC--for the elongation of the life-span and the improvement of QOL].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula

1993
[Complication of gastro-duodenum with intra-hepatic arterial infusion chemotherapy using implantable reservoir system for hepatic tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Administration Schedule; Duodenal Diseases; Female; Fluor

1993
[Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr

1993
Percutaneous hepatic arterial chemotherapy and chemoembolization.
    Cancer nursing, 1993, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

1993
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P

1996
[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorou

1996
[Usefulness of continuous arterial infusion chemotherapy for post operative multiple recurrence and residual hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr

1996
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel

1996
Continuous infusional 5-fluorouracil chemotherapy.
    Annals of surgery, 1996, Volume: 224, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

1996
Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1996, Volume: 8, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Cisplatin;

1996
[Chemosensitivity test on hepatocellular carcinoma (HCC) and drug resistance].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 1996, Volume: 71, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel

1996
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

1997
[Continuous arterial infusion of low-dose cisplatin, 5-fluorouracil as adjuvant therapy in cytoreductive surgery for advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

1997
[The study of continuous infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with primary liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cholangiocarcinoma;

1997
[A case of advanced hepatocellular carcinoma with portal invasion effectively treated by continuous intra-arterial chemotherapy with 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, I

1997
[A case of postoperative recurrence of hepatocellular carcinoma successfully treated with arterial infusion chemotherapy using cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

1997
[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization,

1998
[Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap

1998
[Resection of primary liver cancer following transcatheter arterial chemoembolization: clinicopathological features and postoperative course in cases].
    Zhonghua yi xue za zhi, 1997, Volume: 77, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat

1997
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3

    Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; China; Dihydrouracil Dehydrogenas

1997
Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:1

    Topics: Antibodies; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Cisplatin; f

1999
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
    Clinical & experimental metastasis, 1998, Volume: 16, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight

1998
The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.
    Cancer letters, 1999, Jan-08, Volume: 135, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Casset

1999
Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    American journal of clinical oncology, 1999, Volume: 22, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi

1999
[A case of advanced hepatocellular carcinoma treated by repeated arterial infusion chemotherapy of 5-FU, LV, CDDP with an implanted reservoir].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1999, Volume: 96, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

1999
Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C.
    Journal of gastroenterology and hepatology, 1999, Volume: 14, Issue:8

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellu

1999
[Hepatic arterial infusion of low-dose cisplatin, 5-fluorouracil for hepatocellular carcinoma with tumor thrombi in the portal vein].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

1999
[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

1999
[A case report of hepatocellular carcinoma with hepatic and portal venous tumor thrombus and multiple intrahepatic metastasis who survived over 1 year after the operation with combined locoregional chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined

1999
Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Apoptosis; Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Divi

2000
A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.
    Molecular and cellular biology, 2000, Volume: 20, Issue:20

    Topics: 5' Untranslated Regions; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular;

2000
[Hepatic arterial infusion chemotherapy using totally implantable port system].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D

2000
Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus.
    Journal of clinical gastroenterology, 2000, Volume: 31, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

2000
[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine

2000
[Hepatocellular carcinoma with tumor thrombus in the portal and hepatic veins treated successfully with hepatectomy and chemotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine

2000
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
    Biochemical and biophysical research communications, 2001, Feb-09, Volume: 280, Issue:5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport

2001
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
    Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En

2000
[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:2

    Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Fluorouracil; Hepatitis C, Ch

2001
Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma.
    The British journal of radiology, 2000, Volume: 73, Issue:874

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz

2000
Endovascular occlusion of branches of hepatic artery with poly(2-hydroxyethyl methacrylate) emboli as a single occlusive measure in hepatology.
    Polimery w medycynie, 2000, Volume: 30, Issue:3-4

    Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Arterial Occlusive Diseases; Carcinoid Tumor; Carcinom

2000
[A case of advanced hepatocellular carcinoma (Vp3) with right adrenal gland metastasis successfully treated with repeated arterial infusion chemotherapy using low dose CDDP and 5-FU through an implanted reservoir].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2001, Volume: 98, Issue:9

    Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

2001
Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth.
    Chinese medical journal, 1999, Volume: 112, Issue:8

    Topics: alpha-Fetoproteins; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Fluor

1999
[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour

2001
[A case of hepatocellular carcinoma responding to hepatic arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelli

2001
[Examination of in vitro chemosensitivity test using methylthiazole tetrazolium bromide chemosensitivity (MTT) test with combined drugs in hepatic arterial infusion chemotherapy for carcinoma of the liver].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Color

2001
Preoperative administration of 5-FU and interferon beta may prevent recurrence of hepatitis B and C virus.
    The American journal of gastroenterology, 2002, Volume: 97, Issue:1

    Topics: Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil

2002
[A case of spindle cell type hepatocellular carcinoma responding to hepatic intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dru

2002
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.
    Oncology, 2002, Volume: 62 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil;

2002
Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
    Surgery, 2002, Volume: 131, Issue:3

    Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Ducts, Extrah

2002
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
    Cancer, 2002, Jan-15, Volume: 94, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo

2002
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Cancer, 2002, Jan-15, Volume: 94, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Hepat

2002
[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm

2002
[Apoptosis effects of human liver carcinoma cells induced by 5-fluorouracil].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2002, Volume: 10, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Enzyme Inhibitors; Fluorourac

2002
[The interaction between 5-fluorouracil and marini on QGY cell line in vitro].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2002, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; D

2002
Effect of concanavalin A on tyrosine aminotransferase in rat hepatoma tissue culture cells. Rapid reversible inactivation of soluble enzyme.
    The Journal of biological chemistry, 1977, Apr-25, Volume: 252, Issue:8

    Topics: Alanine Transaminase; Animals; Carcinoma, Hepatocellular; Cell Line; Concanavalin A; Cyclic AMP; Cyc

1977
Chemotherapeutic drugs increase killing of tumor cells by antibody and complement.
    Science (New York, N.Y.), 1975, Apr-04, Volume: 188, Issue:4183

    Topics: Animals; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular;

1975
Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement.
    Cancer research, 1975, Volume: 35, Issue:11 Pt 1

    Topics: Animals; Antibodies, Neoplasm; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carci

1975
Beta-glucuronidase activity of Yoshida ascites hepatomas of different drug-sensitivity and its change after treatment of host rats with various anticancer agents.
    Gan, 1976, Volume: 67, Issue:1

    Topics: Animals; Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Hepatocellular; Chromomycins;

1976
Evaluation of hepatoma chemotherapy by alpha-fetoprotein determination.
    American journal of surgery, 1976, Volume: 132, Issue:3

    Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion

1976
Hepatic dearterialization for nonrespectable primary and secondary tumors of the liver.
    Cancer, 1976, Volume: 38, Issue:6

    Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; Fluorouracil; Hemangiosarcoma; H

1976
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
    The Tohoku journal of experimental medicine, 1977, Volume: 123, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma,

1977
A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.
    Cancer, 1975, Volume: 35, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Drug Therapy

1975
Recent trends in chemotherapy of solid tumors.
    The Medical clinics of North America, 1975, Volume: 59, Issue:2

    Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl

1975
Current status of regional arterial infusion chemotherapy.
    The Medical clinics of North America, 1975, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization;

1975
Current management of hepatic tumors.
    Surgery, gynecology & obstetrics, 1975, Volume: 140, Issue:5

    Topics: Angiography; Biopsy, Needle; Blood Platelet Disorders; Carcinoma, Hepatocellular; Child; Child, Pres

1975
Clinical management of advanced gastrointestinal cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther

1975
A study of trace and minor elements in the solid tumor model 3924A hepatoma before and after treatment with t-fluorouracil.
    Life sciences, 1975, Jul-15, Volume: 17, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cattle; Disease Models, Animal; Female; Fluorouracil; Liver; Liv

1975
Effects of 5-fluorouracil on the cell kinetic and growth parameters of hepatoma 3924A.
    British journal of cancer, 1975, Volume: 32, Issue:1

    Topics: Animals; Carcinoma, Hepatocellular; Cell Count; Connective Tissue; Deoxyuridine; DNA, Neoplasm; Dose

1975
Increased urinary excretion of cyclic guanosine monophosphate in rats bearing Morris hepatoma 3924A.
    Science (New York, N.Y.), 1975, Oct-03, Volume: 190, Issue:4209

    Topics: Animals; Carcinoma, Hepatocellular; Cyclic AMP; Cyclic GMP; Female; Fluorouracil; Liver Neoplasms; N

1975
The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine.
    Cancer research, 1975, Volume: 35, Issue:11 Pt 1

    Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Floxuridine; Fluorouracil; In Vitro Techniques;

1975
[Studies on the fate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), a carcinostatic agent. III. Absorption, distribution, excretion and metabolism after rectal administration of FT-207 (author's transl)].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 1975, Volume: 95, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Male; Neop

1975
Experimental study on drug sensitivity of the rat ascites hepatoma cells in embryonated eggs.
    The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, 1975, Volume: 22, Issue:1-2

    Topics: Animals; Carcinoma, Hepatocellular; Chick Embryo; Drug Evaluation, Preclinical; Fluorouracil; Liver

1975
Malignant hepatoma associated with acquired hepatic cutaneous porphyria.
    Archives of dermatology, 1976, Volume: 112, Issue:1

    Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Feces; Female; Fluorouracil; Hu

1976
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
    Journal of the National Cancer Institute, 1976, Volume: 56, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Do

1976
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
    American journal of surgery, 1976, Volume: 132, Issue:2

    Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect

1976
Primary carcinoma of the liver.
    Surgery, 1976, Volume: 80, Issue:3

    Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Child; Child, Pre

1976
Solid tumour models for the assessment of different treatment modalities: IV. the combined effects of radiation and 5-fluorouracil.
    British journal of cancer, 1976, Volume: 34, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Dose-Response Relationship, Ra

1976
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
    British journal of cancer, 1976, Volume: 34, Issue:3

    Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S

1976
Utilization of 3H from deoxyuridine and thymidine for synthesis of DNA and tother macromolecules in various organs of the rat.
    Biochemical pharmacology, 1977, Jan-01, Volume: 26, Issue:1

    Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Fluorouracil; Intestinal Mucosa;

1977
Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration.
    Cancer biochemistry biophysics, 1976, Volume: 1, Issue:6

    Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Dose-Response Relationship, Drug

1976
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
    The Journal of biological chemistry, 1977, Feb-10, Volume: 252, Issue:3

    Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Deoxyuridine; DNA Replication; Drug Re

1977
Hepatocellular carcinoma in association with androgen therapy.
    The Medical journal of Australia, 1977, Feb-12, Volume: 1, Issue:7

    Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Methyltestosterone

1977
Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma.
    Cancer, 1977, Volume: 39, Issue:4

    Topics: Adult; Carcinoma, Hepatocellular; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; H

1977
Oral fluorouracil therapy of hepatoma.
    Cancer, 1977, Volume: 39, Issue:5

    Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil;

1977
Futraful therapy on liver cancer.
    Clinical oncology, 1977, Volume: 3, Issue:1

    Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Drug Administrat

1977
Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy.
    Proceedings of the National Academy of Sciences of the United States of America, 1977, Volume: 74, Issue:5

    Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver Neoplasms; Neoplasms, Experimental;

1977
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
    The Biochemical journal, 1977, May-15, Volume: 164, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Drug Resistance; Female; Fluorouracil; Isoenzymes; Ki

1977
A case report of hepatoblastoma treated by chemotherapy and hepatic lobectomy.
    World journal of surgery, 1977, Volume: 1, Issue:3

    Topics: Carcinoma, Hepatocellular; Child, Preschool; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Huma

1977
[Effect of 5-fluorouracil and thiophosphamide on the activity and fractional content of phosphatases of Zajdela hepatoma].
    Voprosy onkologii, 1977, Volume: 23, Issue:3

    Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Lysoso

1977
Evidence for role of purine nucleoside phosphorylase in sensitivity of Novikoff hepatoma cells to 5-fluorouracil.
    Advances in enzyme regulation, 1976, Volume: 15

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line; DNA, Neoplasm; Fluorouracil;

1976
Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.
    Journal of the Medical Association of Georgia, 1977, Volume: 66, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Female; Fluorourac

1977
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
    Bulletin du cancer, 1977, Volume: 64, Issue:3

    Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl

1977
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fem

1977
[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].
    Schweizerische medizinische Wochenschrift, 1977, Dec-31, Volume: 107, Issue:52

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Etoposide; Female; Fluorouracil;

1977
Chemotherapy studies in autochthonous rat tumors: hepatomas.
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1977, Nov-18, Volume: 90, Issue:2

    Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Cyclophosphamide; Doxorubicin; Female; Fluorouracil

1977
Synchronization of host and tumor responses for sequential therapy in experimental solid tumors.
    Antibiotics and chemotherapy, 1978, Volume: 23

    Topics: Animals; Bone Marrow Diseases; Carcinoma, Hepatocellular; Cell Cycle; DNA, Neoplasm; Drug Administra

1978
Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts.
    British journal of cancer, 1978, Volume: 37, Issue:5

    Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; DNA; Drug Administration Schedule; Fluorouracil; Li

1978
Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.
    International journal of nuclear medicine and biology, 1978, Volume: 5, Issue:1

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Fluo

1978
Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:2

    Topics: Adult; Carcinoma, Hepatocellular; Carmustine; Contraceptives, Oral; Contraceptives, Oral, Combined;

1978
Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report.
    Cancer, 1978, Volume: 42, Issue:1

    Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Hepatocellular; Disseminated Intravascular Co

1978
Evaluation of a chemotherapeutic regimen for primary liver cancer in children.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Child; Doxorubicin; Drug E

1978
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1978, Volume: 75, Issue:12

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li

1978
Treatment of primary liver cancer: response to regional chemotherapy.
    Clinical oncology, 1979, Volume: 5, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg

1979
Clinical studies in Asian patients with irresectible primary hepatocellular carcinoma treated by adriamycin and prednisolone alone or in combination with 5-fluorouracil, vincristine and prednisolone.
    Singapore medical journal, 1978, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Child; Doxorubicin; Drug Therapy, Combination; F

1978
Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy.
    Acta hepato-gastroenterologica, 1979, Volume: 26, Issue:3

    Topics: Carcinoma, Hepatocellular; Erythropoietin; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male;

1979
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
    Acta medica Okayama, 1979, Volume: 33, Issue:5

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop

1979
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
    Radiology, 1992, Volume: 182, Issue:3

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci

1992
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
    Nuclear medicine communications, 1992, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18;

1992
Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1992, Volume: 18, Issue:2

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastroin

1992
[Hepatic blood flow in patients treated by continuous hepatic artery infusion chemotherapy].
    Kaku igaku. The Japanese journal of nuclear medicine, 1992, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female;

1992
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut

1992
5-Fluorouracil and leucovorin in hepatocellular carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fe

1992
[Treatment of hepatic malignant tumors with percutaneous echoguided injections of absolute alcohol and 5 FU- folinic acid-ultrafluid lipiodol combination. Preliminary results in 17 patients].
    Gastroenterologie clinique et biologique, 1992, Volume: 16, Issue:5

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combina

1992
[The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Administration, Oral; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fibrinogen; Fluoro

1992
[Effects of intra-arterial infusion chemotherapy with radiation therapy for advanced hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy

1992
[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F

1992
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

1992
Chemotherapy can convert unresectable hepatoblastoma.
    Journal of pediatric surgery, 1992, Volume: 27, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

1992
[Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using implantable drug delivery system].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubic

1992
Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31 Suppl

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1992
[Clinical evaluation of operative and non-operative treatment in hepatocellular carcinoma with main portal vein tumor thrombus].
    Nihon Geka Gakkai zasshi, 1992, Volume: 93, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

1992
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
    Hepatology (Baltimore, Md.), 1992, Volume: 16, Issue:1

    Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa

1992
[The efficacy of transcatheter arterial infusion chemotherapy in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Doxorubicin; Femal

1992
[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:7

    Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies

1991
[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D

1991
[Efficacy of anticancer agent-lipiodol emulsion for hepatic arterial infusion and regional hyperthermia in patients with nonresectable hepatoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal

1991
[Intra-arterial infusion chemotherapy for unresectable hepatocellular carcinoma using an implantable reservoir].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; D

1991
[Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel

1991
[Effects of intraarterial infusion chemotherapy on liver function in patients with hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine;

1991
Complete disappearance of unresectable hepatoblastoma by continuous infusion therapy through hepatic artery.
    Journal of pediatric surgery, 1991, Volume: 26, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F

1991
Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1991
Combination chemotherapy in the treatment of hepatoblastoma.
    Pediatric hematology and oncology, 1990, Volume: 7, Issue:2

    Topics: Adenomatous Polyposis Coli; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biom

1990
Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test.
    Oncology, 1991, Volume: 48, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Screening Assays, Antitumo

1991
[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1990
[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:3 Pt 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1990
Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro.
    Japanese journal of cancer research : Gann, 1990, Volume: 81, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

1990
Application of traditional Chinese drugs in comprehensive treatment of primary liver cancer.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 1990, Volume: 10, Issue:1

    Topics: Carcinoma, Hepatocellular; Cobalt Radioisotopes; Combined Modality Therapy; Doxorubicin; Drugs, Chin

1990
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
    Leber, Magen, Darm, 1990, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin

1990
[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Adenoma, Bile Duct; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile

1990
Repeated dearterialization of hepatic tumors with an implantable occluder.
    Cancer, 1990, Sep-15, Volume: 66, Issue:6

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Catheters, Indwelling; Colonic Neoplasms; E

1990
Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines.
    Toxicon : official journal of the International Society on Toxinology, 1990, Volume: 28, Issue:10

    Topics: Abortifacient Agents, Nonsteroidal; Animals; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Ce

1990
Rapid chemosensitivity assay with human normal and tumor cells in vitro.
    In vitro cellular & developmental biology : journal of the Tissue Culture Association, 1990, Volume: 26, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Cells, Cultured; Cisplatin; Dose-Re

1990
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:6 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined

1985
Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil.
    Cancer, 1985, Nov-15, Volume: 56, Issue:10

    Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biodegradation, Env

1985
Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine.
    Cancer, 1988, Sep-15, Volume: 62, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;

1988
[Favorable response of advanced hepatocellular carcinoma to proper hepatic arterial administration of cytokines and the significance of the administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Animals; Carcinoma, Hepatocellular; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Injecti

1988
Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23 Suppl

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular;

1989
Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro.
    British journal of cancer, 1989, Volume: 59, Issue:4

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cisp

1989
[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel

1989
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla

1989
Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23 Suppl

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization, Peripheral; Doxorubicin; Embolization, Ther

1989
[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:4 Pt 2-3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Combined Modality Therapy; Doxorubicin;

1989
[Clinical studies of intermittent hepatic arterial occlusion with infusion chemotherapy for unresectable hepatocellular carcinoma associated with arterioportal or arteriovenous shunts].
    Nihon Gan Chiryo Gakkai shi, 1989, Jan-20, Volume: 24, Issue:1

    Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluor

1989
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv

1989
[Preliminary study of traditional Chinese medicine-Western medicine treatment of patients with primary liver carcinoma].
    Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine, 1989, Volume: 9, Issue:6

    Topics: Adjuvants, Immunologic; Adult; Camptothecin; Carcinoma, Hepatocellular; Cimetidine; Drugs, Chinese H

1989
[New approach for unresectable primary liver cancer--intra-arterial combination chemotherapy during and after operation with local injection of ethanol].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T

1989
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com

1989
[Hepatic arterial infusion chemotherapy of hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug E

1989
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin

1989
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality

1989
[A long-survival case of hepatocellular carcinoma treated by intra-arterial chemotherapy and immunotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular

1989
[Analysis of prognostic factors in patients with hepatocellular cancer treated by hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula

1989
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo

1989
[A case of hepatocellular carcinoma effectively treated by intraarterial infusion of CDDP and other agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Emboliza

1989
[Hepatic artery embolization for primary hepatic carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1989, Volume: 11, Issue:2

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil

1989
[Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].
    Gastroenterologie clinique et biologique, 1989, Volume: 13, Issue:10

    Topics: Adult; Aged; Amiodarone; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular;

1989
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans

1989
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1989, Volume: 86, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N

1989
[The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer].
    Nihon Gan Chiryo Gakkai shi, 1989, Dec-20, Volume: 24, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat

1989
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:10

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil;

1987
Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants.
    Cancer, 1987, Dec-15, Volume: 60, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D

1987
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Fluoro

1987
Clinical management of recurrent hepatocellular carcinoma after primary resection.
    The British journal of surgery, 1988, Volume: 75, Issue:3

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S

1988
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
    British journal of cancer, 1988, Volume: 57, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluat

1988
Intrahepatic chemotherapy for unresectable hepatocellular carcinoma.
    Cancer, 1988, May-15, Volume: 61, Issue:10

    Topics: Adult; Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation;

1988
[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration].
    Gan no rinsho. Japan journal of cancer clinics, 1988, Volume: 34, Issue:6

    Topics: Administration, Oral; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver; Liver Neoplasms

1988
Treatment of unresectable hepatoblastoma with cisplatin, vincristine and 5-fluorouracil.
    European journal of pediatrics, 1988, Volume: 147, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat

1988
[Combined hepatic arterial infusion chemotherapy with transcatheter arterial embolization and hyperthermia in primary liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma,

1988
[Accumulation of lipiodol in hepatocellular carcinoma after transarterial chemoembolization with 5 FU-lipiodol-emulsion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Emulsions; Fluorouracil; Hepatic Artery; Human

1988
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin

1988
[Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Hepatocellular; Cispla

1988
Sensitivity to six antitumor drugs differs between primary and metastatic liver cancers.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:9

    Topics: Aclarubicin; Antineoplastic Agents; Carbazilquinone; Carcinoma, Hepatocellular; Cisplatin; Doxorubic

1988
Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C.
    Hepato-gastroenterology, 1985, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin;

1985
Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma.
    Medical and pediatric oncology, 1985, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat

1985
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.
    Cancer, 1985, Aug-15, Volume: 56, Issue:4

    Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Fluorouracil;

1985
Primary liver tumor in a young man: a brief review of diagnostic strategies and treatment options.
    AJR. American journal of roentgenology, 1985, Volume: 145, Issue:2

    Topics: Adult; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Male; Parenter

1985
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
    Human pathology, 1985, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch

1985
[Low-dose intermittent intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox

1985
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization

1985
Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors.
    The Japanese journal of surgery, 1985, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Hepato

1985
[Physiologic hepatic dearterialization and 5-FU intra-arterial perfusion in primary hepatic carcinoma].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1985, Volume: 23, Issue:9

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Int

1985
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
    Nihon Gan Chiryo Gakkai shi, 1985, Oct-20, Volume: 20, Issue:9

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil;

1985
[Evaluation of intermittent hepatic arterial occlusion with infusion chemotherapy of unresectable hepatocellular carcinoma].
    Nihon Gan Chiryo Gakkai shi, 1986, Feb-20, Volume: 21, Issue:1

    Topics: Aged; Animals; Carcinoma, Hepatocellular; Dogs; Embolization, Therapeutic; Female; Fluorouracil; Hep

1986
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

1986
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1986, Volume: 100

    Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C

1986
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C

1986
[A case of hepatoma effectively treated by TAE and intra-arterial and intraportal infusion chemotherapy].
    Nihon Gan Chiryo Gakkai shi, 1986, Jul-20, Volume: 21, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality

1986
Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance.
    Tumori, 1986, Oct-31, Volume: 72, Issue:5

    Topics: Administration, Cutaneous; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Fluorou

1986
Cardio-pulmonary elimination of 5-fluorouracil after bolus injection in the hepatic artery.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Injections, In

1987
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:4

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula

1987
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
    Gastroenterologia Japonica, 1987, Volume: 22, Issue:1

    Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec

1987
Combination chemotherapy for unresectable hepatoblastoma in children.
    The Japanese journal of surgery, 1987, Volume: 17, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy

1987
Intraarterial injection of anti-tumor drugs dispersed in lipid contrast medium: a choice for initially unresectable hepatoblastoma in infants.
    Journal of pediatric surgery, 1987, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F

1987
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
    American journal of surgery, 1971, Volume: 121, Issue:2

    Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma,

1971
Effect of various anticancer agents on DNA polymerase.
    Gan, 1971, Volume: 62, Issue:2

    Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Bone

1971
Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma.
    Cancer research, 1972, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Age Factors; Alpha-Globulins; Blood Transfusion; Carcinoma, Hepatocellular; Femal

1972
Inhibition of ribosomal ribonucleic acid maturation by 5-azacytidine and 8-azaguanine in Novikoff hepatoma cells.
    Archives of biochemistry and biophysics, 1974, Volume: 160, Issue:1

    Topics: Animals; Azacitidine; Azaguanine; Carcinoma, Hepatocellular; Cells, Cultured; Cytidine; Dactinomycin

1974
Response of alpha-fetoprotein to chemotherapy in patients with hepatomas.
    Cancer, 1974, Volume: 34, Issue:5

    Topics: Adult; Aged; Alpha-Globulins; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular;

1974
[Intra-arterial treatment of malignant neoplasms in children (author's transl)].
    Problemy medycyny wieku rozwojowego, 1972, Volume: 2

    Topics: Adolescent; Carcinoma, Hepatocellular; Child; Female; Fluorouracil; Humans; Injections, Intra-Arteri

1972
Continuous arterial infusion chemotherapy. Experience with 44 cases.
    The American surgeon, 1967, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath

1967
Hepatic artery infusion chemotherapy in hepatoma.
    British medical journal, 1968, Aug-10, Volume: 3, Issue:5614

    Topics: Aged; Alkaline Phosphatase; Angiography; Aorta; Brachial Artery; Carcinoma, Hepatocellular; Catheter

1968
[Loco-regional and sequential chemotherapy of advanced cancer].
    Bulletins et memoires de la Societe medicale des hopitaux de Paris, 1968, Volume: 119, Issue:10

    Topics: Adult; Carcinoma; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Dysgerminoma;

1968
Malignant hepatoma in the Bantu.
    Cancer, 1970, Volume: 25, Issue:6

    Topics: Adenoma, Bile Duct; Africa, Eastern; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotra

1970
Infusion chemotherapy in hepatoma and metastatic liver tumors.
    American journal of surgery, 1967, Volume: 113, Issue:3

    Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury;

1967
Infusion of liver tumours.
    British medical journal, 1968, Aug-10, Volume: 3, Issue:5614

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid

1968
[Primary cancer of the liver in a child detected by angiography and treated by exeresis and antimitotics].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Jun-14, Volume: 44, Issue:29

    Topics: Adolescent; Angiography; Carcinoma, Hepatocellular; Cholangiography; Diagnosis, Differential; Echino

1968
[Apropos of a hepatoma: rôle of regional chemotherapy].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Jun-14, Volume: 44, Issue:29

    Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Hepatomegaly; Humans; Liver Neoplasms; Male; Perfusi

1968
Infusion of liver tumours.
    British medical journal, 1968, Aug-31, Volume: 3, Issue:5617

    Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatomegaly; Hum

1968
[Treatment of cancer of the liver by regional perfusion].
    Journal de chirurgie, 1968, Volume: 95, Issue:2

    Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci

1968
[Comments on the treatment of solid tumors with 5-fluorouracil].
    Therapeutische Umschau. Revue therapeutique, 1969, Volume: 26, Issue:7

    Topics: Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Fluorouracil;

1969
[Clinical study on continuous 5-FU infusion for the treatment of primary liver cancer].
    Gan no rinsho. Japan journal of cancer clinics, 1970, Volume: 16, Issue:1

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Injections, Intra-Arterial; In

1970
[Autopsy case of liver cancer undetected until the terminal stage].
    Iryo, 1970, Volume: 24, Issue:3

    Topics: Aged; Antineoplastic Agents; Autopsy; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Functio

1970
[Some data from a biochemical study of patients with primary cancer of the liver during chemotherapy].
    Vestnik Akademii meditsinskikh nauk SSSR, 1970, Volume: 25, Issue:2

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms

1970
Hepatoma: long-term survival with disseminated tumor treated with 5-fluorouracil.
    American journal of surgery, 1970, Volume: 120, Issue:3

    Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Long-Term Care; Lung Neoplasms; Ma

1970
Cutaneous porphyria due to a malignant primary hepatoma.
    Gastroenterology, 1970, Volume: 59, Issue:5

    Topics: Aged; Carcinoma, Hepatocellular; Feces; Female; Fluorouracil; Humans; Liver Neoplasms; Photosensitiv

1970
Considerations in the development of a predictive system for cancer chemotherapy.
    Archives of surgery (Chicago, Ill. : 1960), 1971, Volume: 102, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; DNA; Floxuridine; Fluorouracil; Liver N

1971
Experience with hepatic arterial infusions.
    Texas medicine, 1971, Volume: 67, Issue:3

    Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall

1971
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
    American journal of surgery, 1971, Volume: 122, Issue:2

    Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C

1971
[Study in man of recirculation and tissue uptake of 5-FU 6 H3].
    Biologie et gastro-enterologie, 1971, Volume: 1

    Topics: Adenoma, Bile Duct; Antimetabolites; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfu

1971
Primary cancer of the liver: a review of 25 cases and report of two prolonged survivals.
    Southern medical journal, 1972, Volume: 65, Issue:1

    Topics: Adult; Aged; Body Weight; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Humans; Live

1972
[Effects of selective administration of anticancer agents in massive dosage combined with fibrolytic enzyme (urokinase) in hepatic cancer].
    Gan no rinsho. Japan journal of cancer clinics, 1972, Volume: 18, Issue:4

    Topics: Carcinoma, Hepatocellular; Fibrinolytic Agents; Fluorouracil; Humans; Liver Neoplasms; Male; Middle

1972
Continuous prolonged intrahepatic infusion of 5-fluorouracil in the treatment of hepatoma in Ibadan.
    The West African medical journal and Nigerian practitioner, 1972, Volume: 21, Issue:1

    Topics: Adult; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Li

1972
[Intra-arterial chemotherapy of primary hepatoma and changes in -fetoprotein levels].
    Nihon rinsho. Japanese journal of clinical medicine, 1972, Volume: 30, Issue:5

    Topics: Aged; Carcinoma, Hepatocellular; Female; Fetal Proteins; Fluorouracil; Humans; Injections, Intra-Art

1972
[Clinical studies of primary hepatic carcinoma].
    Zeitschrift fur Gastroenterologie, 1971, Volume: 9, Issue:8

    Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Alkaline Phosphatase; Autopsy; Biopsy; Carcinoma, Hepat

1971
Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine.
    The Journal of biological chemistry, 1973, Jan-10, Volume: 248, Issue:1

    Topics: Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Cell Line; Electrophoresis; Fluorine; Fluoroura

1973
Clinical management of advanced gastrointestinal cancer.
    Seminars in drug treatment, 1973,Summer, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro

1973
The surgical management of primary hepatocellular carcinoma in Uganda.
    The British journal of surgery, 1973, Volume: 60, Issue:7

    Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Catheterization; Female; Fluorouracil; Hepatectomy; He

1973
Proceedings: Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: ABO Blood-Group System; Adenoma, Bile Duct; Adolescent; Adult; Aged; Alanine Transaminase; Alkaline

1974
Hepatoma, erythrocytosis and increased serum erythropoietin developing in long-standing hemochromatosis.
    The American journal of gastroenterology, 1974, Volume: 61, Issue:3

    Topics: Aged; Animals; Biopsy, Needle; Carcinoma, Hepatocellular; Chronic Disease; Erythropoietin; Female; F

1974
Experience with infusion and resection in cancer of the liver.
    Surgery, gynecology & obstetrics, 1974, Volume: 138, Issue:6

    Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female

1974
The deoxyribonucleoside transport systems of cultured Novikoff rat hepatoma cells.
    Journal of cellular physiology, 1974, Volume: 83, Issue:3

    Topics: Animals; Biological Transport; Carcinoma, Hepatocellular; Cell Line; Cell Membrane Permeability; Cel

1974
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
    Journal of medicine, 1974, Volume: 5, Issue:1

    Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo

1974
Primary liver carcinoma.
    Cancer, 1974, Volume: 33, Issue:6

    Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular;

1974
Polyamine depletion of tumor tissue and subsequent elevation of spermidine in the sera of rats with 3924A hepatomas after 5-fluorouracil administration.
    Cancer research, 1974, Volume: 34, Issue:9

    Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver; Liver Neoplasms; Neoplasms, Experim

1974
Incorporation of precursors and inhibitors of nucleic acid synthesis into hepatomas and liver of the rat.
    Cancer research, 1974, Volume: 34, Issue:12

    Topics: Amino Acids; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line; Fluorouracil; Inje

1974
Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man.
    Cancer, 1974, Volume: 34, Issue:6

    Topics: Administration, Oral; Bile; Carbon Radioisotopes; Carcinoma, Hepatocellular; Chromatography, Thin La

1974
[Treatment of liver cancer with oral administration of N-(2'-furanidyl)-5 fluorouracil (FT207) (author's transl)].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1974, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver N

1974
Studies on the mechanism and prevention of local recurrence of carcinoma at the suture line after colonic resection.
    The Japanese journal of surgery, 1971, Volume: 1, Issue:2

    Topics: Animals; Carcinoma, Hepatocellular; Colon; Colonic Neoplasms; Fluorouracil; Intestinal Mucosa; Liver

1971